

04-27-01

J017 Rec'd PCT/PTO 26 APR 2001

U.S. Application No.

Unknown

International Application No.

PCT/US98/13071

Attorney Docket No.

STERN1.001APC

Date: April 26, 2001

09/830703 Page 1

**TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 USC 371**

International Application No.: PCT/EP00/08071  
International Filing Date: August 18, 2000  
Priority Date Claimed: August 30, 1999  
Title of Invention: TRANSGENIC ANIMAL MODEL FOR NEURODEGENERATIVE DISEASES  
Applicant(s) for DO/EO/US: Lübbert, Hermann

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. (X) This is a **FIRST** submission of items concerning a filing under 35 USC 371.
2. () This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 USC 371.
3. (X) This express request to begin national examination procedures (35 USC 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 USC 371(b) and PCT Articles 22 and 39(1).
4. (X) A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. (X) A copy of the International Application as filed (35 USC 371(c)(2))
  - a) (X) is transmitted herewith (required only if not transmitted by the International Bureau).
  - b) () has been transmitted by the International Bureau.
  - c) () is not required, as the application was filed in the United States Receiving Office (RO/US).
6. () A translation of the International Application into English (35 USC 371(c)(2)).
7. (X) Amendments to the claims of the International Application under PCT Article 19 (35 USC 371(c)(3))
  - a) () are transmitted herewith (required only if not transmitted by the International Bureau).
  - b) () have been transmitted by the International Bureau.
  - c) () have not been made; however, the time limit for making such amendments has NOT expired.
  - d) (X) have not been made and will not be made.
8. () A translation of the amendments to the claims under PCT Article 19 (35 USC 371(c)(3)).
9. (X) An oath or declaration of the inventor(s) (35 USC 371(c)(4)).
10. () A copy of the International Preliminary Examination Report with any annexes thereto, such as any amendments made under PCT Article 34.
11. () A translation of the annexes, such as any amendments made under PCT Article 34, to the International Preliminary Examination Report under PCT Article 36 (35 USC 371(c)(5)).

T06240" 00/08071

U.S. Application No.  
Unknown

International Application No.  
PCT/US98/13071

09/830703

Attorney Docket No.

STERN1.001APC

JCOB Rec'd PCT/PTO 26 APR 2001  
Page 2

Date: April 26, 2001

12. (X) An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
13. (X) An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
14. (X) A FIRST preliminary amendment.  
( ) A SECOND or SUBSEQUENT preliminary amendment.
15. ( ) International Application as published.
16. (X) This applicant qualifies for small entity status.
17. ( ) PCT Form PCT/IPEA/402.
18. ( ) PCT Form PCT/IB/308.
19. (X) PCT request form.
20. (X) Other Items or information:  
1. International Search Report  
2. Notification of the International Application Number and of the International Filing Date
21. (X) A return prepaid postcard.
22. (X) The following fees are submitted:

				FEES
BASIC FEE				\$860
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total Claims	24 - 20 =	4 ×	\$18	\$72
Independent Claims	2 - 3 =	0 ×	\$80	\$0
Multiple dependent claims(s) (if applicable)			\$270	\$0
TOTAL OF ABOVE CALCULATIONS \$				932
Reduction by 1/2 for filing by small entity (if applicable). Verified Small Entity statement must also be filed. (NOTE 37 CFR 1.9, 1.27, 1.28)				\$ -466
TOTAL NATIONAL FEE				\$466
TOTAL FEES ENCLOSED				\$466
amount to be refunded:				\$
amount to be charged:				\$

U.S. Application No.  
Unknown

International Application No.  
PCT/US98/13071

09/830703

Attorney Docket No.

STERN1.001APC

JC08 Rec'd PCT/PTO

26 APR 2001

Page 3

Date: April 26, 2001

23. (X) The fee for submission of the translation of the international application or any annexes to the IPER set forth in 37 CFR 1.492(f) will be paid upon submission of those items.
24. () The fee for later submission of the signed oath or declaration set forth in 37 CFR 1.492(e) will be paid upon submission of the declaration.
25. (X) A check in the amount of \$466 to cover the above fees is enclosed.
26. (X) A check in the amount of \$40 to cover the fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property.
27. (X) The Commissioner is hereby authorized to charge only those additional fees which may be required, now or in the future, to avoid abandonment of the application, or credit any overpayment to Deposit Account No. 11-1410. A duplicate copy of this sheet is enclosed.

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO:

KNOBBE, MARTENS, OLSON & BEAR, LLP  
620 Newport Center Drive  
Sixteenth Floor  
Newport Beach, CA 92660

Signature

Mark R. Benedict

Printed Name

44,531

Registration Number

O:\DOCS\JYH\JYH-1260.DOC:vb /is  
042601



STERN1.001APC

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Lubbert et al. ) Group Art Unit Unknown  
Appl. No. : 09/830,703 ) I hereby certify that this correspondence and all  
Filed : April 26, 2001 ) marked attachments are being deposited with  
For : TRANSGENIC ANIMAL ) the United States Postal Service as first-class  
MODEL FOR ) mail in an envelope addressed to: Assistant  
NEURODEGENERATIVE ) Commissioner for Patents, Washington, D.C.  
DISEASES ) 20231, on  
June 5, 2001  
(Date)  
*Mark R. Benedict*  
Mark R. Benedict, Reg. No. 44,531  
Examiner : Unknown

SUPPLEMENTAL PRELIMINARY AMENDMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Prior to examination on the merits and subsequent to the Preliminary Amendment mailed April 26, 2001, please amend the above-captioned application as follows:

IN THE SPECIFICATION

Please replace the word "more" with --less-- on page 9, line 17.

IN THE CLAIMS

Please amend Claim 1 as follows:

1. (Twice Amended) An isolated or purified polynucleotide encoding a mouse parkin2 protein, containing mutations or deletions in at least one of the exons 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, or 12, or containing a frame-shift mutation in exon 4, wherein said mutation causes Parkinson's disease.

REMARKS

The amendment to the specification (page 9) was made to correct an inadvertent error introduced by the Preliminary Amendment of April 26, 2001. The amendment to Claim 1 was

Appl. No. : 09/830,703  
Filed : April 26, 2001

made in order to more distinctly claim the present invention. Support for the amendment to Claim 1 may be found in Tables 1 and 2, on pages 18 and 19, respectively, as well as on page 8 lines 17-19 of the specification. The specific amendments to the application are shown on a separate set of pages attached hereto and entitled **VERSION WITH MARKINGS TO SHOW CHANGES MADE**, which follows the signature page of this Amendment. On this set of pages, the insertions and [deletions] are indicated.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410. A duplicate copy of this sheet is enclosed.


Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 6/5/01

By: Mark R. Benedict  
Mark/R. Benedict  
Registration No. 44,531  
Attorney of Record  
620 Newport Center Drive  
Sixteenth Floor  
Newport Beach, CA 92660

Appl. No. : 09/830,703  
Filed : April 26, 2001



VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

The paragraph beginning on page 9, line 12, has been deleted and rewritten as follows:

To obtain at least a transgenic non-human animal as a model for neurodegenerative diseases, the natural occurring sequence of the parkin gene in this animal may be replaced on one or both alleles of the chromosomes by a sequence of mPark2, containing mutations or deletions according to the present invention. These animals produce either less or **[more]** less active or no parkin protein.

IN THE CLAIMS:

1. (Twice Amended) An isolated or purified polynucleotide encoding a **[mutant]** mouse parkin2 protein, or a homolog thereof, containing mutations or deletions in at least one of the exons 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, or 12, or containing a frame-shift mutation in exon 4, wherein said **[mutant]** mutation causes Parkinson's disease.

O:\DOCS\CMS\CMS-1340.DOC  
053001

09/830703

JC08 Rec'd PCT/PTO 26 APR 2007  
PATENT

STERN1.001APC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Lubbert et al. ) Group Art Unit Unknown  
Appl. No. : Unknown )  
Filed : Herewith )  
For : TRANSGENIC ANIMAL )  
MODEL FOR )  
NEURODEGENERATIVE )  
DISEASES )  
Examiner : Unknown )

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Preliminary to examination on the merits, please amend the above-captioned U.S. national phase application as follows:

**IN THE SPECIFICATION:**

Please insert the following paragraph and heading, immediately following the title, as follows:

**--Cross-Reference to Related Applications**

This is the U.S. National Phase under 35 U.S.C. § 371 of International Application Number PCT/EP00/08071, filed August 18, 2000 which claims priority to European Application Number 99116766.9, filed August 30, 1999 under 35 U.S.C. § 119, the disclosures of which are incorporated herein by reference.--

Please insert the following heading, immediately following the "Cross-Reference to Related Applications":

**--Field of the Invention--**

Appl. No. : Unknown  
Filed : Herewith

Please replace the paragraph beginning on page 1, line 3, with the following rewritten paragraph:

--This invention relates to a transgenic animal model containing mutated mouse parkin2 DNA and translated protein sequence. The use of a transgenic animal can be used as a model for neurodegenerative diseases, preferably Parkinson's disease.--

Please insert the following heading prior to the paragraph beginning at page 1, line 13:

--Description of the Related Art--

Please replace the word "insults" found on page 1, line 18, with the word --insights--.

Please insert --(PD)-- immediately following "Parkinson's Disease" found on page 2, line 8.

Please insert prior to the paragraph beginning at page 4, line 9, the following heading and paragraph:

--Summary of the Invention--

Please insert the paragraph beginning at page 1, line 3.

Following the "Summary of the Invention" and paragraph, please insert the following heading and paragraph:

--Brief Description of the Drawings--

Please insert the paragraphs beginning at page 25, line 28 and ending at page 26, line 15.

Following the "Brief Description of the Drawings" and inserted paragraphs, please insert the following heading:

--Description of the Preferred Embodiment--

Please replace the word "analysing" found on page 5, line 18, with the word --analyzing--.

Please delete the end of the sentence beginning at page 5, line 17, starting with the word "...whereby it is..."

Please replace the word "content" with --context of-- found on page 7, line 19.

Please replace the word "ore" with --or-- found on page 8, line 2.

Please replace the word "less" with --more-- found on page 9, line 17.

Please delete the word "Briefly" found on page 9, line 28 and begin the sentence with "A vector is..."

Please insert the word --If-- prior to "The vector is..." on page 10, line 1.

Please replace the word "and" with --it-- on page 10, line 1.



Appl. No. : Unknown  
Filed : Herewith

Please replace the word "expiration" with --expression vector-- found on page 16, line 2.

Please replace the words "The pups will usually be..." with --Offspring are generally...-- found on page 20, line 17.

Please insert the word --are-- on page 22, line 12 after the word "Preferred."

Please insert the word --that-- on page 22, line 14 after the word "lines."

Please delete the paragraph beginning at page 26, line 7.

**IN THE CLAIMS:**

**Please cancel the following claims:** 2, 9, 10, 11, 12, 16, 19, 21

**Please amend the remaining claims as follows:**

1. (Amended) An isolated or purified polynucleotide encoding a mutant mouse parkin2 protein, or a homolog thereof, wherein said mutant causes symptoms of Parkinson's disease.

3. (Amended) The polynucleotide of claim 1, wherein said polynucleotide is selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO: 9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, and SEQ ID NO:20.

4. (Amended) A vector, comprising the polynucleotide of claim 1.

5. (Amended) A cell, comprising the polynucleotide of claim 1.

6. (Amended) The cell of claim 5, wherein the cell is a prokaryotic or a eukaryotic cell.

7. (Amended) A parkin mouse protein, comprising any amino acid sequence selected from the group consisting of: SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, and SEQ ID NO:34.

8. (Amended) A transgenic non-human mammal comprising the isolated or purified polynucleotide of claim 1.

13. (Amended) A mammalian cell-line transformed or transfected with the polynucleotide of claim 1.

14. (Amended) A method of producing a transgenic animal, comprising:

Appl. No. : Unknown  
Filed : Herewith

constructing a vector that carries the polynucleotide of claim 1;  
introducing said vector into embryonic stem cells;  
injecting said embryonic stem cells into blastocysts; and  
placing said blastocysts into a pseudopregnant female animal.

15. (Amended) A mammalian model for a neurodegenerative disease comprising the transgenic mammal of claim 8.

17. (Amended) A method for testing the efficacy of a treatment for a neurodegenerative disease, comprising:

subjecting the mammalian model of claim 15 to a putative treatment or agent; and  
determining the efficacy of said treatment by identifying a reduction in the symptoms of said neurodegenerative disease.

18. (Amended) The method of claim 17, wherein said neurodegenerative disease is selected from the group consisting of: Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, Multisystem atrophy, Wilson's disease, Pick's disease, and Prion disease.

20. (Amended) A method for testing whether an active substance is useful for treating the symptoms of Parkinson's disease comprising:

administering said active substance to the transgenic animal of claim 8; and  
determining whether said active substance reduces the symptoms of Parkinson's disease.

22. (Amended) A descendant of the transgenic animal according to claim 8, wherein said animal is obtained by breeding with the same or any other genotype.

**Please add the following claims:**

23. (New) The polynucleotide of claim 1, wherein said mutant comprises a point mutation, deletion or fragment.

24. (New) The polynucleotide of claim 1, wherein said homolog is human.

25. (New) The cell of claim 5, wherein said eukaryotic cell is a fungal, insect or mammalian cell.

26. (New) The cell of claim 25, wherein said fungal cell is a yeast cell.

Appl. No. : Unknown  
Filed : Herewith

27. (New) The cell of claim 25, wherein said prokaryotic cell is a bacterial cell.

28. (New) The polynucleotide of claim 1, wherein said mutants comprise mutations in exon 1 or exon 3.

29. (New) The mammalian model of claim 15, wherein said animal is a mouse or rat.

30. (New) A method of testing agents for efficacy and toxicity in treating a neurodegenerative disease, comprising:

administering said agent to the mammalian model of claim 15; and

identifying whether said agent reduces the symptoms of said neurodegenerative disease or is toxic to said mammal.

31. (New) A method for testing whether an active substance is useful for treating the symptoms of Parkinson's disease, comprising:

administering said active substance to the cell-line of claim 13; and

determining whether said active substance reduces the symptoms of Parkinson's disease.

32. (New) The method of claim 20, further comprising testing various dosages of said active substance.

#### REMARKS

The foregoing amendments more closely conform the application to U.S. practice. The above requested changes to the application do not add new matter, and entry of the amendments is respectfully requested.

The specific changes to the specification are shown on a separate set of pages attached hereto and entitled **VERSION WITH MARKINGS TO SHOW CHANGES MADE**, which follows the signature page of this amendment. On this set of pages, the insertions are underlined while [brackets denote deletions].

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410. A duplicate copy of this sheet is enclosed.

Appl. No. : Unknown  
Filed : Herewith

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: \_\_\_\_\_

4/26/01

By: \_\_\_\_\_

Mark R. Benedict

Mark R. Benedict

Registration No. 44,531

Attorney of Record

620 Newport Center Drive

Sixteenth Floor

Newport Beach, CA 92660

O:\DOCS\JYH\JYH-1241.DOC  
032701

Appl. No. : Unknown  
Filed : Herewith

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**IN THE SPECIFICATION:**

The following paragraph and heading has been added, immediately following the title:

Cross-Reference to Related Applications

This is the U.S. national phase under 35 U.S.C. § 371 of International Application Number PCT/EP00/08071, filed August 18, 2000 which claims priority to European Application Number 99116766.9, filed August 30, 1999 under 35 U.S.C. § 119, the disclosures of which are incorporated herein by reference.

The following heading has been added following the section entitled "Cross-Reference to Related Applications":

Field of the Invention

The paragraph beginning on page 1, line 3, has been deleted and rewritten as follows:

[The present invention relates to a mouse parkin2 DNA- and protein sequence containing naturally occurring or artificially introduced mutations or deletions, which cause Parkinson's disease in a human if they occur in the according human sequence, the construction of a truncated parkin gene, which expresses no, a non-active or a truncated parkin protein and a model of a transgenic animal, expressing such a less or non-active parkin protein instead of the native parkin protein or no parkin protein, as well as to the use of such a transgenic animal as a model for neurodegenerative diseases, preferred Parkinson's disease.] This invention relates to a transgenic animal model containing mutated mouse parkin2 DNA and translated protein sequence. The use of a transgenic animal can be used as a model for neurodegenerative diseases, preferably Parkinson's disease.

The following heading has been added prior to the paragraph beginning at page 1, line 13:

Description of the Related Art

The paragraph beginning at page 1, line 13 has been amended as follows:

Neurodegenerative disorders are some of the most feared illnesses in society. During the last 10 years some of the genetic causes of many of the primary neurodegenerative disorders like Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, prion disease and several ataxic syndromes, have been identified. These findings gave new [insults] insights in the knowledge about the initiating trigger as well as the resulting

Appl. No. : Unknown  
Filed : Herewith

consequences of those diseases. Due to the fact that these diseases have many pathological mechanisms in common it seems possible that only relatively few pathways to neuronal death are involved in these disorders. Thus, treatment strategies for a particular neurodegenerative disease may be found to have value in other related disorders.

The paragraph beginning on page 2, line 8, has been amended as follows:

In both the early and late onset types of Parkinson's disease (PD), the pathology is the same but the abnormalities tend to be more severe and more widespread in cases beginning at an earlier age. The disease is characterised by lesions in brain areas where the cell bodies of the dopaminergic neurons are located mainly in the substantia nigra compacta. In addition intracytoplasmic inclusions known as Lewy bodies can be observed in different brain regions, in particular in substantia nigra and the locus ceruleus.

The following heading and paragraph has been added prior to the paragraph beginning at page 4, line 9 as follows:

#### Summary of the Invention

The present invention relates to a mouse parkin2 DNA- and protein sequence containing naturally occurring or artificially introduced mutations or deletions, which cause Parkinson's disease in a human if they occur in the according human sequence, the construction of a truncated parkin gene, which expresses no, a non-active or a truncated parkin protein and a model of a transgenic animal, expressing such a less or non-active parkin protein instead of the native parkin protein or no parkin protein, as well as to the use of such a transgenic animal as a model for neurodegenerative diseases, preferred Parkinson's disease.

The following heading and paragraph have been added following the section entitled "Summary of the Invention":

#### Brief Description of the Invention

Figure 1 shows the alignment of the deduced amino acid sequences of the human and mouse Parkin2 protein (SEQ ID NO: 4).

Underlined are the conserved ubiquitin like (at the N-terminus) and Ring finger like (at the C-terminus) regions of both proteins.

Figure 2 shows the alignment of the nucleotide sequences of the human and mouse parkin 2 gene. Bold lines represent the exon boundaries identified for the human and mouse sequence.

Appl. No. : Unknown  
Filed : Herewith

Figure 3 represents a flow chart of the cloning procedure of the mouse parkin2 gene - exon3 knock-out construct.

The following heading has been added following the section entitled "Brief Description of the Invention."

Description of the Drawings

The paragraph beginning at page 5, line 17, has been amended as follows:

The transgenic non-human animals according to the present invention can be used as models for [analysing] analyzing the symptoms of neurodegenerative diseases or as a model system for testing the efficacy of a treatment for a neurodegenerative disease[, whereby it is not an object of the present application to provide any method for treating one of the described diseases in a human or animal].

The paragraph beginning at page 7, line 19, has been amended as follows:

"Homologous amino acid sequence" in [content] context of with the mouse parkin2 protein means in the present application an amino acid sequence, wherein at least 70 %, preferably 80 %, more preferably 90 % of the amino acids are identical to one of the proteins of the present invention and wherein the replaced amino acids preferably are replaced by homologous amino acids. As "homologous" amino acids are designated which have similar features concerning hydrophobicity, charge, steric features etc. Most preferred are amino acid sequences, containing the species-dependent differences of the mouse amino acid sequence compared to human parkin protein shown in the alignment Figure No. 1. The alignment of the corresponding polynucleotide sequences with the exon boundaries is shown in Figure No. 2.

The paragraph beginning at page 8, line 2, has been amended as follows:

In the whole application for nucleotides and amino acids the usual designations (one-letter [ore] or three-letter code) are used, known by any person skilled in the art.

The paragraph beginning at page 9, line 17 has been amended as follows:

To obtain at least a transgenic non-human animal as a model for neurodegenerative diseases, the natural occurring sequence of the parkin gene in this animal may be replaced on one or both alleles of the chromosomes by a sequence of mPark2, containing mutations or deletions according to the present invention. These animals produce either less or [less] more active or no parkin protein.

The paragraph beginning at page 9, line 28, has been amended as follows:

Appl. No. : Unknown  
Filed : Herewith

[Briefly, a] A vector is constructed that carries the replacement DNA. Both ends of the replacement DNA are flanked by long DNA sequences homologous to the sequences flanking the target DNA. When the vector is introduced into ES cells, the homologous sequences align and recombination may take place. This results in the target DNA being exchanged for the replacement DNA. If the [The] vector is not replicated in the cells, it [and] will be lost. The frequency of homologous recombination is low; thus, a screening system is used. The replacement DNA will contain a positive marker sequence, usually a neomycin resistance gene. Thus, any cells that incorporate the replacement DNA by homologous recombination will resist neomycin. By growing cells in medium containing the drug neomycin one can select only those cells containing the replacement DNA. The ES cells containing the replacement DNA are then inserted into recipient mouse blastocysts to create chimeric mice. Chimeras with germ cells derived for the altered ES cells transmit the modified genome to their offspring, yielding mice heterozygous for the target DNA (contain one target DNA and one replacement DNA). The heterozygotes are then bred with each other either to create mice homozygous for the replacement DNA and deficient in the target DNA or to maintain transgenic heterozygotes if the homozygotic mice are not viable.

The paragraph beginning on page 16, line 1, has been amended as follows:

Further to the above described techniques a step of expressing the treated sequence may be inserted in the [expiration] expression vector. Therefore the construct is (sub)cloned into any expression vector, which may be brought into a suitable eukaryotic cell. These expression vectors are typically replicable in the host organisms either as episomes or as an integral part of the host chromosomal DNA. Commonly, expression vectors will contain selection markers, e.g., tetracycline resistance or hygromycin resistance, to permit detection and/or selection of those cells transformed with the desired DNA sequences. Polynucleotides encoding a variant parkin2 polypeptide may include sequences that facilitate transcription (expression sequences) and translation of the coding sequences, such that the encoded polypeptide product is produced. Construction of such polynucleotides is well known in the art and is described further in Maniatis et al. Molecular Cloning: A Laboratory Manual, 2nd Ed. (1989), Cold Spring Harbor, N.Y. For example, but not for limitation, such polynucleotides can include a promoter, a transcription termination site (polyadenylation site in eukaryotic expression hosts), a ribosome binding site,



Appl. No. : Unknown  
Filed : Herewith

and, optionally, an enhancer for use in eukaryotic expression hosts, and, optionally, sequences necessary for replication of a vector.

The paragraph beginning on page 20, line 17, has been amended as follows:

[The pups will usually be] Offspring are generally born 16-18 days after introduction of the blastocysts into foster mothers. Chimeric animals will be mated with wild type (wt) mice to create heterozygote transgenics.

The paragraph beginning on page 22, line 12, has been amended as follows:

Preferred are the above described polynucleotide sequences, the proteins and amino acid sequences as well as the transgenic animal models and cell lines that may be used for any method for analysing the symptoms of neurodegenerative diseases.

The paragraph beginning on page 26, line 8, has been deleted:

[a) Restriction endonucleases:

N = NotI, E= Eco RI, B= BamHI, H= HindIII, X= XbaI.

b) Modifications: ()= T4 DNA polymerase treatment in order to remove a restriction site in the resulting plasmid.

c)  =pBluescript KSII (Stratagene) vector sequence

 = λ-Fix vector sequence

d) HSV-tk = herpes simplex promotor and thymidine kinase gene

e) kb = kilobases]

## **IN THE CLAIMS:**

**Claims 2, 9, 10, 11, 12, 16, 19, 21 have been deleted.**

**The remaining claims have been amended as follows.**

1. (Amended) [A] An isolated or purified polynucleotide [sequence] encoding a mutant mouse parkin2 protein, or a homolog thereof, wherein said mutant causes [containing naturally occurring or artificially introduced mutations or deletions, which cause] Parkinson's disease [in a human if they occur in the according human sequence].

3. (Amended) The [sequence] polynucleotide of claim 1 [or 2], wherein [the sequence] said polynucleotide is selected from the group[,] consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:7 SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ

Appl. No. : Unknown  
Filed : Herewith

ID NO:18, and SEQ ID NO:19, SEQ ID NO:20 [or naturally occurring or artificially introduced mutants or fragments thereof].

4. (Amended) A vector, [containing any sequence according to any] comprising the polynucleotide of [claims] claim 1 [to 3].

5. (Amended) A [prokaryotic or eukaryotic] cell, [containing a vector according to] comprising the polynucleotide of claim [4] 1.

6. (Amended) The cell of claim 5, [characterised in that] wherein the cell is [selected from bacterial or yeast cells, insect cells or mammalian cells as primary cells or immortalised cell lines] a prokaryotic or eukaryotic cell.

7. (Amended) A parkin mouse protein, comprising any [with an] amino acid sequence selected from the group consisting of: SEQ ID NO:5, SEQ ID NO:6 SEQ, ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, and SEQ ID NO:34 [or naturally occurring or artificially introduced mutants with a homologous protein sequence or fragments thereof].

8. (Amended) A transgenic non-human [animal] mammal[,] comprising the isolated or purified polynucleotide of claim 1 [whose one or both alleles of a gene encoding a parkin gene are mutated or truncated in a way, that a protein with modified, preferred less activity or no active protein is expressed].

13. (Amended) A mammalian cell-line transformed or transfected with the polynucleotide of claim 1 [any sequence according to any of claims 1 to 3 or a vector according to claim 4 or cell lines or primary cultures derived from the transgenic animal of any of claims 8 to 12].

14. (Amended) A method of producing a transgenic animal, comprising:  
[according to any of claims 8 to 12 or a cell line according to claim 13.]

constructing a vector that carries the polynucleotide of claim 1;

introducing said vector into embryonic stem cells;

injecting said embryonic stem cells into blastocysts; and

placing said blastocysts into pseudopregnant femal animal.

Appl. No. : Unknown  
Filed : Herewith

15. (Amended) [Use of the transgenic non-human animal according to any of claims 8 to 12 or a cell line according to claim 13 as a] A mammalian model for a neurodegenerative [diseases] disease comprising the transgenic mammal of claim 8.

17. (Amended) A method for testing the efficacy of a treatment for a neurodegenerative disease, comprising: [associated with a less active or non-active parkin protein, comprising subjecting any model of claim 15 to a putative treatment and determining the efficacy of said treatment.]

subjecting the mammalian model of claim 15 to a putative treatment or agent; and  
determining the efficacy of said treatment by identifying a reduction in the  
symptoms of said neurodegenerative disease.

18. (Amended) The method [according to] of claim [16 or] 17, wherein said neurodegenerative disease is selected from the group consisting of: Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, Multisystem atrophy, Wilson's disease, Pick's disease, and Prion disease], **or second causes inducing Parkinson's syndromes like toxins, drugs, brain tumors, head trauma, stroke, vascular irregularities, or metabolic irregularities].**

20. (Amended) [Use of any model according to claim 15] A method for testing whether an active substance is useful for treating the symptoms of Parkinson's disease comprising: [a condition associated with non-active parkin protein comprising administering said active substance to the transgenic animal of any of claims 8 to 12 or a cell-line of claim 13, and determining a level of the active substance, which causes an effect in treating the disease.]

administering said active substance to the transgenic animal of claim 8, and  
determining whether said active substance reduces the symptoms of Parkinson's  
disease.

22. (Amended) A descendant [Descendant] of the transgenic animal according to [any of claims] claim 8 [to 12] wherein, said animal is obtained by breeding with the same or any other genotype.

**The following claims have been added.**

23. (New) The polynucleotide of claim 1, wherein said mutant comprises a point mutation, deletion or fragment.

Appl. No. : Unknown  
Filed : Herewith

24. (New) The polynucleotide of claim 1, wherein said homolog is human.
25. (New) The cell of claim 5, wherein said eukaryotic cell is a fungal, insect or mammalian cell.
26. (New) The cell of claim 25, wherein said fungal cell is a yeast cell.
27. (New) The cell of claim 25, wherein said prokaryotic cell is a bacterial cell.
28. (New) The polynucleotide of claim 1, wherein said mutants comprise mutations in exon 1 or exon 3.
29. (New) The mammalian model of claim 15, wherein said animal is a mouse or rat.
30. (New) A method of testing agents for efficacy and toxicity in treating a neurodegenerative disease, comprising:  
administering said agent to the mammalian model of claim 15; and  
identifying whether said agent reduces the symptoms of said neurodegenerative disease or is toxic to said mammal.
31. (New) A method for testing whether an active substance is useful for treating the symptoms of Parkinson's disease, comprising:  
administering said active substance to the cell-line of claim 13; and  
determining whether said active substance reduces the symptoms of Parkinson's disease.
32. (New) The method of claim 20, further comprising testing various dosages of said active substance.

Transgenic animal model for neurodegenerative diseases

The present invention relates to a mouse parkin2 DNA- and protein sequence containing naturally occurring or artificially introduced mutations or deletions, which cause Parkinson's disease in a human if they occur in the according human sequence, the construction of a truncated parkin gene, which expresses no, a non-active or a truncated parkin protein and a model of a transgenic animal, expressing such a less or non-active parkin protein instead of the native parkin protein or no parkin protein, as well as to the use of such a transgenic animal as a model for neurodegenerative diseases, preferred Parkinson's disease.

Neurodegenerative disorders are some of the most feared illnesses in society. During the last 10 years some of the genetic causes of many of the primary neurodegenerative disorders like Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, prion disease and several ataxic syndromes, have been identified. These findings gave new insights in the knowledge about the initiating trigger as well as the resulting consequences of those diseases. Due to the fact that these diseases have many pathological mechanisms in common it seems possible that only relatively few pathways to neuronal death are involved in these disorders. Thus, treatment strategies for a particular neurodegenerative disease may be found to have value in other related disorders.

25

Parkinson's disease is a progressive neurodegenerative movement disorder with severe symptoms like rigidity, bradykinesia or tremor. The disease symptoms appear after degeneration of more than 70-80% of dopaminergic neurons. Broadly speaking the disease falls into two categories, namely late onset and early onset. Late onset, which occurs in older age (55+ years), mainly as consequence of environmental influences, leads to

30

enhanced dopaminergic neuron death at a faster rate and to a more severe degree than normal. Early onset Parkinson's disease is much more infrequent but starts between the ages of 35 and 60 years. There is evidence that three forms of this early type of Parkinson's disease show a tendency to run in families and is therefore known as familial Parkinson's disease.

In both the early and late onset types of Parkinson's disease, the pathology is the same but the abnormalities tend to be more severe and more widespread in cases beginning at an earlier age. The disease is characterised by lesions in brain areas where the cell bodies of the dopaminergic neurons are located mainly in the substantia nigra compacta. In addition intracytoplasmic inclusions known as Lewy bodies can be observed in different brain regions, in particular in substantia nigra and the locus ceruleus.

Recently two loci could be identified associated with early onset PD, one on human chromosome 4q21-23 ("PARK 1" gene locus) with a gene defect to be due to a missense mutation in the  $\alpha$ -synuclein protein (or *parkin1*), a small abundant brain molecule (Polymeropoulos, M. *et al.*, Science 1997; 276:2045-2047), and one on chromosome 2p13 ("PARK 3" gene locus)(Gasser, T. *et al.*, Nat. Genet. 1998; 18: 262-265). Both forms are inherited in an autosomal dominant manner.

Lately an autosomal recessive form of familial Parkinson's disease could be observed, linked to human chromosome 6q25.2-27 ("PARK 2" gene locus) (Matsumine, H. *et al.*, Am J Hum Genet (1997); 60: 588-596). This gene, designated *parkin* (or later *parkin2*) contains 12 exons spanning more than 500 kb and encodes a protein of 465 amino acids (molecular weight 51,652 Dalton) with homology to ubiquitin at the N-terminal portion and a RING-finger like motif at the C-terminal portion.

It has been shown, that mutations in the  $\alpha$ -synuclein gene lead to autosomal dominant Parkinson's disease (Polymeropoulos, M. *et al.*, Science 1997; 276: 2045-2047), as well as mutations in the parkin gene cause autosomal recessive juvenile parkinsonism (Kitada, T. *et al.*, Nature 5 1998; 392: 605-608; Hattori, N. *et al.*, Biochem Biophys Res Comm 1998; 249: 754-758)).

Further Hattori, N. *et al.*, have been shown in Ann Neurol 1998; 44: 935-941, that different deletions in the parkin gene are the reason for 10 truncated parkin proteins, causing autosomal recessive juvenile parkinsonism. Especially intragenic deletional mutations, involving exons 3 to 4, exon 3, exon 4 and exon 5, as well as exon 3 through exon 7 are described as effecting the disease. Deletion of exon 3 of the parkin gene is furthermore described by Lücking, C. *et al.* in the Lancet 1998; 352: 15 1355-1356 to cause autosomal recessive juvenile parkinsonism. Investigations of Abbas, N. *et al.* Human Molecular Genetics 1999; 8: 567-574 and Kitada, T. *et al.*, Nature 1998; 392: 805-808 show that mutations in the ubiquitin-like N-terminal part (exon 2) of the parkin gene can also cause autosomal recessive juvenile parkinsonism, as well as different 20 frameshift- or missense mutations.

Leroy, E. *et al.*, demonstrated in Hum Genet 1998; 103: 424-427 that deletions of exons 5, 6 and 7 of the human parkin gene leads to early onset Parkinson's disease. 25

At present most common therapies are dealing with the increase of dopamine content in PD patients via application of L-dopa as precursor of dopamine, dopamine agonists or MAO-B (Monoamino Oxidase B) inhibitors, e.g. Deprenyl, by blocking the degradation of dopamine. There are no prophylac- 30 tic therapies available to stop the progression of the degenerative disease before onset of symptoms in late onset PD. This is due to the fact that at present diagnosis is only possible when first symptoms occur. So

far it is not clear to which extent genetic components enhance the environmental components responsible for the increased cell death of dopaminergic neurons.

- 5 Although different transgenic animal models for neurodegenerative diseases like Alzheimer's disease have been created, a transgenic animal model for Parkinson's disease has not yet been described.

Homologous recombination may be employed for inactivation or alteration of  
10 genes in a site-directed manner. A number of papers describe the use of homologous recombination in mammalian cells, including human cells. Illustrative of these papers are Kucherlapati *et al.* (1984) Proc. Natl. Acad. Sci. USA 81:3153-3157; Kucherlapati *et al.* (1985) Mol. Cell. Bio. 5:714-720; Smithies *et al.* (1985) Nature 317:230-234; Wake *et al.* (1985)  
15 Mol. Cell. Bio. 8:2080-2089; Ayares *et al.* (1985) Genetics 111:375-388; Ayares *et al.* (1986) Mol. Cell. Bio. 7:1656-1662; Song *et al.* (1987) Proc. Natl. Acad. Sci. USA 84:6820-6824; Thomas *et al.* (1986) Cell 44:419-428; Thomas and Capecchi (1987) Cell 51:503-512; Nandi *et al.* (1988) Proc. Natl. Acad. Sci. USA 85:3845-3849; and Mansour *et al.* (1988) Nature  
20 336:348-352. Various aspects of using homologous recombination to create specific genetic mutations in embryonic stem cells and to transfer these mutations to the germline have been described (Evans and Kaufman (1981) Nature 294:154-146; Dotschman *et al.*, (1987) Nature 330:576-578; Thomas and Capecchi (1987) Cell 51:503-512; Thompson *et al.* (1989) Cell 56:316-  
25 321. The combination of a mutant polyoma enhancer and a thymidine kinase promoter to drive the neomycin gene has been shown to be active in both embryonic stem cells and EC cells by Thomas and Capecchi, *supra*, 1987; Nicholas and Berg (1983) in Teratocarcinoma Stem Cell, eds. Siver, martin and Strikland (Cold Spring Harbor Lab., Cold Spring Harbor, N.Y. (pp. 469-  
30 497); and Linney and Donerly, Cell 35:693-699, 1983.



The object of the present application is to provide the suppositions for a test model for neurodegenerative diseases, preferably Parkinson's disease and a valuable tool in the diagnosis and treatment of these conditions, as well as the development of experimental models of Parkinson's disease that  
5 can be used to define further the underlying biochemical events involved in the pathogenesis of this disease.

This object is met by a polynucleotide sequence encoding a mouse parkin2 protein, containing naturally occurring or artificially introduced  
10 mutations or deletions, which cause Parkinson's disease in a human if they occur in the according human sequence, a vector, containing such a sequence, a prokaryotic or eukaryotic cell, containing such a vector and a transgenic non-human animal, whose one or both alleles of a gene encoding a parkin gene are mutated in a way, that a protein with modified,  
15 preferred less activity or no active protein is expressed.

The transgenic non-human animals according to the present invention can be used as models for analysing the symptoms of neurodegenerative diseases or as a model system for testing the efficacy of a treatment for a neuro-  
20 degenerative disease, whereby it is not an object of the present application to provide any method for treating one of the described diseases in a human or animal.

Such models could presumably be employed, in one application, to screen  
25 for agents that alter the degenerative course of Parkinson's disease. For example, a model system of Parkinson's disease could be used to screen for environmental factors that induce or accelerate the pathogenesis. Further an experimental model could be used to screen for agents that inhibit, prevent, or reverse the progression of Parkinson's disease. Presumably,  
30 such models could be employed to develop pharmaceuticals that are effective in preventing, arresting, or reversing Parkinson's disease. Further such models can be used for examination of behaviour during the

development of a neurodegenerative disease, for examination of physiological and molecular biological correlation of the disease, for studies of drug effects and for determination of effective drug doses and toxicity. These applications should be considered as examples and should not limit the application of the models in any way.

The present invention provides model systems of neurodegenerative diseases, preferred Parkinson's disease, wherein the model system comprises a mutated isoform or a fragment of the mouse parkin2 gene (further designated as *mPark2*), a DNA sequence derived from SEQ ID NO: 1 encoding a mouse parkin2 protein corresponding to the human parkin protein encoded by human chromosome gene region 6q25.2-27 ("PARK 2" gene locus). Preferred the model system contains a mutated *mPark2* sequence or a *mPark2* sequence containing any deletion, coding for a mutated or truncated, less active or non-active parkin protein.

The sequence of human  $\alpha$ -synuclein (*parkin1*) gene, as well as human parkin (*parkin2*) gene is known. Human parkin2 gene (further designated as *hPark2*) contains 12 exons, coding for a protein which has in full length 465 amino acids and a molecular weight of 51,652 Daltons.

The present application shows the full length cDNA of *mPark2* in SEQ ID NO:1, consisting of 12 exons, containing the full length open reading frame for the mouse parkin2 protein (SEQ ID NO:4) which coding region consists of 1395 bp, coding for a protein of 464 amino acids with a calculated molecular weight of 51615 Dalton. Further two shorter cDNAs spanning a coding region of 789 bp (SEQ ID NO: 2 (isolated from mouse brain cDNA library by specific PCR)) and 753 bp (SEQ ID NO: 3 (isolated from mouse kidney cDNA library by specific PCR)) corresponding to amino acid sequences of 262 amino acids (SEQ ID NO:5) and 250 amino acids (SEQ ID NO:6) respectively are provided.

During the work of isolation and sequencing of the sequences SEQ ID NO: 1 to 3 shown in this application Shimizu, N. *et al.* submitted a mouse parkin DNA sequence to the EMBL GenBank database, published in July 1999 with the accession number AB019558. The protein sequence of the mouse parkin protein encoded by the published sequence is identical to SEQ ID No: 4.

The present invention refers to polynucleic acid sequences derived from SEQ ID NO: 1, containing naturally occurring or artificially introduced mutations or deletions, which are known to cause Parkinson's disease in a human if they occur in the according human sequence.

The present invention encompasses further polynucleotide sequences containing naturally occurring mutations according to the wobble principle, which represents the degeneration of the genetical code, as well as according to the polymorphism of the genetical code, encoding any protein which has the same or a homologous amino acid sequence as any of the mutated or truncated mouse parkin2 proteins of the present invention.

"Homologous amino acid sequence" in content with the mouse parkin2 protein means in the present application an amino acid sequence, wherein at least 70 %, preferably 80 %, more preferably 90 % of the amino acids are identical to one of the proteins of the present invention and wherein the replaced amino acids preferably are replaced by homologous amino acids. As "homologous" amino acids are designated which have similar features concerning hydrophobicity, charge, steric features etc. Most preferred are amino acid sequences, containing the species-dependent differences of the mouse amino acid sequence compared to human parkin protein shown in the alignment Figure No. 1. The alignment of the corresponding polynucleotide sequences with the exon boundaries is shown in Figure No. 2.

In the whole application for nucleotides and amino acids the usual designations (one-letter ore three-letter code) are used, known by any person skilled in the art.

- 5 The full length polynucleotide sequence of SEQ ID NO:1 or fragments thereof can be obtained by isolation of genomic DNA, containing exons and introns of the mPark2 gene, by RNA transcripts of the DNA or by the preparation of cDNA, containing only the exons of the mPark2 gene. Further the full length sequence as well as fragments thereof may be obtained by  
10 synthetical polymerisation of nucleotides.

- A preferred polynucleotide sequence of the present application is a polynucleotide sequence derived from SEQ ID NO: 1, which is either mutated or in which parts of the sequence are deleted. Mutations, insertions or  
15 deletions may be located 5'upstream of the open reading frame (i.e. in the promotor-region), or they can concern one or more exons of the open reading frame. More preferred is a sequence, containing either a mutated full length sequence or fragments of SEQ ID NO:1, encoding a truncated parkin2 protein (i.e. by mutations leading to a STOP codon or by  
20 deletions) or no protein (i.e. if the mutation or deletion is located in the promoter-region in exon 1).

- More preferred mutations or deletions concern either exon 1, wherein the promotor region is contained, or exon 3 and/or one or more of the other  
25 exons.

- Most preferred the polynucleotide sequence of the present application is selected from SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID  
30 NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17; SEQ ID NO: 18, SEQ ID NO:19 or SEQ ID NO:20 (see also Table 1 and 2).

One of the polynucleotide sequences SEQ ID NO:1 to 3 may be treated *in vitro* or *in vivo* by random or site-directed mutagenesis, by random or site-directed digestion, by recombination or fusion or any other method known of persons skilled in the art to obtain sequences derived from SEQ ID NO:1 containing mutations or deletions leading to a less active or to no parkin protein. Of course a person skilled in the art will understand that the present invention encompasses as well any construction in which parts of or the whole polynucleotide sequence encoding the parkin gene is deleted or replaced by another sequence (i.e. by a sequence encoding an antibioticum-resistance).

To obtain at least a transgenic non-human animal as a model for neurodegenerative diseases, the natural occurring sequence of the parkin gene in this animal may be replaced on one or both alleles of the chromosomes by a sequence of mPark2, containing mutations or deletions according to the present invention. These animals produce either less or less active or no parkin protein.

The transgenic animals of the present invention are created using targeted gene replacement, a sequence by which a specific DNA sequence of interest (target DNA) is replaced by an altered DNA (replacement DNA). The genome of embryonic stem (ES) cells is modified using homologous recombination (Capecchi, Science 1989; 244:1288 and U.S. Pat. No. 5,487,992). The embryonic stem cells are injected in blastocysts as an early state of the developing embryo. The blastocysts are then placed in a pseudopregnant female animal.

Briefly, a vector is constructed that carries the replacement DNA. Both ends of the replacement DNA are flanked by long DNA sequences homologous to the sequences flanking the target DNA. When the vector is introduced into ES cells, the homologous sequences align and recombination may take place. This results in the target DNA being exchanged for the replacement

DNA. The vector is not replicated in the cells and will be lost. The frequency of homologous recombination is low; thus, a screening system is used. The replacement DNA will contain a positive marker sequence, usually a neomycin resistance gene. Thus, any cells that incorporate the replacement DNA by homologous recombination will resist neomycin. By growing cells in medium containing the drug neomycin one can select only those cells containing the replacement DNA. The ES cells containing the replacement DNA are then inserted into recipient mouse blastocysts to create chimeric mice. Chimeras with germ cells derived from the altered ES cells transmit the modified genome to their offspring, yielding mice heterozygous for the target DNA (contain one target DNA and one replacement DNA). The heterozygotes are then bred with each other either to create mice homozygous for the replacement DNA and deficient in the target DNA or to maintain transgenic heterozygotes if the homozygotic mice are not viable.

The DNA will comprise at least a portion of the gene(s) at the particular locus with introduction of a lesion into at least one, usually both copies, of the native gene(s), so as to prevent expression of a functional parkin protein. The lesion may be an insertion, deletion, replacement or combination thereof. When the lesion is introduced into only one copy of the gene being inactivated, the (heterozygote) cells having a single unmutated copy of the target gene are amplified and may be subjected to a second transformation, where the lesion may be the same or different from the first lesion, usually different, and where a deletion, or replacement is involved, may be overlapping at least a portion of the lesion originally introduced. The resulting transformants are screened for the absence of the functional protein of interest and the DNA of the cell may be further screened to ensure the absence of a wild-type target gene. Alternatively, homozygosity as to a phenotype may be achieved by breeding hosts heterozygous for the mutation.

For the construction of a transgenic animal model according to the present application any suitable animal may be employed, however mammals are preferred. More preferred are rodents and most preferred are rats and mice.

5

In the following the single steps of creating the animal models will be described in detail.

Starting from a polynucleotide sequence encoding a parkin gene, preferably  
10 from a sequence encoding a mPark2 gene, more preferably from a sequence according to any of SEQ ID NO:1 to 3, most preferred from SEQ ID NO: 1 a desired mutation, insertion or deletion is introduced to the sequence. Methods to create mutations by random or site-directed mutagenesis or desired insertions or deletions by random or site-directed digestion  
15 and/or replacement are commonly known to persons skilled in the art and broadly described in the literature. The method how a mutation, insertion or deletion is introduced in the sequence is not relevant, however falls under the scope of the present invention, as long as any of the later described nucleotides, amino acids or sequences are involved.

20

The constructs may be modified to include functional entities other than the mutated sequence which may find use in the preparation of the construct, amplification, transformation of the host cell, and integration of the construct into the host cell.

25

The homologous sequence for targeting the construct may have one or more deletions, insertions, substitutions or combinations thereof. For example, the mPark2 gene may include a deletion at one site and an insertion at another site which includes a gene which may be used for selection, where  
30 the presence of the inserted gene will result in a defective inactive protein product. Preferably, substitutions are employed. For an inserted gene, of particular interest is a gene which provides a marker, e.g.,

antibiotic resistance such as neomycin resistance, including G418 resistance.

- The deletion will be at least about 50 bp, or more usually at least about 100 bp, and generally not more than about 20 kbp, where the deletion will normally include at least a portion of the coding region including a portion of or one or more exons, a portion of one or more introns, and may or may not include a portion of the flanking non-coding regions, particularly the 5'-non-coding region (transcriptional regulatory region).
- Thus, the homologous region may extend beyond the coding region into the 5'-non-coding region or alternatively into the 3'-non-coding region. Insertions will generally not exceed 10 kbp, usually not exceed 5 kbp, generally being at least 50 bp, more usually at least 200 bp.
- The homologous sequence should include at least about 100 bp, preferably at least about 150 bp, more preferably at least about 300 bp of the target sequence and generally not exceeding 20 kbp, usually not exceeding 10 kbp, preferably less than about a total of 5 kbp, usually having at least about 50 bp on opposite sides of the insertion and/or the deletion in order to provide for double crossover recombination.

- Upstream and/or downstream from the target gene construct may be a gene which provides a tool to select out primary random integration of the construct in the genome. For this purpose, the herpes simplex virus thymidine kinase gene may be employed, since the presence of the thymidine kinase gene may be detected by the use of nucleoside analogs, such as Gancyclovir or Acyclovir, for their cytotoxic effects on cells that contain a functional HSV-tk gene. The absence of sensitivity to these nucleoside analogs indicates that homologous recombination has occurred.

30

The presence of the marker gene inserted into the gene of interest establishes the integration of the target construct into the host genome.



However, DNA analysis might be required in order to establish whether homologous or non-homologous recombination occurred. This can be determined by employing probes for the insert and then sequencing the 5' and 3' regions flanking the insert for the presence of the gene of interest extending beyond the flanking regions of the construct or identifying the presence of a deletion, when such deletion is introduced.

The polymerase chain reaction (PCR) may be used, with advantage in detecting the presence of homologous recombination (Kim and Smithies, (1988) Nucleic Acid Res. 16:8887-8903; and Joyner et al (1989) Nature 338:153-156). Primers may be used which are complementary to a sequence within the construct, usually complementary to the selection marker gene, and complementary to a sequence outside the construct and at the target locus. In this way, one can only obtain DNA duplexes having both of the primers present in the complementary chains in homologous recombination has occurred. By demonstrating the presence of the primer sequences or the expected size sequence, the occurrence of homologous recombination is supported. Any person skilled in the art knows how to determine the suitable PCR primers and conditions.

The construct may further include a replication system which is functional in the mammalian host cell. For the most part, these replication systems will involve viral replication systems, such as Simian Virus 40, Epstein-Barr virus, papilloma virus, adenovirus and the like.

Where a marker gene is involved, as an insert, and/or flanking gene, depending upon the nature of the gene, it may have the wild-type transcriptional regulatory regions, particularly the transcriptional initiation regulatory region or a different transcriptional initiation region. Whenever a gene is from a host where the transcriptional initiation region is not recognized by the transcriptional machinery of the mammalian host cell, a different transcriptional initiation region

will be required. This region may be constitutive or inducible, preferably inducible. A wide variety of transcriptional initiation regions have been isolated and used with different genes. Of particular interest as promoters are the promoters of metallothionein-I and II from a mammalian host, thymidine kinase, beta-actin, immunoglobulin promoter, human cytomegalovirus promoters, and SV40 promoters. In addition to the promoter, the wild-type enhancer may be present or an enhancer from a different gene may be joined to the promoter region.

- 10 The construct may further include a replication system for prokaryotes, particularly *E. coli*, for use in preparing the construct, cloning after each manipulation, allowing for analysis, such as restriction mapping or sequencing, followed by expansion of a clone and isolation of the plasmid for further manipulation. When necessary, a different marker may be  
15 employed for detecting bacterial transformants.

Once the vector has been prepared, it may be further manipulated by deletion of the bacterial sequences as well as linearisation, where a short deletion may be provided in the homologous sequence, generally not exceeding about 500 bp, generally being from about 50 to 300 bp. The small deletion will generally be near one or other end of the targeted structural gene.

The construction of the desired polynucleotide sequence may be carried out in a cloning vector and linearised prior to the transfection of ES cells. A broad range of cloning vectors as well as vectors for the homologous recombination are commercially available and may be selected according to the desired construction.

- 30 Cloning vectors are usually replicated in prokaryotic cells, which renders the selection and multiplication of the desired construct. It is not

critical which prokaryotic organism is used, but usually E.coli or a yeast strain is preferred.

E. coli is one prokaryotic host useful particularly for cloning the DNA sequences of the present invention. Other microbial hosts suitable for use include bacilli, such as *Bacillus subtilis*, and other enterobacteriaceae, such as *Salmonella*, *Serratia*, and various *Pseudomonas* species. In these prokaryotic hosts, one can also make expression vectors, which will typically contain expression control sequences compatible with the host cell (e.g., an origin of replication). In addition, any number of a variety of well-known promoters will be present, such as the lactose promoter system, a tryptophan (trp) promoter system, a beta-lactamase promoter system, or a promoter system from phage lambda. The promoters will typically control expression, optionally with an operator sequence, and have ribosome binding site sequences and the like, for initiating and completing transcription and translation.

Other microbes, such as yeast, may also be used for expression. *Saccharomyces* is a preferred host, with suitable vectors having expression control sequences, such as promoters, including 3-phosphoglycerate kinase or other glycolytic enzymes, and an origin of replication, termination sequences and the like as desired.

Homologous recombination may be used to insert a mutant sequence into a host genome at a specific site, for example, at a host parkin locus. In one type of homologous recombination, one or more host sequence(s) are replaced; for example, a host parkin allele (or portion thereof) is replaced with a mutant parkin allele (or portion thereof). In addition to such gene replacement methods, homologous recombination may be used to target a mutant parkin allele to a specific site other than a host parkin locus. Homologous recombination may be used to produce transgenic non-human animals and/or cells that incorporate mutant parkin alleles.

Further to the above described techniques a step of expressing the treated sequence may be inserted in the expiration. Therefore the construct is (sub)cloned into any expression vector, which may be brought into a suitable eukaryotic cell. These expression vectors are typically replicable in the host organisms either as episomes or as an integral part of the host chromosomal DNA. Commonly, expression vectors will contain selection markers, e.g., tetracycline resistance or hygromycin resistance, to permit detection and/or selection of those cells transformed with the desired DNA sequences. Polynucleotides encoding a variant parkin2 polypeptide may include sequences that facilitate transcription (expression sequences) and translation of the coding sequences, such that the encoded polypeptide product is produced. Construction of such polynucleotides is well known in the art and is described further in Maniatis et al. *Molecular Cloning: A Laboratory Manual*, 2nd Ed. (1989), Cold Spring Harbor, N.Y. For example, but not for limitation, such polynucleotides can include a promoter, a transcription termination site (polyadenylation site in eukaryotic expression hosts), a ribosome binding site, and, optionally, an enhancer for use in eukaryotic expression hosts, and, optionally, sequences necessary for replication of a vector.

Any suitable eukaryotic cell may be used, but insect cells or mammalian cells as primary cells or immortalized cell lines are preferred.

A number of suitable host cell lines capable of secreting intact human proteins have been developed in the art, and include the CHO cell lines, various COS cell lines, HeLa cells, myeloma cell lines, Jurkat cells, etc. Baculovirus expression systems are useful for high level expression of heterologous genes in eukaryotic cells. Knops et al. (1991) *J. Biol. Chem.* 266(11):7285. Expression vectors for these cells can include expression control sequences, such as an origin of replication, a promoter, an enhancer (Queen et al. (1986) *Immunol. Rev.* 89:49, and necessary

processing information sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites, and transcriptional terminator sequences. Preferred expression control sequences are promoters derived from immunoglobulin genes, SV40, Adenovirus, Bovine Papilloma Virus, and the like. The vectors containing the DNA segments of interest can be transferred into the host cell by well-known methods, which vary depending on the type of cellular host. For example, calcium chloride transfection is commonly utilized for prokaryotic cells, whereas calcium phosphate treatment, microinjection of DNA into the nucleus or electroporation may be used for other cellular hosts. (See, generally, Maniatis, et al. Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup>. Ed. Cold Spring Harbor Press, (1989). The DNA may be single or double stranded, linear or circular, relaxed or supercoiled DNA. For various techniques for transforming mammalian cells, see Keown et al., Methods in Enzymology (1990) 185:527-537.

For the creation of an animal model according to the present invention each polynucleotide sequence can be used, containing mutations, insertions or deletions which are known to cause Parkinson's disease in a human, when they occur in the corresponding human sequence. Preferred polynucleotide sequences for the creation of an animal model according to the present invention are those which mutations are shown in table 2. More preferred are polynucleotide sequences containing mutations or deletions shown in table 1. The most preferred polynucleotide sequence for the construction of a transgenic animal of the present invention is SEQ ID NO: 7. Further enclosed to the present invention is an animal model wherein the parkin sequence is replaced by an according sequence of another mammal (i.e. by the human sequence, containing one of the mutations, insertions or deletions described in the present application) or by a sequence encoding a marker, i.e. an antibioticum.

Table 1: Mutations or deletions in mPark2 cDNA (SEQ ID NO:1)

Position in SEQ ID NO:1	Replacement (DNA)	Replacement (protein)	SEQ ID NO (DNA seq)	SEQ ID NO (prot seq)
NT 300-540	Exon3	Frameshift, Truncation	7	21
NT 300-659	Exon3-4	ORF, deletion of 121 aa	8	22
NT 300-996	Exon3-7	Frameshift, Truncation	9	23
NT 541-659	Exon 4	Frameshift, Truncation	10	24
NT 659-744	Exon 5	Frameshift, Truncation	11	25
NT 660-996	Exon 5-7	Frameshift, Truncation	12	26
NT 996-1208	Exon 8-9	Frameshift, Truncation	13	27
NT: 229-230 (aa 34)	deletion AG	Gln→Stop at aa 38, nonsense	14	28
NT: 282 (aa 52)	deletion A	Asn→Stop at aa 54, nonsense	15	29
NT: 350-351 (aa 74)	deletion AG	Arg→Stop at aa 78, nonsense	16	30
NT: 136-299	Exon 2	Frameshift, Truncation	17	31

aa = amino acid

NT = nucleotide

Table 2: Replaced amino acids in mPark2 cDNA (SEQ ID NO:1)

Position in SEQ ID NO:1	Replacement (DNA)	Replacement (protein)	SEQ ID NO (DNA seq)	SEQ ID NO (prot seq)
NT: 608	G→T,	Lys→Asn (aa 161)	18	32
NT: 1369	C→A,	Thr→Asn (aa 415)	19	33
NT: 1483	G→A,	Trp→Stop (aa 453)	20	34

aa = amino acid

5 NT = nucleotide

Once the construct has been prepared and manipulated, the DNA is isolated from the procaryotic host according to any method known in the art. Before the DNA construct is introduced into the target cells for homologous

10 recombination undesired sequences may be removed from the vector, e.g. the undesired bacterial sequences. As target cells an embryonic stem (ES) cell line may be used. As already indicated above for the expression system, any convenient technique for introducing the DNA into the target cells may be employed. After transformation of the target cells, many target cells  
15 are selected by means of positive and/or negative markers, as previously indicated, neomycin resistance and Acyclovir or Gancyclovir resistance. Those cells which show the desired phenotype may then be further analyzed by restriction analysis, electrophoresis, Southern analysis, polymerase chain reaction or the like. By identifying fragments which show the  
20 presence of the lesion(s) at the target gene site, one can identify cells in which homologous recombination has occurred to inactivate the target gene.

For embryonic stem cells, after mutation, the cells may be plated onto a  
25 feeder layer in an appropriate medium, e.g., fetal bovine serum enhanced DMEM. Cells containing the construct may be detected by employing a selective medium and after sufficient time for colonies to grow, colonies

may be picked and analyzed for the occurrence of homologous recombination. As described previously, the polymerase chain reaction may be used, with primers within and without the construct sequence but at the target locus. Those colonies which show homologous recombination may then be used for

5 embryo manipulating by blastocyst injection. Blastocysts may be obtained from 4 to 6 week old superovulated females by flushing the uterus 3.5 days after ovulation. The embryonic stem cells may then be trypsinized and the modified cells added to a droplet containing the blastocysts. At least

10 one, usually at least about 10, and up to about 15 of the modified embryonic stem cells may be injected into the blastocoel of the blastocyst. After injection, at least one and not more than about 15 of the blastocysts are returned to each uterine horn of pseudopregnant females. Alternatively, any of the common techniques, i.g. microinjection of the mutated gene, or a fragment thereof, into a one-cell embryo

15 followed by incubation in a foster mother can be used.

The pups will usually be born 16-18 days after introduction of the blastocysts into foster mothers. Chimeric animals will be mated with wild type (wt) mice to create heterozygote transgenics.

20 With these methods it is possible to obtain transgenic non-human animals, whose one or both alleles of a gene encoding a parkin gene are mutated in a way, that a parkin protein with modified, preferred less activity or no active parkin protein is expressed.

25 "Mutated" means in this content replacements, insertions or deletions of nucleotides or polynucleotide sequences.

In consequence of the mutated parkin gene these animals produce a mutated

30 or truncated parkin protein or no parkin protein. Preferred - if a parkin protein is expressed - the parkin protein expressed by the transgenic animal contains any of the mutations or deletions shown in table 1 and 2,



represented by any of the proteins with an amino acid sequence of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34 or naturally occurring or artificially introduced mutants with a homologous protein sequence or fragments thereof, particularly preferred a parkin protein with a sequence according to SEQ ID NO:21 is expressed.

The expression of one of these proteins or no parkin protein in the transgenic non-human animals causes these animals to display features of a neurodegenerative disease. These features can be manifested in developing physiological, biochemical or molecular biological modifications in e.g. cells, tissues, organs or neuronal structures.

In accordance with standard protocols, cultured eukaryotic cells, either primary cultures or immortalised cell lines, may be transfected, either transiently or stably, with a mutant or fragmented mPark2 allele so that the cultured eukaryotic cell expresses a mutant parkin2 polypeptide.

The present application further refers to cells, typically mammalian cells and preferably mammalian cells of the neural, glial, or astrocytic lineage, that have been transformed or transfected with any DNA sequence according to the present invention, as well as to any cells which have been derived from a transgenic non-human animal, whereby the cells express any of the mutated parkin2 proteins isoforms according to the present invention, preferred any of the isoforms shown in table 1 or 2 or fragments thereof, or they contain a parkin sequence which is mutated in a way that they don't express a parkin protein. The cells derived from the transgenic animals may be cultured as cell-lines or as primary cultures.

Once established, all such cell lines can be grown continuously in culture and may be used for a variety of in vitro experiments to study parkin expression and processing.

- 5 The present invention further refers to a method of producing transgenic non-human animals and transformed cells that contain any polynucleotide sequence encoding any mutant mouse parkin2 protein isoform according to the present invention, preferably such as shown in table 1 or 2 or naturally occurring or artificially introduced mutants or fragments  
10 thereof.

- Preferred the above described polynucleotide sequences, the proteins and amino acid sequences as well as the transgenic animal models and cell lines may be used for any method for analysing the symptoms of  
15 neurodegenerative diseases.

- Such neurodegenerative diseases encompass among others Parkinson's disease, Alzheimer's disease, Huntigton's disease, amyotrophic lateral sclerosis, Multisystem atrophy, Wilson's disease, Pick's disease, Prion  
20 disease, or second causes inducing Parkinson's syndromes like toxins (e.g. Mn, Fe, 6-hydroxydopamine, MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), CO), drugs, brain tumors, head trauma, stroke, vascular irregularities, or metabolic irregularities.

- 25 Enclosed to these methods are methods outside of a living body, which are methods of molecular biology like PCR, Southern and Northern blot analysis, construction of DNA or RNA probes, as well as Western blot analysis, preparation of epitopes from the protein or amino acid sequences mentioned in this application, production of monoclonal and polyclonal  
30 antibodies. These methods may be used for screening of samples, preferred of biological fluids for either the expression of parkin protein as a method for detecting the presence of the protein, or in a nucleic acid

sample or another sample removed from a subject, the presence of the gene for Parkinson's disease comprising identifying a genetic alteration in a gene sequence coding for parkin. Further enclosed are pathobiochemical, immunobiological and neurological as well as histochemical methods carried out after sacrificing the animal for considering the effects of neurodegenerative diseases, particularly Parkinson's disease to the living body. Further methods for locating the presence of genetic alterations associated with Parkinson's disease are provided. These methods may be used outside of a living body to predict the development of the disease prior to onset or for genetic screening.

However, particularly preferred is a method of testing the efficacy of a treatment for a neurodegenerative disease associated with a less active or non-active parkin protein, comprising subjecting any of the created transgenic animals as a model to a putative treatment and determining the efficacy of said treatment.

These testing methods preferably comprise administering an active substance, whose effect can be determined by any of the above described methods, to a transgenic animal according to the present invention.

By the use of the transgenic animals described in the present application it is possible the first time to test in a model system whether an active substance is useful for treating a condition associated with non-active parkin protein and determining a level of the active substance, which causes an effect in treating the disease.

Treatments may carried out as single dose applications, but it is preferred to use the transgenic animals in long-time experiments with multiple dose applications.

The transgenic animals of the present application may be particularly used as model systems for screening for drugs and evaluating drug effectiveness. Additionally, such model systems provide a tool for defining the underlying biochemistry of neurodegenerative diseases, which thereby provides a basis for rational drug design. The models may be used further for studies of behaviour, physiological and molecular biological examinations, pharmacological and toxicological studies and several other applications.

10 Having detected the genetic mutation in the gene sequence coding for parkin protein in an individual not yet showing overt signs of Parkinson's disease, using any of the methods of the present invention, it may be possible to employ gene therapy, in the form of gene implants, to prevent the development of the disease.

15 Additional embodiments directed to modulation of the production of variant parkin proteins include methods that employ specific antisense polynucleotides complementary to all or part of a variant parkin sequence according to any of the sequences mentioned in this application, or for  
20 some embodiments a wild-type parkin sequence. Such complementary antisense polynucleotides may include nucleotide substitutions, additions, deletions, or transpositions, so long as specific hybridisation to the relevant target sequence is retained as a property of the polynucleotide. Thus, an antisense polynucleotide must preferentially bind to a variant  
25 parkin sequence as compared to a wild-type parkin. It is mostly preferred that the antisense polynucleotide reflects the exact nucleotide sequence of the variant allele (or wild-type allele where desired) and not a degenerate sequence.

30 Complementary antisense polynucleotides include soluble antisense RNA or DNA oligonucleotides which can hybridise specifically to a variant parkin mRNA species and prevent transcription of the mRNA species and/or

translation of the encoded polypeptide (Ching et al. (1989) Proc. Natl. Acad. Sci. U.S.A. 86:10006; Broder et al. (1990) Ann. Int. Med. 113:604; Loreau et al. (1990) FEBS Letters 274:53-56); Holcenberg et al. W091/11535; U.S. Pat. No. 7,530,165 ("New human CRIPTO gene"--publicly available through Derwent Publications Ltd., Rochdale House, 128 Theobalds Road, London, UK); W091/09865; W091/04753; W090/13641; and EP 386563, each of which is incorporated herein by reference). The antisense polynucleotides therefore inhibit production of the variant parkin polypeptides.

10

Antisense polynucleotides may be produced from a heterologous expression cassette in a transfectant cell or transgenic cell or animal, such as a transgenic neural, glial, or astrocytic cell, preferably where the expression cassette contains a sequence that promotes cell-type specific expression (Wirak et al. loc. cit.). Alternatively, the antisense polynucleotides may comprise soluble oligonucleotides that are administered to the external milieu, either in the culture medium in vitro or in the circulatory system or interstitial fluid in vivo. Soluble antisense polynucleotides present in the external milieu have been shown to gain access to the cytoplasm and inhibit translation of specific mRNA species. In some embodiments the antisense polynucleotides comprise methylphosphonate moieties. For general methods relating to antisense polynucleotides, see Antisense RNA and DNA, (1988), D. A. Melton, Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.).

25

Legends to the figures:

Figure 1 shows the alignment of the deduced amino acid sequences of the human and mouse Parkin2 protein (SEQ ID NO: 4).

Underlined are the conserved ubiquitin like (at the N-terminus) and Ring finger like (at the C-terminus) regions of both proteins.

Figure 2 shows the alignment of the nucleotide sequences of the human and mouse parkin 2 gene. Bold lines represent the exon boundaries identified for the human and mouse sequence.


- 5 Figure 3 represents a flow chart of the cloning procedure of the mouse parkin2 gene - exon3 knock-out construct.

Abbreviations:

a) Restriction endonucleases:

N = NotI, E= Eco RI, B= BamHI, H= HindIII, X= XbaI.

- 10 b) Modifications: ()= T4 DNA polymerase treatment in order to remove a restriction site in the resulting plasmid.

c)  pBluescript KSII (Stratagene) vector sequence

 =  $\lambda$ -Fix vector sequence

d) HSV-tk = herpes simplex promotor and thymidine kinase gene

- 15 e) kb = kilobases

The following examples are provided for illustration and are not intended to limit the invention to the specific example provided.

## 20 Example 1

Isolation of mouse Parkin2 cDNA clones:

- 25 Arrayed mouse brain and mouse kidney cDNA libraries (Biofrontera Pharmaceuticals/ Bio Systems) were screened by PCR under standard conditions using the primers Ex2s:*tcaggttcaactccagctatggc* and Ex2as:*tgccctgcgaaaatcacacgcagc* . The cycle conditions were the following: 3 min. 95°C, (30sec. 95°C, 30sec. 56°C, 1min. 72°C) x 35 cycles.

Single colonies containing the mPark2 genes were verified by colony hybridisation according to the protocol described by Maniatis *et al.* 1989 (see above).

5 Construction of the Del Exon3 parkin gene (according to SEQ ID NO: 7)

All the further described cloning steps are shown in Figure 3. A genomic lambda ZIP clone (genomic mouse  $\lambda$ -Fix library, Stratagene) containing the exon 3 of the parkin gene was isolated by PCR using exon3 specific primer  
10 of the mPark2 gene. A 3.1 kb BamHI/HindIII fragment of the lambda ZIP clone containing genomic DNA 3' end to the exon3 of mPark2 was cloned into the cloning vector pBluescript KS (Stratagene) to obtain the plasmid pmPark2-BH. Secondly, a 5 kb HindIII/EcoRI genomic DNA fragment was inserted into the HindIII site of the pmPark2-BH-clone. The EcoRI and  
15 HindIII sites were destroyed by T4 DNA polymerase treatment. As result the plasmid pmPark2-BE- with a 8.1 kb long genomic region to the 3'-end of the exon 3 could be obtained.

A 2.0 kb XbaI/XhoI (the XbaI restriction site is located within the  
20 multiple cloning sequence (mcs) of Lambda Fix) genomic DNA fragment containing the genomic region 5' to the exon3 was cloned into the EcoRI site of the pNeoloxp-vector (Giese *et al.* Science, 1998, 279:870-3 ) after generation of blunt ends by T4 DNA polymerase treatment. The BamHI-site (5'-to the EcoRI-site) of this vector was used subsequently for the  
25 insertion of the 2.5 kb HSV-tk-marker gene. Again T4 DNA polymerase was used to generate blunt ends before ligation in order to eliminate the used cloning site. The resulting vector was digested with the restriction enzymes NotI and XhoI to obtain a 6.5 kb fragment containing the HSV-tk, the 2kb XhoI/XbaI genomic region to 5'-end of exon3, and the neo-marker.  
30 The vector pmPark2-BE was digested with XhoI to linearise the plasmid. Both the isolated 6.5 kb fragment as well as the linear vector were

treated with T4 DNA polymerase prior to ligation to eliminate the used restriction sites.

This plasmid pmPark2del-ex3 was linearised with the restriction enzyme  
5 NotI prior to transfection into ES cells.

## Example 2

### Transfection of ES cells:

10

#### Isolation and Freezing of the ES cells:

14 days old embryos were isolated, head and organs were removed from embryos, the remaining tissue was minced, and washed with 1x PBS. 1x trypsin (0,5g/l) / EDTA (0,2g/l) was used for dissolve the tissue by  
15 incubating them at 37°C for 5 min. The reaction was stopped by adding 1 vol. EF medium (Embryonic Feeder medium: 1x DMEM, 10% FCS Serum, 2mM Glutamine, all obtained from LIFE Technologies), and cells were dissolved by pipetting several time up and down. The supernatant was centrifuged with 1000 rpm for 5 min. The fibroblasts from one embryo were seeded into  
20 a 175 cm<sup>2</sup> flask with 30 ml medium. The medium was changed after 24 h. When the fibroblasts form a confluent monolayer they were splitted 1:3, and thereafter they were frozen when the cells are confluent again. Cells from 175 cm<sup>2</sup> flask were frozen into one tube. Therefore first empty tubes are  
25 place on ice, freezing medium is added (EF medium + 20% DMSO (Dimethylsulfoxid)), cells with 0.5 ml EF medium are added, mixed, putted in a styrofoam box, which is cooled down in a -80°C freezer, and the next day the tubes are transferred into liquid N<sub>2</sub>(l) tank.

#### Sub-culturing, inactivation and feeder layer:

30 The fibroblasts can be cultured on gelatine-coated plastic ware. The cells were splitted carefully 1:3 after 3 days. When feeder layer are needed for ES cell culturing, the fibroblasts should be division-inactivated by



mitomycin C. 2 mg mitomycin C are dissolved in 10 ml PBS, which can be stored at -20°C. This stock solution is diluted 1:20 with EF medium for inactivation; the nearly confluent fibroblasts in a 175 cm<sup>2</sup> flask are incubated in 20-30 ml of medium with mitomycin C for 2 h at 37°C.

- 5 Mitomycin C is then removed by 2x washing with PBS, and the inactivated fibroblasts are recovered in EF medium for 24 h before they are frozen or used for ES cell culturing after a few days. The cells are stored 37°C until they are used (maximally 10 days;) or they are frozen. For feeder layer, plate cells onto the same area; here the plastic ware has to be  
10 coated by gelatine.

Sub-culturing the ES-cells:

- The ES cells were kept for 2-4 passages in culture. The medium is ES medium (1x DMEM, 15% FCS Serum, 2mM Glutamine, 1x nonessential amino  
15 acids, 7µl B Mercaptoethanol, with supplement containing LIF (Leukemia Inhibitory Factor, 2.5x10<sup>5</sup> to 10<sup>6</sup> U/l), all obtained from LIFE Technologies), and the cells are splitted 1:6 every second day. Cells were refedeed 2 h before passaging.

## 20 Stable Transfection of ES Cells

- After digestion of the gene targeting construct the DNA is extracted with phenol/CHCl<sub>3</sub> (24/23) and precipitated with EtOH (wash 2x with 75% EtOH); the rest of EtOH is removed carefully and air dried for approx. 15 min under steril conditions (laminar flow). The DNA is suspended in H<sub>2</sub>O (final  
25 conc.: 3 mg/ml). 5x10<sup>7</sup> cells of a monolayer are treated with 1x trypsin to detach them from the ground of the flask, suspended in 0.8 ml medium and electroporated with DNA (30 µg linear DNA, 800 V, 3 µF, BioRad Gene Pulser). After 20 min at 4°C, cells are diluted with 9.5 ml medium and are plated onto dishes (9 cm diameter). 24 h after electroporation G418 (150-  
30 175 mg /ml) is added to start selection. The medium is changed every day; after 7-9 days of selection colonies can be picked.

Picking colonies and culturing of picked colonies:

24 colonies were picked with Eppendorf tips under an inverted microscope. The colonies were transferred into the wells of a 96-well plate (round bottom), 30  $\mu$ l 1xtrypsin/EDTA are added, and the plates are incubated 10 min at 37°C. Thereafter 100  $\mu$ l ES-medium are added and the cells are suspended by pipetting up and down 12x with a multichannel pipette. The trypsinized cells are solitarily plated into a 24-well plate. The medium is exchanged every 24 h. 3-4 days after picking the cells are detached from the ground of the plates. Therefore the medium is removed, 60  $\mu$ l 1xtrypsin/EDTA are added and the plates are incubated for 7 min at 37°C. The treatment is stopped by adding 200  $\mu$ l medium and the cells are resuspended. 200  $\mu$ l of the cell suspension is added to 200 ml medium with 20 % DMSO and the cells are frozen as described above.

### 15 Example 3

DNA isolation and southern blot analysis for control and identification of picked colonies:

To characterize the clones, picked in example 2, DNA is isolated from the cells and examined. Therefore 500  $\mu$ l medium are added into any well of a picked colony which should still contain 60  $\mu$ l cell suspension (see example 2). The cells are cultured continuously 3-4 days until confluent for DNA isolation. 500  $\mu$ l lysis buffer (12 ml 1 M Tris-HCl (pH 8.3); 1.2 ml 0.5 M EDTA; 2.4 ml 10 % SDS; 4.8 ml 5 M NaCl; 1.2 ml 10 mg/ml proteinase K; 98.4 ml H<sub>2</sub>O) is added, and it is incubated over night at 55°C. DNA is precipitated by adding 1 vol. 2-propanol and at least 15 min shaking at RT, and transferred with an Eppendorf tip into a 1.5 ml tube with 1 ml 70% EtOH. The tube is centrifuged for 10 min at RT to spin down the DNA. EtOH is removed and pellets are air dried for least one hour. DNA is dissolved afterward in 100  $\mu$ l TE for over night at 55°C.

Southern blot analysis:

1/3 of the isolated DNA was used for one digestion. The digestion was carried out for over night at 37°C. Loading buffer was added, and DNAs are separated in an agarose gel for least 6 hours. The gels were incubated in 0.2 N HCl for 15 min at room temperature; after 15 min HCl solution was  
5 replaced by 0.4 N NaOH and the gel was incubated therein for 15 min at RT. The DNA was transferred onto nylon membranes (Amersham) over night using 0.4 N NaOH as transfer buffer using a vacuum blot machine (Stratagene). The membranes were neutralized in 2x SSC for 1 min, and air dried for least one hour. After UV-Crosslinking the DNA onto the membrane  
10 hybridisation with DNA probes (probes are shown in figure 3) was carried out under standard conditions (QuickHyb from Clontech, 65°C, wash twice with 2x SSC, 0.1 % SDS at 65°C).

#### Production of transgenic animals with mutant parkin allele:

15 10-15 recombinant ES cells are injected into blastocysts. The blastocysts are implanted in pseudopregnant mice. The chimeric spring offs are crossed with wild type mice to obtain heterocytotic recombinant F1 mice. These mice are analysed by southern blot analysis as described above. Transgenic  
20 mice are crossed with each other to obtain mice with both alleles modified (homozygote animals).

Descendants of the transgenic animals may be used for breeding with mice strains representing the same or any other genotype, preferred mice  
25 strains showing neurological abnormalities, more preferred with strains showing neurodegenerative abnormalities. These other mouse strains may be selected from wild type mice, mice containing knock-ins or knock-outs, mice containing mutants of genes or mice which overexpress any gene product. The most preferred partners for breeding are mice which represent  
30 a model for Alzheimer's disease, Huntigton' disease, amyotrophic lateral sclerosis, Multisystem atrophy, Wilson's disease, Pick's disease or Prion disease.

### Use of Transgenic Mice:

The animal can be used to test potential therapeutic agents. The test  
5 group of mice is treated with the test compound administered in an  
appropriate fashion for a set period. At the conclusion of the test  
period, the animals are assessed behaviourally, biochemically, and  
histologically for any possible effects of the test compound. The exact  
10 protocol depends on the anticipated mechanism of action of the test  
compound. Compounds that may have utility in treating Parkinson's disease  
can be identified using this approach.

Such analysis can be carried out in the animal ,in primary tissue cultures  
of the expressing cells or in immortalised cells derived from those  
15 animals.

Mice expressing the truncated parkin2 protein gene or variants of the  
described one can be used for testing the development of Parkinson's  
disease during ageing of the animals. Beside the enhanced progression of  
20 cell death in substantia nigra area, increased sensitivity to selective  
neurotoxins like MPTP or 6-hydroxydopamine and enhanced response to  
dopaminergic precursors like L-dopa may be examined.

## Claims

1. A polynucleotide sequence encoding a mouse parkin2 protein, containing naturally occurring or artificially introduced mutations or deletions,  
5 which cause Parkinson's disease in a human if they occur in the according human sequence.
2. The sequence of claim 1, wherein the sequence is genomic DNA, coding for a full-length parkin gene or fragments thereof, cDNA of a full  
10 length parkin gene or fragments thereof, or RNA of a full length parkin gene or fragments thereof.
3. The sequence of claim 1 or 2, wherein the sequence is selected from the group, consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:7 SEQ ID NO:8,  
15 SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20 or naturally occurring or artificially introduced mutants or fragments thereof.
- 20 4. A vector, containing any sequence according to any of claims 1 to 3.
5. A prokaryotic or eukaryotic cell, containing a vector according to claim 4.
- 25 6. The cell of claim 5, characterised in that the cell is selected from bacterial or yeast cells, insect cells or mammalian cells as primary cells or immortalised cell lines.
7. A parkin mouse protein with an amino acid sequence of SEQ ID NO:5, SEQ  
30 ID NO:6 SEQ, ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34 or

naturally occurring or artificially introduced mutants with a homologous protein sequence or fragments thereof.

8. A transgenic non-human animal, whose one or both alleles of a gene encoding a parkin gene are mutated or truncated in a way, that a protein with modified, preferred less activity or no active protein is expressed.
9. The transgenic animal of claim 8, wherein the parkin gene has any mutation or deletion which are known to cause Parkinson's disease in a human if they occur in the according human sequence.
10. The transgenic non-human animal of claim 8 or 9, carrying a mutation or deletion in one or both alleles of a gene encoding a parkin protein, such that expression of said parkin gene produces a mutated or truncated protein or no protein, which causes said animal to display any physiological, biochemical or molecular biological features of a neurodegenerative disease.
11. The transgenic non-human animal of claim 10, carrying a deletion in one or both alleles of any of the exons of the gene encoding the parkin protein.
12. The transgenic non-human animal of any of claims 8 to 11, carrying a DNA sequence according to any of the sequences SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:7 SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19 or SEQ ID NO:20.
13. A mammalian cell-line transformed or transfected with any sequence according to any of claims 1 to 3 or a vector according to claim 4 or

cell lines or primary cultures derived from the transgenic animal of any of claims 8 to 12.

14. A method of producing a transgenic animal according to any of claims  
5 8 to 12 or a cell line according to claim 13.

15. Use of the transgenic non-human animal according to any of claims 8  
to 12 or a cell line according to claim 13 as a model for  
neurodegenerative diseases.

16. A method for analyzing the symptoms of neurodegenerative diseases,  
either outside of a living body using any of the polynucleotide  
sequences of any of claims 1 to 4, any of the protein sequences of  
claim 7, or using any model according to claim 15.

17. A method for testing the efficacy of a treatment for a  
neurodegenerative disease associated with a less active or non-active  
parkin protein, comprising subjecting any model of claim 15 to a  
putative treatment and determining the efficacy of said treatment.

18. The method according to claim 16 or 17, wherein said  
neurodegenerative disease is selected from the group consisting of  
Parkinson's disease, Alzheimer's disease, Huntigton's disease,  
amyotrophic lateral sclerosis, Multisystem atrophy, Wilson's disease,  
25 Pick's disease, Prion disease, or second causes inducing Parkinson's  
syndromes like toxins, drugs, brain tumors, head trauma, stroke,  
vascular irregularities, or metabolic irregularities.

19. The method of any of claims 17 to 19, wherein said treatment  
30 comprises administering an active substance to the model.

20. Use of any model according to claim 15 for testing whether an active substance is useful for treating a condition associated with non-active parkin protein comprising administering said active substance to the transgenic animal of any of claims 8 to 12 or a cell-line of claim 13, and determining a level of the active substance, which causes an effect in treating the disease.

21. Use of the animal according to any of claims 8 to 12 as a model for examination of behaviour during the development of a neurodegenerative disease, or any model according to claim 15 for examination of pathobiochemical, immunobiological, neurological as well as histochemical effects of neurodegenerative diseases, physiological and molecular biological correlation of the disease, for studies of drug effects and for determination of effective drug doses and toxicity.

22. Descendant of the transgenic animal according to any of claims 8 to 12, obtained by breeding with the same or any other genotype.



hpARK2 mpARK2	1 1	10 10	20 20	30 30	40 40	50 50
		MIVFVRFNSS	HGFPVEVDS	TSIFQLKEVV	AKRQGVPAQ	LRVIFAGKEL
hpARK2 mpARK2	51 51	60 60	70 70	80 80	90 90	100 100
		RNDWTVQNCD	LDQQSIVHIV	QRPWRKGOEM	NATGGDDPRN	AAGGCEREPO
		P.HL	E	R.RSH.T	S...E.QS	TSE.SIW.SK
hpARK2 mpARK2	101 101	110 110	120 120	130 130	140 140	150 150
		SLTRVDLSS	VLPGDSVGLA	VILHTDSRKD	SPPAGSPAGR	SIYNSFYVYC
		H	T.V	D...KR.	EA.RG.V-K	PT...FI..
hpARK2 mpARK2	151 151	160 160	170 170	180 180	190 190	200 200
		KGPCQVRQPG	KLRVQCSTCR	QATLTLTQGP	SCWDDVLIPN	RMSGECQSPH
		HK	G..K	A...		D
hpARK2 mpARK2	201 201	210 210	220 220	230 230	240 240	250 250
		CPGTSAEFF	KCGAHPTSDK	ETPVALLHLIA	TNSRNITCIT	CTDVRSPVLV
		R...		D.S...N..T	S.R.S.P..A	
hpARK2 mpARK2	251 251	260 260	270 270	280 280	290 290	300 300
		FQCNSRHVIC	LDCFHLYCVT	RLNDRQFVHD	PQLGYSILPCV	AGCPNSLIKE
		H			A	
hpARK2 mpARK2	301 301	310 310	320 320	330 330	340 340	350 350
		LHHFRILGEE	QYNRYQQYGA	EECVLQMGV	LCPRPGCGAG	LLPEPDQKRV
			T			QG
hpARK2 mpARK2	351 351	360 360	370 370	380 380	390 390	400 400
		TCEGGNGLGC	GFAFCRECKE	AYHEGEC SAV	FEASGTTTQA	YRVDERAAEQ
			V..D...	D.D.SL	L.P..A.S..	K
hpARK2 mpARK2	401 401	410 410	420 420	430 430	440 440	450 450
		ARWEAASKET	IKKTTKPCPR	CHVPVEKNGG	CMHMKCPQPQ	CRLEWCWNCG
		E		N.I		K
hpARK2 mpARK2	451 451	460 460	470 470	480 480	490 490	500 500
		CEWNRVCMGD	HWFDV*			
		A				

Fig. 1

2a/3

hPARK2	1	TCCGG	10	20	30	40	50
mPARK2	1	CT.A.CGAGG	60	70	80	90	100
hPARK2	51	CGCTGCTGGG	110	120	130	140	150
mPARK2	51	CGCTGCTGGG	110	120	130	140	150
hPARK2	101	GGCCCGCAGC	160	170	180	190	200
mPARK2	101	AACTCCAGCC	210	220	230	240	250
hPARK2	151	CCAGCTCAAG	260	270	280	290	300
mPARK2	151	TGCGTGTGAT	310	320	330	340	350
hPARK2	201	AAATGTGACC	360	370	380	390	400
mPARK2	201	GAGTGTGTTG	410	420	430	440	450
hPARK2	251	TTCGCGAGGG	460	470	480	490	500
mPARK2	251	CTGTGAGCGG	510	520	530	540	550
hPARK2	301	AGCAGCTCAG	560	570	580	590	600
mPARK2	301	CAATCTACAA	610	620	630	640	650
hPARK2	351	GAGAAAGGT	660	670	680	690	700
mPARK2	351	CAATCTACAA	710	720	730	740	750
hPARK2	401	CGCGGGGAGG	760	770	780	790	800
mPARK2	401	CT.A.AG..	810	820	830	840	850
hPARK2	451	AGCAGCTCAG	860	870	880	890	900
mPARK2	451	CAATCTACAA	910	920	930	940	950
hPARK2	501	CACTGACAGC	960	970	980	990	1000
mPARK2	501	CACTGACAGC	960	970	980	990	1000
hPARK2	551	CAATCTACAA	1010	1020	1030	1040	1050
mPARK2	551	CAATCTACAA	1010	1020	1030	1040	1050
hPARK2	601	CAGCCGGGAA	1060	1070	1080	1090	1100
mPARK2	601	CAGCCGGGAA	1060	1070	1080	1090	1100
hPARK2	651	CACCTTGACC	1110	1120	1130	1140	1150
mPARK2	651	CACCTTGACC	1110	1120	1130	1140	1150
hPARK2	701	GGATGAGTGG	1160	1170	1180	1190	1200
mPARK2	701	GGATGAGTGG	1160	1170	1180	1190	1200
hPARK2	751	TTTTTCTTTA	1210	1220	1230	1240	1250
mPARK2	751	TTTTTCTTTA	1210	1220	1230	1240	1250

Fig 2

2b/3

hpARK2	801	810	820	830	840	850
mPark2	801	AGCTTTGCAC	CTGATCGCAA	CAAATAGTCG	GAACATCACT	TGCATTACGT
		.....A..	.....A.C..	GC..C..G..	C.G....C..	.....AG...
hpARK2	851	860	870	880	890	900
mPark2	851	GCACAGACGT	CAGGAGCCCC	GTCTCTGGTTT	TCCAGTGCAA	CTCCCCGCCAC
		.....T..	.....T..	.....C..	.....T..	.CA...T...
hpARK2	901	910	920	930	940	950
mPark2	901	GTGATTGTCT	TAGACTGTTT	CCACTTATAC	TGTGTGACAA	GACTCAATGA
		.....C..T	.G.....G..T	.....G..T	.....C....	.....C....
hpARK2	951	960	970	980	990	1000
mPark2	951	TCGGCAGTTT	GTTCACGACC	CTCAACTTGG	CTACTCCCTG	CCTTGTGTGG
		.....	.C.....TG	.....	.....	.G.....A..
hpARK2	1001	1010	1020	1030	1040	1050
mPark2	1001	CTGGCTGTCC	CAACTCCTTG	ATTAAAGAGC	TCCATCACTT	CAGGATTCTG
		.....	.....C..	.....	.....	.....C..T
hpARK2	1051	1060	1070	1080	1090	1100
mPark2	1051	GGAGAAGAGC	AGTACAACCG	GTACCAGCAG	TATGGTGCAG	AGGAGTGTGT
		.....	. .....CTA.	.....	.....G..C..	.....A..C..
hpARK2	1101	1110	1120	1130	1140	1150
mPark2	1101	CCTGCAGATG	GGGGCGGTGT	TATGCCCCCG	CCCTGGCTGT	GGAGCGGGGC
		G.....A..	.A..T...C	.G.....	T.....	.....T..A..
hpARK2	1151	1160	1170	1180	1190	1200
mPark2	1151	TGCTGCCGGA	GCCTGACCAG	AGGAAAGTCA	CCTGCGAAGG	GGGCAATGGC
		...A..T..	A..AG..	.....	.....	.....C....
hpARK2	1201	1210	1220	1230	1240	1250
mPark2	1201	CTGGGCTGTG	GGTTTGCCTT	CTGCCGGGAA	TGTAAGAAG	CGTACCATGA
		.....C..	. .....TT..	.....C	.....G....	.A.....
hpARK2	1251	1260	1270	1280	1290	1300
mPark2	1251	AGGGGAGTGC	AGTGCCGTAT	TTGAAGCCTC	AGGAACAACT	ACTCAGGCCT
		.....T..	GACT.AC.GC	.C...C..	.....G.C....	T.....
hpARK2	1301	1310	1320	1330	1340	1350
mPark2	1301	ACAGAGTCGA	TGAAAGAGCC	GCCGAGCAGG	CTCGTTGGGA	AGCAGCCTCC
		.....G..G..	CA.....	.T.....A..	.....C....	G..AG.....
hpARK2	1351	1360	1370	1380	1390	1400
mPark2	1351	AAAGAAACCA	TCAAGAAAAC	CACCAAGCCC	TGTCCCCGCT	GCCATGTACC
		.G.....	.....G..	.....	.....T..	.A.C..G..
hpARK2	1401	1410	1420	1430	1440	1450
mPark2	1401	AGTGGAATAA	AATGGAGGCT	GCATGCACAT	GAAGTGTCCG	CAGCCCCAGT
		.A..T.....	.C .A..	.T.....	.....	.....
hpARK2	1451	1460	1470	1480	1490	1500
mPark2	1451	GCAGGCTCGA	GTGTGCTGG	AACTGTGGCT	GCGAGTGGAA	CCGCGTCTGC
		...A..G..	.....	.....	.T.....	.....A.C....
hpARK2	1501	1510	1520	1530	1540	1550
mPark2	1501	ATGGGGAGCC	ACTGTTTCGA	CGTGTAGCCA	GGGCGGCCGG	GCGCCCCATC
		.....A..T.	.....T..	.....AG.	.A..AT..T..AC	TT.G...TGG
hpARK2	1551	1560	1570	1580	1590	1600
mPark2	1551	GC-CACATCC	TGGGGGAGCA	TACCCAG--T	GTCTACCTTC	ATTT.....
		A.G.....A..	.CAA..GAA.	CT..G.AGA.	TC.....	C..A.....




Fig 3

**DECLARATION & POWER OF ATTORNEY - USA PATENT APPLICATION**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I believe I am the original, first and sole inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled: **TRANSGENIC ANIMAL MODEL FOR NEURODEGENERATIVE DISEASES**, the specification of which:

- (a) ☐ is attached hereto; or
- (b) ☐ was filed on \_\_\_\_\_ as Application No. \_\_\_\_\_;  
or
- (c) ☒ was described and claimed in PCT International Application No. **PCT/EP00/08071** filed on **August 18, 2000** and as amended under PCT Article 19 on \_\_\_\_\_ (if any) and/or under PCT Article 34 on \_\_\_\_\_ (if any).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above;

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, § 1.56;

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent, design or inventor's certificate or any PCT international application(s) listed below and have also identified below any foreign application(s) for patent, design or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed for the same subject matter having a filing date before that of the application(s) of which priority is claimed:

**PRIOR FOREIGN APPLICATION(S)**

COUNTRY (OR INDICATE IF PCT)	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 37 U.S.C. § 119
Europe	991167669	30/08/99	<input checked="" type="checkbox"/> YES NO <input type="checkbox"/>
			<input type="checkbox"/> YES NO <input type="checkbox"/>
			<input type="checkbox"/> YES NO <input type="checkbox"/>
			<input type="checkbox"/> YES NO <input type="checkbox"/>

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below, and insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Prior U.S.A. Application(s)

Application No.

N/A

Filing Date

N/A

Status

N/A

**POWER OF ATTORNEY:** I hereby appoint the registrants of Knobbe, Martens, Olson & Bear, LLP, 620 Newport Center Drive, Sixteenth Floor, Newport Beach, California 92660, Telephone (949) 760-0404, **Customer No. 20,995.**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful, false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor: Hermann LübbertInventor's signature H. LübbertDay 3 Month April Year 01

Residence (city and country): Leverkusen, Germany

Citizenship: German

Post Office Address: LÜBBERT, Hermann, Höhenstrasse 59, D-51381 Leverkusen, Germany☐ **Additional Inventors Listed on Attached Pages**

Send Correspondence To:  
KNOBBE, MARTENS, OLSON & BEAR, LLP  
**Customer No. 20,995**

## SEQUENZPROTOKOLL

&lt;110&gt; Firma Biofrontera GmbH

&lt;120&gt; Transgenic animal model for neurodegenerative diseases

&lt;130&gt; 5807EPAlleSequenzen

&lt;140&gt;

&lt;141&gt;

&lt;160&gt; 34

&lt;170&gt; PatentIn Ver. 2.1

&lt;210&gt; 1

&lt;211&gt; 3255

&lt;212&gt; DNA

&lt;213&gt; mouse

&lt;400&gt; 1

```

ctcagcgagg ggaaggggga ggaggcctgg atgactaaac ctgacagaaa cgctgggtggg 60
aggctcgggc gggcgccagt gcccgcgtag gtcttctctg acccgagcc accaccgcc 120
cgggtgaccat gatagtgttt gtcaggttca actccagcta tggcttccca gtggaggctg 180
attctgacac cagcatcttg cagctcaagg aagtgggtgc taagcgacag ggggttccag 240
ctgaccagct gcgtgtgatt tttgccggga aggagcttcc gaatcacctg acggttcaaa 300
actgtgacct ggaacaacag agtattgtac acatagtaca gagaccacgg aggagaagtc 360
atgaaacaaa tgcattctgga ggggacgaac cccagagcac ctgagagggc tccatatggg 420
agtccaggag cttgacacga gtggacctga gcagccatac cctgccggtg gactctgtgg 480
ggctggcggt cattctggac acagacagta agagggttc agaagcagcc agagggtccag 540
ttaaaccac ctacaacagc tttttcatct actgcaaagg cccctgccac aagggtccagc 600
ctggaaagct ccgagttcag tgtggcacct gcaaacaagc aacctcacc ttggcccagg 660
gcccattctg ctgggacgat gtcttaattc caaaccggat gagtgggtgag tgccagtctc 720
cagactgcc tggaaaccaga gctgaatttt tctttaaatg tggagcacac ccaacctcag 780
acaaggacac gtcggtagct ttgaacctga tcaccagcaa caggcgagc atcccttgca 840
tagcgtgcac agatgtcagg agccctgtcc tggctctcca gtgtaaccac cgtcacgtga 900
tctgtttgga ctgtttccac ttgtattgtg tcacaagact caacgatcgg cagtttgtcc 960
acgatgctca acttggttac tccctgccgt gtgtagctgg ctgtcccaac tccctgatta 1020
aagagctcca tcaattcagg atccttgagg aagagcagta cactaggtac cagcagtatg 1080
gggcccagga atgcgtgctg caaatgggag gtgtgctgtg ccccgctcct ggctgtggag 1140
ctggactgct acctgaacag ggccagagga aagtcacctg cgaagggggc aacggcctgg 1200
gctgcgggtt tgttttctgc cgggactgta aggaagcata ccatgaaggg gattgcgact 1260
cactgctcga acctcagga gccacttctc aggcctacag ggtggacaaa agagccgctg 1320
agcaagctcg ctgggaggag gcctccaagg aaaccatcaa gaagaccacc aagccttgct 1380
ctcgctgcaa cgtgccaatt gaaaaaacg gaggatgtat gcacatgaag tgtcctcagc 1440
cccagtgcaa gctggagtgg tgctggaact gtggctgtga gtggaaccga gcctgcatgg 1500
gagatcactg gtttgacgtg tagagagaga tgtcacttgg ccctggacgc acaacctcaa 1560
gggaaactcc gaagattcct accttcctta gccatttctt cttctcgatg catataagca 1620

```

cataaatgcg cacacacaaa cacaggctgc agattacaga agcagccctt agatcctttc 1680  
 tagggcaccc acagaaaacc acagcaccgc ctggccccag ggggaggagg cacttttcagc 1740  
 ctctggctca ctggaatgtc agagcttaga tgagggtgca ccttttggtt ggattctgta 1800  
 gaagccatga gtgagggtgg aagtgttttc cagggttggt gccacgccct gggtaagtaa 1860  
 cacctctgag gattctcaga agcacacttg agatctgagg aacgctgctc tcatgtagta 1920  
 atcatctatt cccaaagggc cccctgcagt agtcaaaact atttgtttat cccccaaat 1980  
 cctatcttta caaatggtgc tgatgagatt acaaccctc tgtgtactaa tcagcttatc 2040  
 aaccaagtga gaacctagga aagctaattg gatggcagac tgcttaaate gcaggaggga 2100  
 ctcagaagcc aaacctactt ccgttcgttt cattatctgc aacttttagaa agaaatgatc 2160  
 tttttttccc cctgaaaaga taacaaagtc tgcaatttgg tttggagtat tcctactgca 2220  
 gcctggaagt ttagcttcac tgtgaattta acagagaaag tgcctataaa gggggcggtt 2280  
 ttaagagaca atcccatgat gctgcgcaa tgctaacaac agggtaaga aacacaatgt 2340  
 ttatagaagg agcatccctc gaccatctga atgagagtat gcctgacccc ttccaccaca 2400  
 agtggggaca cctctgcata tctgtccct cctctgctgt taagccccag ggagccccat 2460  
 ccaccagtg gtcctacaga cagggaata cacacacacc aagatagcct tcagatcaac 2520  
 atgcatcaca ctcaagtgtt aatctttcaa ggttttcttt tctttttcct gttttttatt 2580  
 tgttttgctt ttgctttttt tttttttttt tttgggtgtg gtggggctac caaacttgag 2640  
 gcctagagct aaaaatcata tagaaatgat gttatcttgt ggtgtgagga aaggccagct 2700  
 ggcctaagtt cacacttttg tcccagtggt cctagactcc acccagccag ctcccaaat 2760  
 gaaaagacca cctgtcaagc agcagtcagg agtctgatgt caccatcac tatttttttt 2820  
 ccacatctgt gcttgccctc gctccttcc acaccgctgt gacgtaatcg cattgggaag 2880  
 ccaggacaat gtttgctgtt ctgctttggg taaagggaact ccctgaagct ctgtggctct 2940  
 ccagtatggt cctttttcct tcctaacaga tgcatatgtt ttcttcagaa tacaatagt 3000  
 attcttaaaa taaccacaaa gacaggcatc cacagtgtgt gagcatgaat cacagcctgc 3060  
 attgtgtgag tgtgaatagt gggataaaag tggatgtcag aagagtggaa atcaaacctc 3120  
 tgcaaagcaa tctttctctt tctgtgaagt gtattaagaa atacctgaag tctgtgtgtg 3180  
 tggtggtacc cagactgtca atcaataaag acccagactg tcaatgaaaa aaaaaaaaaa 3240  
 aaaaaaaaaa aaaaaa 3255

&lt;210&gt; 2

&lt;211&gt; 1459

&lt;212&gt; DNA

&lt;213&gt; mouse

&lt;400&gt; 2

ctacagggga ggaggccttg gatgactaaa cctgacagaa acgctgggtg gaggctcggg 60  
 cgggcgccag tgcccgcgta ggtccttctc gaccgcagc caccaccgc ccggtgacca 120  
 tgatagtgtt tgtcagggtc aactccagct atggcttccc agtggagggtc gattctgaca 180  
 ccagcatctt gcagctcaag gaagtgggtg ctaagcgaca gggggttcca gctgaccagc 240  
 tgcgtgtgat ttttgccggg aaggagcttc cgaatcacct gacgggtcaa aactgtgacc 300  
 tggaacaaca gagtattgta cacatagtac agagaccacg gaggagaagt catgaaacaa 360  
 atgcatctgg aggggacgaa cccagagca cctcagaggg ctccatattg gagtccagga 420  
 gcttgacacg agtggaacct agcagccata cctgcccgt ggactctgtg gggctggcgg 480  
 tcattctgga cacagacagt aagagggtt cagaagcagc cagaggtcca gcagttaaac 540  
 ccacctaaa cagctttttc atctactgca aaggcccttg ccacaagggtc cagcctggaa 600  
 agctccgagt tcagtgtggc acctgcaaac aagcaacct cacttggcc cagggcccat 660  
 cttgctggga cgatgtctta attccaaacc ggatgagtggt tgagtgccag tctccagact 720  
 gccttggaa cagagctgaa tttttcttta aatgtggagc acaccaacc tcagacaagg 780



```

acacgtcggg agctttgaac ctgatcacca gcaacaggcg cagcatccct tgcatagcgt 840
gcacagatgt cagtcattct cctctgtcat ctggtgcctc cgtgtggact cggcctcatc 900
tccactgaac cttgttcttt aggactgtgc aatagggtcgt cacctcctac tgagaacaag 960
gcagcttctg gtctcttggg ttccttgctt ccaacggcag cattgactgt acacccttca 1020
gtcctaccaa cccattacc tgggtgattt ctttaccgct tagcttctcc aagatgccta 1080
tttccacaca cagtttcttg tcttcccat ccccccata gtttatgcgc atgagtaagc 1140
accgcacctc atgagtttgt gcttctgata caagacttcc tgggatcccc gcttgagccc 1200
tagaatcccc tggaactggg ttcagtcacc tatcttcaat agcctctttt aaaagtgagt 1260
tcttgggctg gtgagatggc tcagtgggta agagcaccgc actgctcttc cgaagtccag 1320
agttcaaaat cccagcaacc acatgggtggc tcacaacat ccgtaacaag atctgactcc 1380
ctcttctggg gtgtctgaag acagctacag tgtacttaca taaaataata aataaatctt 1440
aaaaaaaaaa aaaaaaaaaa

```

1459

&lt;210&gt; 3

&lt;211&gt; 857

&lt;212&gt; DNA

&lt;213&gt; mouse

&lt;400&gt; 3

```

ctcagatgac taaacctgac agaaacgctg gtgggaggct cgggcggggc ccagtgcctg 60
cgtaggtcct tctcgacctg cagccaccac ccgccgggtg accatgatag tgtttgctag 120
gttcaactcc agctatggct tcccagtggg ggtcgattct gacaccagca tcttgcagct 180
caaggaagtg gttgctaagc gacagggggt tccagctgac cagctgcgtg tgatttttgc 240
cgggaaggag cttccgaatc acctgacggt tcaaaactgt gacctggaac aacagagtat 300
tgtacacata gtacagagac cacggaggag aagtcatgaa acaaatgcat ctggagggga 360
cgaaccccag agcacctcag agggctccat atgggagtcg aggagcttga cacgagtggg 420
cctgagcagc cataccctgc cgttggactc tgtggggctg gcggtcattc tggacacaga 480
cagtaagagg gattcagaag cagccagagg tccagcagtt aaaccacct acaacagctt 540
tttcatctac tgcaaaggcc cctgccacaa ggtccagcct ggaaagctcc gagttcagtg 600
tggcacctgc aaacaagcaa ccctcacctt ggcccagggc ccatcttgct gggacgatgt 660
cttaattcca aaccggatga gtggtgagtg ccagtctcca gactgccctg gaaccagagc 720
tgaatttttc tttaaatgtg gagcacaccc aacctcagac aaggacacgt cggtagcttt 780
gaacctgatc accagcaaca ggcgagcagc cccttgcata gcgtgcacag atgtcagggt 840
tatgcgcatg agttagc

```

857

&lt;210&gt; 4

&lt;211&gt; 464

&lt;212&gt; PRT

&lt;213&gt; mouse

&lt;400&gt; 4

```

Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu
  1             5             10             15

```

```

Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys
      20             25             30

```

```

Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys

```

35                      40                      45  
 Glu Leu Pro Asn His Leu Thr Val Gln Asn Cys Asp Leu Glu Gln Gln  
     50                      55                      60  
 Ser Ile Val His Ile Val Gln Arg Pro Arg Arg Arg Ser His Glu Thr  
     65                      70                      75                      80  
 Asn Ala Ser Gly Gly Asp Glu Pro Gln Ser Thr Ser Glu Gly Ser Ile  
                     85                      90                      95  
 Trp Glu Ser Arg Ser Leu Thr Arg Val Asp Leu Ser Ser His Thr Leu  
                     100                      105                      110  
 Pro Val Asp Ser Val Gly Leu Ala Val Ile Leu Asp Thr Asp Ser Lys  
                     115                      120                      125  
 Arg Asp Ser Glu Ala Ala Arg Gly Pro Val Lys Pro Thr Tyr Asn Ser  
                     130                      135                      140  
 Phe Phe Ile Tyr Cys Lys Gly Pro Cys His Lys Val Gln Pro Gly Lys  
     145                      150                      155                      160  
 Leu Arg Val Gln Cys Gly Thr Cys Lys Gln Ala Thr Leu Thr Leu Ala  
                     165                      170                      175  
 Gln Gly Pro Ser Cys Trp Asp Asp Val Leu Ile Pro Asn Arg Met Ser  
                     180                      185                      190  
 Gly Glu Cys Gln Ser Pro Asp Cys Pro Gly Thr Arg Ala Glu Phe Phe  
                     195                      200                      205  
 Phe Lys Cys Gly Ala His Pro Thr Ser Asp Lys Asp Thr Ser Val Ala  
                     210                      215                      220  
 Leu Asn Leu Ile Thr Ser Asn Arg Arg Ser Ile Pro Cys Ile Ala Cys  
     225                      230                      235                      240  
 Thr Asp Val Arg Ser Pro Val Leu Val Phe Gln Cys Asn His Arg His  
                     245                      250                      255  
 Val Ile Cys Leu Asp Cys Phe His Leu Tyr Cys Val Thr Arg Leu Asn  
                     260                      265                      270  
 Asp Arg Gln Phe Val His Asp Ala Gln Leu Gly Tyr Ser Leu Pro Cys  
                     275                      280                      285  
 Val Ala Gly Cys Pro Asn Ser Leu Ile Lys Glu Leu His His Phe Arg

290                      295                      300  
 Ile Leu Gly Glu Glu Gln Tyr Thr Arg Tyr Gln Gln Tyr Gly Ala Glu  
 305                      310                      315                      320  
 Glu Cys Val Leu Gln Met Gly Gly Val Leu Cys Pro Arg Pro Gly Cys  
                     325                      330                      335  
 Gly Ala Gly Leu Leu Pro Glu Gln Gly Gln Arg Lys Val Thr Cys Glu  
                     340                      345                      350  
 Gly Gly Asn Gly Leu Gly Cys Gly Phe Val Phe Cys Arg Asp Cys Lys  
                     355                      360                      365  
 Glu Ala Tyr His Glu Gly Asp Cys Asp Ser Leu Leu Glu Pro Ser Gly  
                     370                      375                      380  
 Ala Thr Ser Gln Ala Tyr Arg Val Asp Lys Arg Ala Ala Glu Gln Ala  
 385                      390                      395                      400  
 Arg Trp Glu Glu Ala Ser Lys Glu Thr Ile Lys Lys Thr Thr Lys Pro  
                     405                      410                      415  
 Cys Pro Arg Cys Asn Val Pro Ile Glu Lys Asn Gly Gly Cys Met His  
                     420                      425                      430  
 Met Lys Cys Pro Gln Pro Gln Cys Lys Leu Glu Trp Cys Trp Asn Cys  
                     435                      440                      445  
 Gly Cys Glu Trp Asn Arg Ala Cys Met Gly Asp His Trp Phe Asp Val  
                     450                      455                      460

<210> 5  
 <211> 262  
 <212> PRT  
 <213> mouse

<400> 5  
 Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu  
   1                      5                      10                      15  
 Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys  
                     20                      25                      30

Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys  
 35 40 45  
 Glu Leu Pro Asn His Leu Thr Val Gln Asn Cys Asp Leu Glu Gln Gln  
 50 55 60  
 Ser Ile Val His Ile Val Gln Arg Pro Arg Arg Arg Ser His Glu Thr  
 65 70 75 80  
 Asn Ala Ser Gly Gly Asp Glu Pro Gln Ser Thr Ser Glu Gly Ser Ile  
 85 90 95  
 Trp Glu Ser Arg Ser Leu Thr Arg Val Asp Leu Ser Ser His Thr Leu  
 100 105 110  
 Pro Val Asp Ser Val Gly Leu Ala Val Ile Leu Asp Thr Asp Ser Lys  
 115 120 125  
 Arg Asp Ser Glu Ala Ala Arg Gly Pro Ala Val Lys Pro Thr Tyr Asn  
 130 135 140  
 Ser Phe Phe Ile Tyr Cys Lys Gly Pro Cys His Lys Val Gln Pro Gly  
 145 150 155 160  
 Lys Leu Arg Val Gln Cys Gly Thr Cys Lys Gln Ala Thr Leu Thr Leu  
 165 170 175  
 Ala Gln Gly Pro Ser Cys Trp Asp Asp Val Leu Ile Pro Asn Arg Met  
 180 185 190  
 Ser Gly Glu Cys Gln Ser Pro Asp Cys Pro Gly Thr Arg Ala Glu Phe  
 195 200 205  
 Phe Phe Lys Cys Gly Ala His Pro Thr Ser Asp Lys Asp Thr Ser Val  
 210 215 220  
 Ala Leu Asn Leu Ile Thr Ser Asn Arg Arg Ser Ile Pro Cys Ile Ala  
 225 230 235 240  
 Cys Thr Asp Val Ser His Leu Pro Leu Ser Ser Gly Ala Ser Val Trp  
 245 250 255  
 Thr Arg Pro His Leu His  
 260

&lt;210&gt; 6

&lt;211&gt; 250

&lt;212&gt; PRT

&lt;213&gt; mouse

&lt;400&gt; 6

```

Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu
  1             5             10             15

Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys
      20             25             30

Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys
      35             40             45

Glu Leu Pro Asn His Leu Thr Val Gln Asn Cys Asp Leu Glu Gln Gln
      50             55             60

Ser Ile Val His Ile Val Gln Arg Pro Arg Arg Arg Ser His Glu Thr
      65             70             75             80

Asn Ala Ser Gly Gly Asp Glu Pro Gln Ser Thr Ser Glu Gly Ser Ile
      85             90             95

Trp Glu Ser Arg Ser Leu Thr Arg Val Asp Leu Ser Ser His Thr Leu
      100            105            110

Pro Val Asp Ser Val Gly Leu Ala Val Ile Leu Asp Thr Asp Ser Lys
      115            120            125

Arg Asp Ser Glu Ala Ala Arg Gly Pro Ala Val Lys Pro Thr Tyr Asn
      130            135            140

Ser Phe Phe Ile Tyr Cys Lys Gly Pro Cys His Lys Val Gln Pro Gly
      145            150            155            160

Lys Leu Arg Val Gln Cys Gly Thr Cys Lys Gln Ala Thr Leu Thr Leu
      165            170            175

Ala Gln Gly Pro Ser Cys Trp Asp Asp Val Leu Ile Pro Asn Arg Met
      180            185            190

Ser Gly Glu Cys Gln Ser Pro Asp Cys Pro Gly Thr Arg Ala Glu Phe
      195            200            205

Phe Phe Lys Cys Gly Ala His Pro Thr Ser Asp Lys Asp Thr Ser Val
      210            215            220

Ala Leu Asn Leu Ile Thr Ser Asn Arg Arg Ser Ile Pro Cys Ile Ala
      225            230            235            240

```

Cys Thr Asp Val Arg Phe Met Arg Met Ser  
245 250

<210> 7  
<211> 3014  
<212> DNA  
<213> mouse

<400> 7

```

ctcagcgagg ggaaggggga ggaggcctgg atgactaaac ctgacagaaa cgctgggtggg 60
aggctcgggc gggcgccagt gcccgcgtag gtccttctcg acccgagcc accacccgcc 120
cggtgaccat gatagtgttt gtcaggttca actccagcta tggcttccca gtggaggtcg 180
attctgacac cagcatcttg cagctcaagg aagtgggtgc taagcgacag ggggttccag 240
ctgaccagct gcgtgtgatt tttgccggga aggagcttcc gaatcacctg acggttcaat 300
taaaccaccc tacaacagct ttttcatcta ctgcaaagge ccttgccaca aggtccagcc 360
tggaaagctc cgagttcagt gtggcacctg caaacaagca accctcacct tggcccaggg 420
cccatcttgc tgggacgatg tcttaattcc aaaccggatg agtgggtgagt gccagtctcc 480
agactgccct ggaaccagag ctgaattttt ctttaaatgt ggagcacacc caacctcaga 540
caaggacacg tcggtagctt tgaacctgat caccagcaac aggcgcagca tcccttgcat 600
agcgtgcaca gatgtcagga gccctgtcct ggtcttccag tgtaaccacc gtcacgtgat 660
ctgtttggac tgtttccact tgtattgtgt cacaagactc aacgatcggc agtttgtcca 720
cgatgctcaa cttggctact ccctgccgtg tgtagctggc tgtcccaact ccctgattaa 780
agagctccat cacttcagga tccttgagga agagcagtac actaggtacc agcagtatgg 840
ggccgaggaa tgcgtgctgc aaatgggagg tgtgctgtgc ccccgctcctg gctgtggagc 900
tggactgcta cctgaacagg gccagaggaa agtcacctgc gaagggggca acggcctggg 960
ctgcgggttt gttttctgcc gggactgtaa ggaagcatac catgaagggg attgcgactc 1020
actgctcgaa ccctcaggag ccacttctca ggcctacagg gtggacaaaa gagccgctga 1080
gcaagctcgc tgggaggagg cctccaagga aaccatcaag aagaccacca agccttgtcc 1140
tcgctgcaac gtgccaattg aaaaaaacgg aggatgtatg cacatgaagt gtcctcagcc 1200
ccagtgcagg ctggagtggg gctggaactg tggctgtgag tggaaaccgag cctgcatggg 1260
agatcactgg tttgacgtgt agagagagat gtcacttggc cctggacgca caacctcaag 1320
ggaaactccg aagattccta ccttccttag ccatttcttc ttctcgatgc atataagcac 1380
ataaatgccc acacacaaac acaggctgca gattacagaa gcagccccta gatcctttct 1440
agggcaccca cagaaaacca cagcacccgc tggccccagg gggaggaggc actttcagcc 1500
tctggctcac tcgaatgtca gagcttagat gagggtgcac ctttggtttg gattctgtag 1560
aagccatgag tgagggtggg agtgttttcc agggttgttg ccacgccctg ggtaagtaac 1620
acctctgagg attctcagaa gcacacttga gatctgagga acgctgctct catgtagtaa 1680
tcatctattc ccaaagggcc ccctgcagta gtcaaaacta tttgtttatc ccccaaatc 1740
ctatctttac aaatggtgct gatgagatta caaccctct gtgtactaat cagcttatca 1800
accaagttag aacctaggaa agctaattgg atggcagact gcttaaactc cagggaggac 1860
tcagaagcca aacctacttc cgttcgtttc attatctgca actttagaaa gaaatgatct 1920
ttttttcccc ctgaaaagat aacaaagtct gcaatttggt ttggagtatt cctactgcag 1980
cctggaagtt tagcttcaact gtgaatttaa cagagaaagt gcctataaag ggggcgtttt 2040
taagagacaa tcccatgatg ctgcgccaat gctaacaaca gggtaagaa acacaatggt 2100
tatagaagga gcacccctcg accatctgaa tgagagtatg cctgaccctc tccaccacaa 2160
gtggggacac ctctgcatat ctgtccctc ctctgctggt aagccccagg gagccccatc 2220

```

```

caccagtggtg tectacagac agggcaatac acacacacca agatagcctt cagatcaaca 2280
tgcacacac tcaagtgtta atctttcaag gttttctttt ctttttcctg ttttttattt 2340
gttttgcttt tgcttttttt tttttttttt ttggtggtgg tggggctacc aaacttgagg 2400
cctagagcta aaaatcatat agaaatgatg ttatcttggt gtgtgaggaa aggccagctg 2460
gcctaagttc acacttttgt cccagtggtc ctagactcca cccagccagc tcccaaatg 2520
aaaagaccac ctgtcaagca gcagtcagga gtctgatgtc acccatcact attttttttc 2580
catcattgtg cttgcctctg cctccttcca caccgctgtg acgtaatcgc attgggaagc 2640
caggacaatg tttgctgttc tgctttgggt aaagggactc cctgaagctc tgtggctctc 2700
cagtatggtc ccttttcctt cctaacagat gcatatgttt tcttcagaat acaatagtga 2760
ttcttaaaat aacccaaaag acaggcatcc acagtgtgtg agcatgaatc acagcctgca 2820
ttgtgtgagt gtgaatagtg ggataaaagt ggatgtcaga agagtggaaa tcaaacctct 2880
gcaaagcaat ctttctcttt ctgtgaagtg tattaagaaa tacctgaagt ctgtgtgtgt 2940
ggtggtaccc agactgtcaa tcaataaaga cccagactgt caatgaaaaa aaaaaaaaaa 3000
aaaaaaaaaa aaaa 3014

```

&lt;210&gt; 8

&lt;211&gt; 2895

&lt;212&gt; DNA

&lt;213&gt; mouse

&lt;400&gt; 8

```

ctcagcgagg ggaaggggga ggaggcctgg atgactaaac ctgacagaaa cgctggtggg 60
aggctcgggc gggcgccagt gcccgcgtag gtcttctctg acccgagcc accaccgcc 120
cggtgaccat gatagtgttt gtcaggttca actccagcta tggcttccca gtggaggtcg 180
attctgacac cagcatcttg cagctcaagg aagtggttgc taagcgacag ggggttccag 240
ctgaccagct gcgtgtgatt tttgcccggga aggagcttcc gaatcacctg acggttcaag 300
gcccattctg ctgggacgat gtcttaattc caaacggat gagtgggtgag tgccagtctc 360
cagactgccc tggaaccaga gctgaatttt tctttaaatg tggagcacac ccaacctcag 420
acaaggacac gtcggtagct ttgaacctga tcaccagcaa caggcgagc atcccttgca 480
tagcgtgcac agatgtcagg agccctgtcc tggcttcca gtgtaaccac cgtcacgtga 540
tctgtttgga ctgtttccac ttgtattgtg tcacaagact caacgatcgg cagtttgtcc 600
acgatgtcga acttggtctac tccctgccgt gtgtagctgg ctgtcccaac tccctgatta 660
aagagctcca tcaactcagg atccttgagg aagagcagta cactaggtac cagcagtatg 720
gggcccaggga atgcgtgctg caaatgggag gtgtgctgtg ccccgctctt ggctgtggag 780
ctggactgct acctgaacag ggccagagga aagtcacctg cgaagggggc aacggcctgg 840
gctgcggggt tgttttctgc cgggactgta aggaagcata ccatgaaggg gattgcgact 900
cactgctcga accctcagga gccacttctc aggcctacag ggtggacaaa agagccgctg 960
agcaagctcg ctgggaggag gcctccaagg aaacctcaa gaagaccacc aagccttgct 1020
ctcgctgcaa cgtgccattt gaaaaaacg gaggatgtat gcacatgaag tgcctcagc 1080
cccagtgcaa gctggagtgg tgctggaact gtggctgtga gtggaaccga gcctgcatgg 1140
gagatcactg gtttgacgtg tagagagaga tgtcacttgg ccctggagc acaacctcaa 1200
gggaaaactc gaagattcct accttcctta gccatttctt cttctcgatg catataagca 1260
cataaatgag cacacacaaa cacaggctgc agattacaga agcagccctt agatcctttc 1320
tagggcaccc acagaaaacc acagcaccgg ctggccccag ggggaggagg cactttcagc 1380
ctctggctca ctogaatgtc agagcttaga tgagggtgca cctttggttt ggattctgta 1440
gaagccatga gtgagggtgg aagtgttttc cagggttgtt gccacgccct gggtaagtaa 1500
cacctctgag gattctcaga agcacacttg agatctgagg aacgctgctc tcatgtagta 1560
atcatctatt cccaaagggc cccctgcagt agtcaaaact atttgtttat cccccaaat 1620

```

```

cctatcttta caaatgggtgc tgatgagatt acaacccttc tgtgtactaa tcagcttata 1680
aaccaagtga gaacctagga aagctaattg gatggcagac tgcttaaata gcagggagga 1740
ctcagaagcc aaacctactt ccgttcgttt cattatctgc aacttttagaa agaaatgata 1800
tttttttccc cctgaaaaga taacaaagtc tgcaatttgg tttggagtat tcctactgca 1860
gcctggaagt ttagcttcac tgtgaattta acagagaaag tgcctataaa gggggcggtt 1920
ttaagagaca atcccatgat gctgcgcaa tgctaacaac agggtaaga aacacaatgt 1980
ttatagaagg agcatccctc gaccatctga atgagagtat gcctgacccc ttccaccaca 2040
agtggggaca cctctgcata tctgctccct cctctgctgt taagcccag ggagcccat 2100
ccaccagtg gtcctacaga cagggaata cacacacacc aagatagcct tcagatcaac 2160
atgcatcaca ctcaagtgtt aatctttcaa gggtttcttt tcttttctct gttttttatt 2220
tgttttgctt ttgctttttt tttttttttt tttgggtgtg gtggggctac caaacttgag 2280
gcctagagct aaaaatcata tagaatgat gttatcttgt ggtgtgagga aaggccagct 2340
ggcctaagtt cacacttttg tcccagtgcc cctagactcc acccagccag ctcccaaat 2400
gaaaagacca cctgtcaagc agcagtcagg agtctgatgt caccatcac tatttttttt 2460
ccatcattgt gcttgccctc gcctccttcc acaccctgt gacgtaatcg cattgggaag 2520
ccaggacaat gtttgctgtt ctgctttggg taaagggact ccctgaagct ctgtggctct 2580
ccagtatggt cccttttctt tctaacaga tgcataatgt ttcttcagaa tacaatagt 2640
attcttaaaa taacccaaaa gacaggcatc cacagtgtgt gagcatgaat cacagcctgc 2700
attgtgtgag tgtgaatagt gggataaaag tggatgtcag aagagtggaa atcaaacctc 2760
tgcaaagcaa tctttctctt tctgtgaagt gtattaagaa atacctgaag tctgtgtgtg 2820
tggtggtacc cagactgtca atcaataaag acccagactg tcaatgaaa aaaaaaaaaa 2880
aaaaaaaaa aaaaaa

```

&lt;210&gt; 9

&lt;211&gt; 2558

&lt;212&gt; DNA

&lt;213&gt; mouse

&lt;400&gt; 9

```

ctcagcgagg ggaaggggga ggaggcctgg atgactaaac ctgacagaaa cgctggtggg 60
aggctcgggc gggcgccagt gcccgctag gtcttctctg acccgagcc accaccgccc 120
cggtgaccat gatagtgttt gtcaggttca actccagcta tggcttccca gtggaggtcg 180
attctgacac cagcatcttg cagctcaagg aagtgggtgc taagcgacag ggggttccag 240
ctgaccagct gcgtgtgatt tttgccggga aggagcttcc gaatcacctg acggttcaac 300
tggtgtctcc aactccctga ttaaagagct ccatcacttc aggatccttg gagaagagca 360
gtacactagg taccagcagt atggggccga ggaatgcgtg ctgcaaatgg gaggtgtgct 420
gtgccccgt cctggctgtg gagctggact gctacctgaa cagggccaga ggaaagtcac 480
ctgcgaaggg ggcaacggcc tgggctgcgg gtttgttttc tgccgggact gtaaggaaagc 540
ataccatgaa ggggattgag actcactgct cgaacctca ggagccactt ctcaggccta 600
cagggtggac aaaagagccg ctgagcaagc tcgctgggag gaggcctcca aggaaccat 660
caagaagacc accaagcctt gtctctgctg caacgtgcca attgaaaaaa acggaggatg 720
tatgcacatg aagtgtcttc agccccagt caagctggag tgggtgctgga actgtggtcg 780
tgagtggaa cagagcctgca tgggagatca ctggtttgac gtgtagagag agatgtcact 840
tggccctgga cgcacaacct caagggaac tccgaagatt cctaccttcc ttagccattt 900
cttcttctcg atgcatataa gcacataaat gcgcacacac aaacacaggc tgcagattac 960
agaagcagcc cctagatcct ttctagggca ccacagaaa accacagcac ccgtggccc 1020
cagggggagg aggcacttct agcctctggc tcaactcgaa gtcagagctt agatgagggt 1080
gcacctttgg tttggattct gtagaagcca tgagtgggt gggaaagtgt ttccagggtt 1140

```



```

gttgccacgc cctgggtaag taacacctct gaggattctc agaagcacac ttgagatctg 1200
aggaacgctg ctctcatgta gtaatcatct attcccaaag ggccccctgc agtagtcaaa 1260
actatttggt tatcccccca aatcctatct ttacaaatgg tgctgatgag attacaaccc 1320
ctctgtgtac taatcagctt atcaaccaag tgagaacctt ggaaagctaa ttggatggca 1380
gactgcttaa atcgagggga ggactcagaa gccaaacctt cttccgttcg ttccattatc 1440
tgcaacttta gaaagaaatg atcttttttt cccctgaaa agataacaaa gtctgcaatt 1500
tggtttggag tattcctact gcagcctgga agtttagctt cactgtgaat ttaacagaga 1560
aagtgcctat aaagggggcg tttttaagag acaatcccat gatgctgcgc caatgctaac 1620
aacaggggtca agaaacacaa tgtttataga aggagcatcc ctcgaccatc tgaatgagag 1680
tatgcctgac cccttcacc acaagtgggg acacctctgc atatctgtc cctcctctgc 1740
tgtaagccc cagggagccc catccacca gtggtcctac agacagggca atacacacac 1800
accaagatag ccttcagatc aacatgcatc acactcaagt gttaatcttt caaggttttc 1860
ttttcttttt cctgtttttt atttgttttg cttttgtctt tttttttttt ttttttggtg 1920
gtggtggggc taccaaactt gaggcctaga gctaaaaatc atatagaaat gatgttatct 1980
tgtggtgtga ggaaaggcca gctggcctaa gttcacactt ttgtcccagt ggccctagac 2040
tccaccacgc cagctcccaa aatgaaaaga ccacctgtca agcagcagtc aggagtctga 2100
tgtcaccat cactattttt ttccatcatc tgtgcttgcc tctgcctcct tccacaccgc 2160
tgtgacgtaa tcgcattggg aagccaggac aatgtttgct gttctgcttt gggtaaaggg 2220
actccctgaa gctctgtggc tctccagtat ggtccctttt ccttcctaac agatgcatat 2280
gttttcttca gaatacaata gtgattctta aaataaccca aaagacaggc atccacagtg 2340
tgtgagcatg aatcacagcc tgcattgtgt gagtgtgaat agtgggataa aagtggatgt 2400
cagaagagtg gaaatcaaac ctctgcaaag caatctttct cttctctgtga agtgtattaa 2460
gaaatacctg aagtctgtgt gtgtggtggt acccagactg tcaatcaata aagaccaga 2520
ctgtcaatga aaaaaaaaaa aaaaaaaaaa aaaaaaaa 2558

```

&lt;210&gt; 10

&lt;211&gt; 3136

&lt;212&gt; DNA

&lt;213&gt; mouse

&lt;400&gt; 10

```

ctcagcgagg ggaaggggga ggaggcctgg atgactaaac ctgacagaaa cgctgggtggg 60
aggctcgggc gggcgccagt gcccgcgtag gtccctctcg acccgagcc accaccgcc 120
cggtgaccat gatagtgttt gtcagggttca actccagcta tggcttccca gtggaggtcg 180
attctgacac cagcatcttg cagctcaagg aagtggttgc taagcgacag ggggttccag 240
ctgaccagct cgtgtgtgatt tttgccggga aggagcttcc gaatcacctg acggttcaaa 300
actgtgacct ggaacaacag agtattgtac acatagtaca gagaccacgg aggagaagtc 360
atgaaacaaa tgcattctgga ggggacgaac ccagagcac ctcagagggc tccatatggg 420
agtccaggag cttgacacga gtggacctga gcagccatac cctgccgggtg gactctgtgg 480
ggctggcggg cattctggac acagacagta agagggatc agaagcagcc agaggtccag 540
ggcccatctt gctgggacga tgtcttaatt ccaaaccgga tgagtgggtga gtgccagtct 600
ccagactgcc ctggaaccag agctgaattt ttctttaaat gtggagcaca cccaacctca 660
gacaaggaca cgtcggtagc tttgaacctg atcaccagca acaggcgag catcccttgc 720
atagcgtgca cagatgtcag gagccctgtc ctggtcttcc agtgtaacca ccgtcacgtg 780
atctgtttgg actgtttcca cttgtattgt gtcacaagac tcaacgatcg gcagtttgtc 840
cacgatgtc aacttggcta ctccctgccg tgtgtagctg gctgtcccaa ctccctgatt 900
aaagagctcc atcacttcag gatccttgga gaagagcagt aactaggta ccagcagtat 960
ggggccgagg aatgcgtgct gcaaattggga ggtgtgctgt gccccgtcc tggctgtgga 1020

```

```

gctggactgc tacctgaaca gggccagagg aaagtcacct gcgaaggggg caacggcctg 1080
ggctgcggggt ttgtttttctg cggggactgt aaggaagcat accatgaagg ggattgcgac 1140
tactgctcg aacctcagg agccacttct caggcctaca ggggtggacaa aagagccgct 1200
gagcaagctc gctgggagga ggccctcaaag gaaaccatca agaagaccac caagccttgt 1260
cctcgctgca acgtgccaat tgaaaaaac ggaggatgta tgcacatgaa gtgtcctcag 1320
ccccagtgc agctggagtg gtgctggaac tgtggctgtg agtggaaaccg agcctgcatg 1380
ggagatcact ggtttgacgt gtagagagag atgtcacttg gccctggacg cacaacctca 1440
agggaaactc cgaagattcc taccttcctt agccatttct tcttctcgat gcatataagc 1500
acataaatgc gcacacacaa acacaggctg cagattacag aagcagcccc tagatccttt 1560
ctagggcacc cacagaaaac cacagcacc gctggcccca gggggaggag gcactttcag 1620
cctctggctc actcgaatgt cagagcttag atgagggtgc acctttggtt tggattctgt 1680
agaagccatg agtgagggtg gaagtgtttt ccagggttgt tgccacgccc tgggtaagta 1740
acacctctga ggattctcag aagcacactt gagatctgag gaacgctgct ctcatgtagt 1800
aatcatctat tcccaaaggg cccctgcag tagtcaaac tatttgttta tcccccaaa 1860
tcctatcttt acaaattggt ctgatgagat tacaaccct ctgtgtacta atcagcttat 1920
caaccaagtg agaacctagg aaagctaatt ggatggcaga ctgcttaaat cgcaggagg 1980
actcagaagc caaacctact tccgttcgtt tcattatctg caactttaga aagaaatgat 2040
ctttttttcc ccctgaaaag ataacaaagt ctgcaatttg gtttgaggta ttctactgct 2100
agcctggaag tttagcttca ctgtgaattt aacagagaaa gtgcctataa agggggcggt 2160
tttaagagac aatcccatga tgctgcgcca atgctaacaa cagggtcaag aaacacaatg 2220
tttatagaag gagcatccct cgaccatctg aatgagagta tgctgacct cttccaccac 2280
aagtggggac acctctgcat atctgtctcc tcctctgtg ttaagcccca gggagcccca 2340
tccaccagtg ggtcctacag acagggaat acacacacac caagatagcc ttcagatcaa 2400
catgcatcac actcaagtgt taatctttca aggttttctt ttctttttcc tgttttttat 2460
ttgttttgct ttgtcttttt tttttttttt ttttggtggt ggtggggcta ccaaacttga 2520
ggcctagagc taaaaatcat atagaaatga tgttatcttg tgggtgtgagg aaaggccagc 2580
tggcctaagt tcacactttt gtcccagtg ccctagactc caccagcca gctcccaaaa 2640
tgaaaagacc acctgtcaag cagcagtcag gagtctgatg tcacccatca ctattttttt 2700
tccatcattg tgcttgctc tgctccttc cacaccctg tgacgtaatc gcattgggaa 2760
gccaggacaa tgtttgctgt tctgttttg gtaaaggac tcctgaagc tctgtggctc 2820
tccagtatgg tcccttttcc ttctaacag atgcataatg tttcttcaga atacaatagt 2880
gattcttaaa ataaccctaa agacaggcat ccacagtgtg tgagcatgaa tcacagcctg 2940
cattgtgtga gtgtgaatag tgggataaaa gtggatgtca gaagagtgga aatcaaacct 3000
ctgcaaagca atctttctct ttctgtgaag tgtattaaga aatacctgaa gtctgtgtgt 3060
gtggtgttac ccagactgtc aatcaataaa gaccagact gtcaatgaaa aaaaaaaaaa 3120
aaaaaaaaaa aaaaaa 3136

```

&lt;210&gt; 11

&lt;211&gt; 3170

&lt;212&gt; DNA

&lt;213&gt; mouse

&lt;400&gt; 11

```

ctcagcgagg ggaaggggga ggaggcctgg atgactaaac ctgacagaaa cgctgggtggg 60
aggctcgggc gggcgccagt gcccgctag gtcttctctg acccgagcc accacccgcc 120
cggtgaccat gatagtgttt gtcaggttca actccagcta tggcttccca gtggagggtcg 180
attctgacac cagcatcttg cagctcaagg aagtgggtgc taagcgacag ggggttccag 240
ctgaccagct gcgtgtgatt ttgcccggga aggagcttcc gaatcacctg acggttcaaa 300

```

actgtgacct ggaacaacag agtattgtac acatagtaca gagaccacgg aggagaagtc 360  
 atgaaacaaa tgcattctgga ggggacgaac cccagagcac ctcagagggc tccatatggg 420  
 agtccaggag cttgacacga gtggacctga gcagccatac cctgccgggtg gactctgtgg 480  
 ggctggcggg cattctggac acagacagta agagggattc agaagcagcc agaggtccag 540  
 ttaaaccacac ctacaacagc tttttcatct actgcaaagg cccctgccac aaggtccagc 600  
 ctggaagct ccgagttcag tgtggcacct gcaacaagc aacctcacc ttggcccaga 660  
 atttttcttt aaatgtggag cacaccaac ctcagacaag gacacgtcgg tagctttgaa 720  
 cctgatcacc agcaacaggc gcagcatccc ttgcatagcg tgcacagatg tcaggagccc 780  
 tgtcctggtc ttccagtgt accaccgtca cgtgatctgt ttggactgtt tccacttgta 840  
 ttgtgtcaca agactcaacg atcggcagtt tgtccacgat gctcaacttg gctactccct 900  
 gccgtgtgta gctggctgtc ccaactccct gattaaagag ctccatcact tcaggatcct 960  
 tggagaagag cagtacacta ggtaccagca gtatggggcc gaggaatgcg tgctgcaa 1020  
 gggaggtgtg ctgtgcccc gtcctggctg tggagctgga ctgctacctg aacagggcc 1080  
 gaggaagtc acctgcgaag ggggcaacgg cctgggctgc gggtttgtt tctgccggga 1140  
 ctgtaaggaa gcataccatg aaggggattg cgactcactg ctcgaacctc caggagccac 1200  
 ttctcaggcc tacagggtgg acaaaagagc cgctgagcaa gctcgtggg aggaggccctc 1260  
 caaggaaacc atcaagaaga ccaccaagcc ttgtcctcgc tgcaacgtgc caattgaaa 1320  
 aaacggagga tgtatgcaca tgaagtgtcc tcagccccag tgcaagctgg agtgggtgtg 1380  
 gaactgtggc tgtgagtggg accgagcctg catgggagat cactggtttg acgtgtagag 1440  
 agagatgtca cttggccctg gacgcacaac ctcaaggga actccgaaga ttctacctt 1500  
 ccttagccat ttcttcttct cgatgcatat aagcacata atgcgcacac acaaacacag 1560  
 gctgcagatt acagaagcag cccctagatc ttttctaggg caccacaga aaaccacagc 1620  
 acccgctggc cccaggggga ggaggcactt tcagcctctg gctcactcga atgtcagagc 1680  
 ttagatgagg gtgcacctt ggtttggatt ctgtagaagc catgagttag gtgggaagt 1740  
 ttttcagggt ttgttgccac gccctgggta agtaaacct ctgaggattc tcagaagcac 1800  
 acttgagatc tgaggaaagc tgctctcatg tagtaatcat ctattcccaa agggccccct 1860  
 gcagtagtca aaactatttg tttatcccc caaatcctat ctttacaat ggtgctgatg 1920  
 agattacaac cctctgtgt actaatcagc ttatcaacca agtgagaacc taggaaagct 1980  
 aattggatgg cagactgctt aaatcgagg gaggactcag aagccaaacc tacttccgtt 2040  
 cgtttcatta tctgcaactt tagaaagaaa tgatcttttt tccccctga aaagataaca 2100  
 aagtctgcaa tttggtttgg agtatctcta ctgcagcctg gaagtttagc ttcactgtga 2160  
 atttaacaga gaaagtgcct ataaaggggg cgtttttaag agacaatccc atgatgtgc 2220  
 gccaatgcta acaacagggt caagaaacac aatgtttata gaaggagcat ccctcgacca 2280  
 tctgaatgag agtatgcctg accccttcca ccacaagtgg ggacacctct gcatactgc 2340  
 tccctcctct gctgttaagc cccagggagc cccatccacc cagtggctct acagacaggg 2400  
 caatacacac acaccaagat agccttcaga tcaacatgca tcacactcaa gtgttaatct 2460  
 ttcaaggttt tcttttcttt ttctgtttt ttattgttt tgcttttgc ttttttttt 2520  
 ttttttttgg tgggtgtggg gctacaaaac ttgaggccta gagctaaaa tcatatagaa 2580  
 atgatgttat cttgtgtgtg gaggaaggc cagctggcct aagttcacac tttgtccca 2640  
 gtggccctag actccaccca gccagctccc aaaatgaaaa gaccacctgt caagcagcag 2700  
 tcaggagtct gatgtcacc atcactattt tttttccatc attgtgcttg cctctgcctc 2760  
 cttccacacc cgtgtgacgt aatcgattg ggaagccagg acaatgtttg ctgttctgct 2820  
 ttgggtaaag ggactccctg aagctctgtg gctctccagt atggctccct ttccttcta 2880  
 acagatgcat atgttttctt cagaatacaa tagtgattct taaaataacc caaaagacag 2940  
 gcatccacag tgtgtgagca tgaatcacag cctgcattgt gtgagtgtga atagtggat 3000  
 aaaagtggat gtcagaagag tggaaatcaa acctctgcaa agcaatctt ctctttctgt 3060  
 gaagtgtatt aagaaatacc tgaagtctgt gtgtgtgggt gtaccagac tgtcaatcaa 3120  
 taaagacca gactgtcaat gaaaaaaaa aaaaaaaaa aaaaaaaaa 3170

&lt;210&gt; 12

&lt;211&gt; 2918

&lt;212&gt; DNA

&lt;213&gt; mouse

&lt;400&gt; 12

```

ctcagcagagg ggaaggggga ggaggcctgg atgactaaac ctgacagaaa cgctgggtggg 60
aggctcggggc gggcgccagt gccgcgtag gtcccttctcg acccgagcc accacccgcc 120
cggtgaccat gatagtgttt gtcaggttca actccagcta tggcttccca gtggaggctg 180
attctgacac cagcatcttg cagctcaagg aagtgggtgc taagcgacag ggggttccag 240
ctgaccagct gcgtgtgatt tttgccggga aggagcttcc gaatcacctg acggttcaaa 300
actgtgacct ggaacaacag agtattgtac acatagtaca gagaccacgg aggagaagtc 360
atgaaacaaa tgcattctgga ggggacgaac cccagagcac ctgagagggc tccatatggg 420
agtccaggag cttgacacga gtggacctga gcagccatac cctgccggtg gactctgtgg 480
ggctggcgggt cattctggac acagacagta agagggattc agaagcagcc agagggtccag 540
ttaaacccac ctacaacagc tttttcatct actgcaaagg cccctgccac aagggtccagc 600
ctggaaagct ccgagttcag tgtggcacct gcaacaagc aaccctcacc ttggcccagc 660
tggctgtccc aactccctga ttaaagagct ccatcacttc aggatccttg gagaagagca 720
gtacactagg taccagcagt atggggccga ggaatgcgtg ctgcaaattg gaggtgtgct 780
gtgcccccggt cctggctgtg gagctggact gctacctgaa cagggccaga ggaaagtcac 840
ctgcgaaggg ggcaacggcc tgggctgcgg gtttgttttc tgccgggact gtaaggaagc 900
ataccatgaa ggggattgct actcactgct cgaaccctca ggagccactt ctcaggccta 960
caggggtggac aaaagagccg ctgagcaagc tcgctgggag gaggcctcca aggaaacat 1020
caagaagacc accaagcctt gtccctcgtg caacgtgcc aattgaaaaa acggaggatg 1080
tatgcacatg aagtgtcctc agccccagtg caagctggag tgggtgctgga actgtggctg 1140
tgagtggaa cagagcctgca tgggagatca ctggtttgac gtgtagagag agatgtcact 1200
tggccctgga cgcacaacct caaggggaaac tccgaagatt cctaccttc ttagccattt 1260
cttcttctcg atgcatataa gcacataaat gcgcacacac aaacacaggc tgcagattac 1320
agaagcagcc cctagatcct ttctagggca cccacagaaa accacagcac ccgctggccc 1380
cagggggagg aggcactttc agcctctggc tcaactcgaat gtcagagctt agatgagggt 1440
gcacctttgg tttggattct gtagaagcca tgagttaggt gggaagtgtt ttccagggtt 1500
gttgccacgc cctgggtaag taacacctct gaggattctc agaagcacac ttgagatctg 1560
aggaacgctg ctctcatgta gtaatcatct attcccaaag ggccccctgc agtagtcaaa 1620
actatttggt tatcccccca aatcctatct ttacaaatgg tgctgatgag attacaaccc 1680
ctctgtgtac taatcagctt atcaaccaag tgagaacctt ggaaagctaa ttggatggca 1740
gactgcttaa atcgaggga ggactcagaa gccaaacctt cttccgttcg tttcattatc 1800
tgcaacttta gaaagaaatg atcttttttt cccctgaaa agataacaaa gtctgcaatt 1860
tggtttgagg tattcctact gcagcctgga agtttagctt cactgtgaat ttaacagaga 1920
aagtgcctat aaagggggcg tttttaagag acaatcccat gatgctgcgc caatgctaac 1980
aacagggtca agaaacacaa tgtttataga aggagcatcc ctcgaccatc tgaatgagag 2040
tatgcctgac cccttcacc acaagtgggg acacctctgc atatctgctc cctcctctgc 2100
tgttaagccc caggagagccc catccacca gtggtcttac agacagggca atacacacac 2160
accaagatag ccttcagatc aacatgcac acactcaagt gttaatcttt caagggtttt 2220
ttttcttttt cctgtttttt atttgttttg cttttgtctt tttttttttt ttttttgggtg 2280
gtggtggggc taccaaaactt gaggcctaga gctaaaaatc atatagaaat gatgttatct 2340
tgtggtgtga ggaaaggcca gctggcctaa gttcacactt ttgtcccagt ggccctagac 2400
tccaccagc cagctcccaa aatgaaaaga ccacctgtca agcagcagtc aggagtctga 2460

```

```

tgtcacccat cactatTTTT tttccatcat tgtgcttgcc tctgcctcct tccacacccg 2520
tgtgacgtaa tgcgattggg aagccaggac aatgtttgct gttctgcttt gggtaaagg 2580
actccctgaa gctctgtggc tctccagtat ggtccctttt ccttcctaac agatgcatat 2640
gttttcttca gaatacaata gtgattctta aaataaccca aaagacaggc atccacagt 2700
tgtgagcatg aatcacagcc tgcattgtgt gagtgtgaat agtgggataa aagtggatgt 2760
cagaagagtg gaaatcaaac ctctgcaaag caatctttct ctttctgtga agtgatttaa 2820
gaaatacctg aagtctgtgt gtgtggtggt acccagactg tcaatcaata aagaccaga 2880
ctgtcaatga aaaaaaaaaa aaaaaaaaaa aaaaaaaa 2918

```

&lt;210&gt; 13

&lt;211&gt; 3043

&lt;212&gt; DNA

&lt;213&gt; mouse

&lt;400&gt; 13

```

ctcagcgagg ggaaggggga ggaggcctgg atgactaaac ctgacagaaa cgctggtggg 60
aggctcgggc gggcgccagt gcccgcgtag gtcttctctg accgcagcc accaccggc 120
cggtgaccat gatagtgtt gtcaggttca actccagcta tggcttccca gtggaggctg 180
attctgacac cagcatcttg cagctcaagg aagtggttgc taagcgacag ggggttccag 240
ctgaccagct gcgtgtgatt tttgccggga aggagcttcc gaatcacctg acggttcaaa 300
actgtgacct ggaacaacag agtattgtac acatagtaca gagaccagc aggagaagtc 360
atgaaacaaa tgcattctga ggggacgaac cccagagcac ctgagagggc tccatatggg 420
agtcaggagg cttgacacga gtggacctga gcagccatac cctgccggtg gactctgtgg 480
ggctggcggt cattctggac acagacagta agagggatc agaagcagcc agagggtccag 540
ttaaacccac ctacaacagc tttttcatct actgcaaagg cccctgccac aagggtccagc 600
ctggaaagct ccgagttcag tgtggcacct gcaacaagc aacctcacc ttggcccagg 660
gcccattctg ctgggacgat gtcttaattc caaacggat gagtgggtgag tgccagtctc 720
cagactgccc tggaaaccaga gctgaatttt tctttaaatg tggagcacac ccaacctcag 780
acaaggacac gtcggtagct ttgaacctga tcaccagcaa caggcgagc atcccttgca 840
tagcgtgcac agatgtcagg agccctgtcc tggcttccca gtgtaaccac cgtcacgtga 900
tctgtttgga ctgtttccac ttgtattgtg tcacaagact caacgatcgg cagtttgtcc 960
acgatgctca acttggttac tccctgccgt gtgtagtttg ttttctgccg ggactgtaag 1020
gaagcatacc atgaagggga ttgcgactca ctgctcgaac cctcaggagc cacttctcag 1080
gcctacaggg tggacaaaag agccgctgag caagctcgct gggaggaggc ctccaaggaa 1140
accatcaaga agaccaccaa gccttgctc ctgtgcaacg tgccaattga aaaaaacgga 1200
ggatgtatgc acatgaagtg tcctcagccc cagtgcagc tggagtgggt ctggaactgt 1260
ggctgtgagt ggaaccgagc ctgcatggga gatcactggt ttgacgtgta gagagagatg 1320
tcacttggcc ctggacgcac aacctcaagg gaaactccga agattcctac cttccttagc 1380
catttcttct tctcgatgca tataagcaca taaatgcgca cacacaaaca caggctgcag 1440
attacagaag cagcccctag atcctttcta gggcaccac agaaaaccac agcaccgct 1500
ggccccaggg ggaggaggca ctttcagcct ctggctcact cgaatgtcag agcttagatg 1560
aggggtgcac tttggtttgg attctgtaga agccatgagt gaggtgggaa gtgttttcca 1620
gggtgtgtgc cagccctgg gtaagtaaca cctctgagga ttctcagaag cacacttag 1680
atctgaggaa cgtgctctc atgtagtaat catctattcc caaagggcc cctgcagtag 1740
tcaaaactat ttgtttatcc ccccaaactc tatctttaca aatggtgctg atgagattac 1800
aaccctctg tgtactaatc agcttatcaa ccaagtgaga acctaggaaa gctaattgga 1860
tggcagactg cttaaactgc agggaggact cagaagccaa acctacttcc gttcgtttca 1920
ttatctgcaa ctttagaaag aaatgatctt tttttcccc tgaaaagata acaaagtctg 1980

```

```

caatttggtt tggagtattc ctactgcagc ctggaagttt agcttcactg tgaatttaac 2040
agagaaagtg cctataaagg gggcggtttt aagagacaat cccatgatgc tgcgccaatg 2100
ctaacaacag ggtcaagaaa cacaatgttt atagaaggag catccctcga ccatctgaat 2160
gagagtatgc ctgacccctt ccaccacaag tggggacacc tctgcatatc tgctccctcc 2220
tctgctgtta agccccaggg agccccatcc acccagtggg cctacagaca gggcaatata 2280
cacacaccaa gatagccttc agatcaacat gcatcacact caagtgttaa tctttcaagg 2340
ttttcttttc tttttcctgt tttttatttg ttttgctttt gctttttttt tttttttttt 2400
tgggtgggtgg tggggctacca aacttgaggc cttagagctaa aaatcatata gaaatgatgt 2460
tatcttgttg tgtgaggaaa ggccagctgg cctaagttca cacttttgtc ccagtggccc 2520
tagactccac ccagccagct cccaaaatga aaagaccacc tgtcaagcag cagtcaggag 2580
tctgatgtca cccatcaacta ttttttttcc atcattgtgc ttgcctctgc ctcttccac 2640
accctgtgta cgtaatcgca ttgggaagcc aggacaatgt ttgctgttct gctttgggta 2700
aagggactcc ctgaagctct gtggctctcc agtatgggcc cttttccttc ctaacagatg 2760
catatgtttt cttcagaata caatagtgat tcttaaaata acccaaaaga caggcatcca 2820
cagtgtgtga gcatgaatca cagcctgcat tgtgtgagtg tgaatagtgg gataaaagtg 2880
gatgtcagaa gagtggaaat caaacctctg caaagcaatc tttctctttc tgtgaagtgt 2940
attaagaaat acctgaagtc tgtgtgtgtg gtggtaccca gactgtcaat caataaagac 3000
ccagactgtc aatgaaaaaa aaaaaaaaaa aaaaaaaaaa aaa 3043

```

&lt;210&gt; 14

&lt;211&gt; 3253

&lt;212&gt; DNA

&lt;213&gt; mouse

&lt;400&gt; 14

```

ctcagcgagg ggaaggggga ggaggcctgg atgactaaac ctgacagaaa cgctgggtggg 60
aggctcgggc gggcgccagt gccgcgtag gtccttctcg acccgagcc accaccgcc 120
cggtgaccat gatagtgttt gtcaggttca actccagcta tggcttccca gtggaggtcg 180
attctgacac cagcatcttg cagctcaagg aagtgggtgc taagcgacgg gggtccagct 240
gaccagctgc gtgtgatttt tgccgggaag gagcttccga atcacctgac gggtcaaaac 300
tgtgacctgg aacaacagag tattgtacac atagtacaga gaccacggag gagaagtcac 360
gaaacaaatg catctggagg ggacgaaccc cagagcacct cagagggtc catatgggag 420
tccaggagct tgacacgagt ggacctgagc agccataccc tgccggtgga ctctgtgggg 480
ctggcggtca ttctggacac agacagtaag agggattcag aagcagccag aggtccagtt 540
aaaccacct acaacagctt tttcatctac tgcaaaggcc cctgccacaa ggtccagcct 600
ggaaagctcc gagttcagtg tggcacctgc aaacaagcaa ccctcacctt ggcccagggc 660
ccatcttgct gggacgatgt cttaattcca aaccggatga gtggtgagtg ccagtctcca 720
gactgccctg gaaccagagc tgaatttttc tttaaatgtg gagcacaccc aacctcagac 780
aaggacacgt cggtagcttt gaacctgac accagcaaca ggcgcagcat cccttgcata 840
gcgtgcacag atgtcaggag ccctgtcctg gtcttccagt gtaaccaccg tcacgtgatc 900
tgtttggaact gtttccactt gtattgtgtc acaagactca acgatcggca gtttgtccac 960
gatgtcaaac ttggctactc cctgccgtgt gtagctggct gtcccaactc cctgattaaa 1020
gagctccatc acttcaggat ccttgaggaa gagcagtaca ctaggtagca gcagtatggg 1080
gccgaggaat gcgtgctgca aatgggaggt gtgctgtgcc cccgtcctgg ctgtggagct 1140
ggactgctac ctgaacaggg ccagagggaa gtcacctgcg aagggggcaa cggcctgggc 1200
tgcggttttg tttctgccc ggactgtaag gaagcatacc atgaagggga ttgcgactca 1260
ctgctcgaac cctcaggagc cacttctcag gcctacaggg tggacaaaag agccgctgag 1320
caagctcgct gggaggaggc ctccaaggaa accatcaaga agaccaccaa gccttgctct 1380

```

cgctgcaacg tgccaattga aaaaaacgga ggatgtatgc acatgaagtg tcctcagccc 1440  
cagtgcgaagc tggagtgggtg ctggaactgt ggctgtgagt ggaaccgagc ctgcatggga 1500  
gatcactgggt ttgacgtgta gagagagatg tcacttggcc ctggacgcac aacctcaagg 1560  
gaaactccga agattccctac cttccttagc catttcttct tctcgatgca tataagcaca 1620  
taaattgcga cacacaaaca caggctgcag attacagaag cagcccctag atcctttcta 1680  
gggcacccac agaaaaccac agcacccgct ggccccaggg ggaggaggca ctttcagcct 1740  
ctggctcact cgaatgtcag agcttagatg aggggtgcacc tttggtttgg attctgtaga 1800  
agccatgagt gaggtgggaa gtgttttcca ggggtgttgc cagccctgg gtaagtaaca 1860  
cctctgagga ttctcagaag cacacttgag atctgaggaa cgctgctctc atgtagtaat 1920  
catctattcc caaagggccc cctgcagtag tcaaaactat ttgtttatcc ccccaaatcc 1980  
tatctttaca aatggtgctg atgagattac aaccctctg tgtactaatc agcttatcaa 2040  
ccaagtgaga acctaggaaa gctaattgga tggcagactg cttaaatcgc agggaggact 2100  
cagaagccaa acctacttcc gttcgtttca ttatctgcaa ctttagaaag aaatgatctt 2160  
tttttcccc tgaaaagata acaaagtctg caatttggtt tggagtattc ctactgcagc 2220  
ctggaagttt agcttcactg tgaatttaac agagaaagtg cctataaagg gggcggtttt 2280  
aagagacaat cccatgatgc tgcgccaatg ctaacaacag ggtcaagaaa cacaatgttt 2340  
atagaaggag catccctcga ccacttgaat gagagtatgc ctgaccctt ccaccacaag 2400  
tggggacacc tctgcatatc tgctccctcc tctgctgtta agccccaggg agcccatcc 2460  
accagtggt cctacagaca gggcaatata cacacacca gatagcctc agatcaacat 2520  
gcatcacact caagtgttaa tctttcaagg ttttctttt ttttctctgt tttttatttg 2580  
ttttgctttt gctttttttt tttttttttt tgggtgggtg ggggctacca aacttgaggc 2640  
ctagagctaa aaatcatata gaaatgatgt tatcttgtgg tgtgaggaaa ggccagctgg 2700  
cctaagttca cacttttgtc ccagtggccc tagactccac ccagccagct cccaaaatga 2760  
aaagaccacc tgtcaagcag cagtcaggag tctgatgtca cccatcacta ttttttttcc 2820  
atcattgtgc ttgcctctgc ctccctccac acccggtgta cgtaatcgca ttgggaagcc 2880  
aggacaatgt ttgctgttct gctttgggtg aagggactcc ctgaagctct gtggctctcc 2940  
agtatggtcc ctttctcttc ctaacagatg catatgtttt cttcagaata caatagtgat 3000  
tcttaaaata acccaaaaga caggcatcca cagtgtgtga gcatgaatca cagcctgcat 3060  
tgtgtgagtg tgaatagtgg gataaaagtg gatgtcagaa gagtggaaat caaacctctg 3120  
caaagcaatc tttctcttcc tgtgaagtgt attaagaaat acctgaagtc tgtgtgtgtg 3180  
gtggtaccca gactgtcaat caataaagac ccagactgtc aatgaaaaaa aaaaaaaaaa 3240  
aaaaaaaaaa aaa 3253

&lt;210&gt; 15

&lt;211&gt; 3254

&lt;212&gt; DNA

&lt;213&gt; mouse

&lt;400&gt; 15

ctcagcgagg ggaaggggga ggaggcctgg atgactaaac ctgacagaaa cgctgggtggg 60  
aggctcgggc gggcgccagt gcccgcgtag gtccttctcg accgcagcc accaccgcc 120  
cgggtgaccat gatagtgttt gtcaggttca actccagcta tggcttccca gtggagggtcg 180  
attctgacac cagcatcttg cagctcaagg aagtggttgc taagcgacag ggggttccag 240  
ctgaccagct gcgtgtgatt tttgccggga aggagcttcc gatcacctga cggttcaaaa 300  
ctgtgacctg gaacaacaga gtattgtaca catagtacag agaccacgga ggagaagtca 360  
tgaaacaaat gcactctggag gggacgaacc ccagagcacc tcagagggct ccatatggga 420  
gtccaggagc ttgacacgag tggacctgag cagccatacc ctgccggtgg actctgtggg 480  
gctggcggtc attctggaca cagacagtaa gagggattca gaagcagcca gaggtccagt 540

```

taaaccacc tacaacagct ttttcatcta ctgcaaaggc ccctgccaca aggtccagcc 600
tggaaagctc cgagttcagt gtggcacctg caaacaagca accctcacct tggcccaggg 660
cccatcttgc tgggacgatg tcttaattcc aaaccggatg agtggtgagt gccagtctcc 720
agactgccct ggaaccagag ctgaattttt ctttaaatgt ggagcacacc caacctcaga 780
caaggacacg tcggtagctt tgaacctgat caccagcaac aggcgcagca tcccttgcac 840
agcgtgcaca gatgtcagga gccctgtcct ggtcttccag tctaaccacc gtcacgtgat 900
ctgtttggac tgtttccact tgtattgtgt cacaagactc aacgatcggc agtttgtcca 960
cgatgctcaa cttggctact ccctgccgtg tgtagctggc tgtcccaact ccctgattaa 1020
agagctccat cacttcagga tccttggaga agagcagtac actagggtacc agcagtatgg 1080
ggccgaggaa tgcgtgctgc aaatgggagg tgtgctgtgc ccccgtcctg gctgtggagg 1140
tggactgcta cctgaacagg gccagaggaa agtcacctgc gaagggggca acggcctggg 1200
ctgcccgttt gttttctgcc gggactgtaa ggaagcatac catgaagggg attgcgactc 1260
actgctcgaa ccctcaggag ccacttctca ggcctacagg gtggacaaaa gagccgctga 1320
gcaagctcgc tgggaggagg cctccaagga aaccatcaag aagaccacca agccttgtcc 1380
tcgctgcaac gtgccaatg aaaaaaacgg aggatgtatg cacatgaagt gtcctcagcc 1440
ccagtgcagg ctggagtggg gctggaactg tggctgtgag tggaaaccgag cctgcatggg 1500
agatcactgg tttgacgtgt agagagagat gtcacttggc cctggacgca caacctcaag 1560
ggaaactccg aagattccta ccttccttag ccatttcttc ttctcgatgc atataagcac 1620
ataaatgccc acacacaaac acaggctgca gattacagaa gcagccccta gatcctttct 1680
agggcaccca cagaaaacca cagcaccgcc tggcccaggg gggaggaggc actttcagcc 1740
tctggctcac tcgaatgtca gagcttagat gaggtgtcac ctttggtttg gattctgtag 1800
aagccatgag tgaggtggga agtgttttcc agggttgttg ccacgccctg ggtaagtaac 1860
acctctgagg attctcagaa gcacacttga gatctgagga acgctgctct catgtagtaa 1920
tcattctatc ccaaagggcc ccctgcagta gtcaaaacta tttgtttatc ccccaaatc 1980
ctattctttac aaatgggtgt gatgagatta caaccctct gtgtactaat cagcttatca 2040
accaagtgag aacctaggaa agctaattgg atggcagact gcttaaatcg caggaggagc 2100
tcagaagcca aacctacttc cgttcgtttc attatctgca actttagaaa gaaatgatct 2160
ttttttcccc ctgaaaagat aacaaagtct gcaatttggg ttggagtatt cctactgcag 2220
cctggaagtt tagcttcaat gtgaatttaa cagagaaagt gcctataaag ggggcgtttt 2280
taagagacaa tcccatgatg ctgcgccaat gctaacaaca gggtaagaa acacaatgtt 2340
tatagaagga gcatccctcg accatctgaa tgagagtatg cctgaccctc tccaccacaa 2400
gtggggacac ctctgcatac ctgtccctc ctctgctgtt aagccccagg gagccccatc 2460
caccagtggt tctacagac agggcaatac acacacacca agatagcctt cagatcaaca 2520
tgcatacac tcaagtgtta atctttcaag gttttctttt ctttttctctg ttttttattt 2580
gttttgcttt tgcctttttt tttttttttt ttgggtgggtg tggggctacc aaacttgagg 2640
cctagagcta aaaatcatat agaaatgatg ttatcttggt gtgtgaggaa aggcagctg 2700
gcctaagttc acacttttgt ccagtgggc ctgactcca cccagccagc tcccaaatg 2760
aaaagaccac ctgtcaagca gcagtcagga gtctgatgtc acccatcact attttttttc 2820
catcattgtg cttgcctctg cctccttcca caccgctgtg acgtaatcgc attgggaagc 2880
caggacaatg tttgctgttc tgccttgggt aaagggactc cctgaagctc tgtggctctc 2940
cagtatggtc ctttttctt cctaacagat gcatatgttt tcttcagaat acaatagtga 3000
ttcttaaaat aacccaaaag acaggcatcc acagtgtgtg agcatgaatc acagcctgca 3060
ttgtgtgagt gtgaatagtg ggataaaagt ggatgtcaga agagtggaaa tcaaacctct 3120
gcaaagcaat ctttctcttt ctgtgaagtg tattaagaaa tacctgaagt ctgtgtgtgt 3180
gggtgtaccc agactgtcaa tcaataaaga cccagactgt caatgaaaaa aaaaaaaaaa 3240
aaaaaaaaaa aaaa

```

3254

&lt;210&gt; 16



&lt;211&gt; 3253

&lt;212&gt; DNA

&lt;213&gt; mouse

&lt;400&gt; 16

```

ctcagcgagg ggaaggggga ggaggcctgg atgactaaac ctgacagaaa cgctggtggg 60
aggctcgggc gggcgccagt gcccgcgtag gtccttctcg acccgagcc accaccgcc 120
cggtgaccat gatagtgttt gtcaggttca actccagcta tggcttccca gtggaggctg 180
attctgacac cagcatcttg cagctcaagg aagtggttgc taagcgacag ggggttccag 240
ctgaccagct gcgtgtgatt tttgccggga aggagcttcc gaatcacctg acggttcaaa 300
actgtgacct ggaacaacag agtattgtac acatagtaca gagaccacgg gagaagtcac 360
gaaacaaatg catctggagg ggacgaaccc cagagcacct cagagggctc catatgggag 420
tccaggagct tgacacgagt ggacctgagc agccataccc tgccggtgga ctctgtgggg 480
ctggcgggtca ttctggacac agacagtaag agggattcag aagcagccag aggtccagtt 540
aaaccacct acaacagctt ttcatctac tgcaaaggcc cctgccacaa ggtccagcct 600
ggaaagctcc gagttcagtg tggcacctgc aaacaagcaa cctcacctt ggcccagggc 660
ccatcttgct gggacgatgt cttaatcca aaccggatga gtggtgagtg ccagtctcca 720
gactgccctg gaaccagagc tgaatttttc tttaaatgtg gagcacaccc aacctcagac 780
aaggacacgt cggtagcttt gaacctgac accagcaaca ggcgagcat cccttgcata 840
gcgtgcacag atgtcaggag ccctgtcctg gtcttccagt gtaaccaccg tcacgtgac 900
tgtttggaact gtttccactt gtattgtgtc acaagactca acgatcggca gtttgtccac 960
gatgtcgaac ttggctactc cctgcctgtg gtagctggct gtcccaactc cctgattaaa 1020
gagctccatc acttcaggat ccttgagaa gagcagtaca ctaggtagca gcagtatggg 1080
gccgaggaat gcgtgctgca aatgggaggt gtgctgtgcc cccgtcctgg ctgtggagct 1140
ggactgctac ctgaacaggg ccagaggaaa gtcacctgcg aagggggcaa cggcctgggc 1200
tgccgggttg ttttctgccc ggactgtaag gaagcatacc atgaagggga ttgcgactca 1260
ctgctcgaac cctcaggagc cacttctcag gcctacaggg tggacaaaag agccgtgag 1320
caagctcgct gggaggaggc ctccaaggaa accatcaaga agaccaccaa gccttgctc 1380
cgctgcaacg tgccaattga aaaaaacgga ggatgtatgc acatgaagtg tcctcagccc 1440
cagtgcgaagc tggagtgggt ctggaactgt ggctgtgagt ggaaccgagc ctgcatggga 1500
gatcactggt ttgacgtgta gagagagatg tcacttggcc ctggacgcac aacctcaagg 1560
gaaactccga agattcctac cttccttagc catttcttct tctcgtatga tataagcaca 1620
taaattgcga cacacaaaca caggctgcag attacagaag cagcccctag atcctttcta 1680
gggcacccac agaaaaccac agcaccgcct ggccccaggg ggaggaggca ctttcagcct 1740
ctggctcact cgaatgtcag agcttagatg aggggtgcacc tttggtttgg attctgtaga 1800
agccatgagt gaggtgggaa gtgttttcca gggtgtgtgc cagccctgg gtaagtaaca 1860
cctctgagga ttctcagaag cacacttgag atctgaggaa cgctgctctc atgtagtaat 1920
catctattcc caaagggcc cctgcagtag tcaaaactat ttgtttatcc ccccaaatcc 1980
tatctttaca aatgggtgctg atgagattac aaccctctg tgtactaatc agcttatcaa 2040
ccaagtgaga acctaggaaa gctaattgga tggcagactg cttaaactgc agggaggact 2100
cagaagccaa acctacttcc gtctgtttca ttatctgcaa ctttagaaag aaatgatctt 2160
tttttcccc tgaaaagata acaaagtctg caatttgggt tggagtattc ctactgcagc 2220
ctggaagtgt agcttcactg tgaatttaac agagaaagtg cctataaagg gggcgttttt 2280
aagagacaat cccatgatgc tgcgccaatg ctaacaacag ggtcaagaaa cacaatgttt 2340
atagaaggag catccctcga ccacttgaat gagagtatgc ctgaccctt ccaccacaag 2400
tggggacacc tctgcatatc tgetccctcc tctgctgtta agccccaggg agccccatcc 2460
accagtggc cctacagaca gggcaataca cacacaccaa gatagccttc agatcaacat 2520
gcatcacact caagtgttaa tctttcaagg ttttcttttc ttttctctgt tttttatttg 2580

```

```

ttttgctttt gctttttttt tttttttttt tgggtgggtggg ggggctacca aacttgaggc 2640
ctagagctaa aaatcatata gaaatgatgt tatcttgtgg tgtgaggaaa ggccagctgg 2700
cctaagttca cacttttgtc ccagtggccc tagactccac ccagccagct cccaaaatga 2760
aaagaccacc tgtcaagcag cagtcaggag tctgatgtca cccatcacta ttttttttcc 2820
atcattgtgc ttgcctctgc ctccctccac acccgtgtga cgtaatcgca ttgggaagcc 2880
aggacaatgt ttgctgttct gctttgggta aagggaactcc ctgaagctct gtggctctcc 2940
agtatgggcc cttttccctc ctaacagatg catatgtttt cttcagaata caatagtgat 3000
tcttaaaata acccaaaaga caggcatcca cagtgtgtga gcatgaatca cagcctgcat 3060
tgtgtgagtg tgaatagtgg gataaaagtg gatgtcagaa gagtggaaat caaacctctg 3120
caaagcaatc tttctctttc tgtgaagtgt attaagaaat acctgaagtc tgtgtgtgtg 3180
gtggtaccca gactgtcaat caataaagac ccagactgtc aatgaaaaaa aaaaaaaaaa 3240
aaaaaaaaaa aaa 3253

```

&lt;210&gt; 17

&lt;211&gt; 3092

&lt;212&gt; DNA

&lt;213&gt; mouse

&lt;400&gt; 17

```

ctcagcgagg ggaaggggga ggaggcctgg atgactaaac ctgacagaaa cgctgggtggg 60
aggctcgggc gggcgccagt gcccgcgtag gtccctctctg acccgcagcc accaccgcc 120
cggtgaccat gatagtaact gtgacctgga acaacagagt attgtacaca tagtacagag 180
accacggagg agaagtcattg aaacaaatgc atctggaggg gacgaacccc agagcacctc 240
agagggctcc atatgggagt ccaggagctt gacacgagtg gacctgagca gccataccct 300
gccggtggac tctgtggggc tggcggtcat tctggacaca gacagtaaga gggattcaga 360
agcagccaga ggtccagtta aaccaccta caacagcttt ttcattctact gcaaaggccc 420
ctgccacaag gtccagcctg gaaagctccg agttcagtggt ggcacctgca aacaagcaac 480
cctcaccttg gcccaggggc catcttgctg ggacgatgtc ttaattccaa accggatgag 540
tgggtgagtgc cagtctccag actgccctgg aaccagagct gaatttttct ttaaattgtgg 600
agcacacca acctcagaca aggacacgtc ggtagctttg aacctgatca ccagcaacag 660
gcgcagcatc ccttgcatag cgtgcacaga tgtcaggagc cctgtcctgg tcttcagtg 720
taaccaccgt cacgtgatct gtttggaactg tttccacttg tattgtgtca caagactcaa 780
cgatcggcag tttgtccacg atgctcaact tggctactcc ctgccgtgtg tagctggctg 840
tcccaactcc ctgattaaag agctccatca cttcaggatc cttggagaag agcagtacac 900
taggtaccag cagtatgggg ccgaggaatg cgtgctgcaa atgggaggtg tgctgtgcc 960
cgtcctggc tgtggagctg gactgctacc tgaacagggc cagaggaaag tcacctgca 1020
agggggcaac ggcctgggct gcgggtttgt tttctgccgg gactgtaagg aagcatacca 1080
tgaaggggat tgcgactcac tgctcgaacc ctcaggagcc acttctcagg cctacagggt 1140
ggacaaaaga gccgctgagc aagctcgctg ggaggaggcc tccaaggaaa ccatcaagaa 1200
gaccaccaag ccttgctctc gctgcaacgt gccaattgaa aaaaacggag gatgtatgca 1260
catgaagtgt cctcagcccc agtgcaagct ggagtgggtg tggaaactgtg gctgtgagtg 1320
gaaccgagcc tgcattgggag atcactgggt tgcagtgtag agagagatgt cacttgggcc 1380
tggacgcaca acctcaaggg aaactccgaa gattcctacc ttccttagcc atttcttctt 1440
ctcgatgcat ataagcacat aaatgcgcac acacaaacac aggctgcaga ttacagaagc 1500
agcccctaga tcttttctag ggcacccaca gaaaaccaca gcaccgctg gccccagggg 1560
gaggaggcac tttcagcctc tggctcactc gaatgtcaga gcttagatga ggggtgcacct 1620
ttggtttgga ttctgtagaa gccatgagtg aggtgggaag tgttttccag gggtgttgcc 1680
acgccttggg taagtaaacac ctctgaggat tctcagaagc acacttgaga tctgaggaaac 1740

```

```

gctgctctca tgtagtaatc atctatcccc aaagggcccc ctgcagtagt caaaactatt 1800
tgtttatccc cccaaatcct atctttacaa atgggtgctga tgagattaca acccctctgt 1860
gtactaatca gcttatcaac caagtgaagaa cctaggaaag ctaattggat ggcagactgc 1920
ttaaatcgca gggaggactc agaagccaaa cctacttccg ttcgtttcat tatctgcaac 1980
tttagaaaga aatgatcttt ttttccccct gaaaagataa caaagtctgc aatttggttt 2040
ggagtattcc tactgcagcc tggaagtta gcttcaactgt gaatttaaca gagaaagtgc 2100
ctataaaggg ggcgttttta agagacaatc ccatgatgct gcgccaatgc taacaacagg 2160
gtcaagaaac acaatgttta tagaaggagc atccctcgac catctgaatg agagtatgcc 2220
tgaccccttc caccacaagt ggggacacct ctgcatatct gctccctcct ctgctgttaa 2280
gccccaggga gccccatcca cccagtggtc ctacagacag ggcaatacac acacaccaag 2340
atagccttca gatcaacatg catcacactc aagtgttaat ctttcaagggt tttcttttct 2400
ttttcctgtt ttttatgtgt tttgcttttg cttttttttt tttttttttt ggtggtggtg 2460
gggctaccaaa acttgaggcc tagagctaaa aatcatatag aaatgatgtt atcttggtgt 2520
gtgaggaaag gccagctggc ctaagtccac acttttgtcc cagtggccct agactccacc 2580
cagccagctc ccaaaatgaa aagaccacct gtcaagcagc agtcaggagt ctgatgtcac 2640
ccatcactat tttttttcca tcattgtgct tgccctctgc tccttccaca cccgtgtgac 2700
gtaatcgcat tgggaagcca ggacaatgtt tgctgttctg ctttgggttaa agggactccc 2760
tgaagctctg tggctctcca gtatggtccc ttttccctcc taacagatgc atatgttttc 2820
ttcagaatac aatagtgtt cttaaaataa cccaaaagac aggcattccac agtgtgtgag 2880
catgaatcac agcctgcatt gtgtgagtgt gaatagtggg ataaaagtgg atgtcagaag 2940
agtggaatc aaacctctgc aaagcaatct ttctctttct gtgaagtgt ttaagaaata 3000
cctgaagtct gtgtgtgtgg tggtagccag actgtcaatc aataaagacc cagactgtca 3060
atgaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa 3092

```

&lt;210&gt; 18

&lt;211&gt; 3255

&lt;212&gt; DNA

&lt;213&gt; mouse

&lt;400&gt; 18

```

ctcagcgagg ggaaggggga ggaggcctgg atgactaaac ctgacagaaa cgctggtggg 60
aggctcgggc gggcgccagt gccgcgtag gtccctctcg acccgagcc accaccgccc 120
cggtgaccat gatagtgttt gtcaggttca actccagcta tggcttccca gtggaggtcg 180
attctgacac cagcatcttg cagctcaagg aagtggttgc taagcgacag ggggttccag 240
ctgaccagct gcgtgtgatt tttgccgga aggagcttcc gaatcacctg acggttcaaa 300
actgtgacct ggaacaacag agtattgtac acatagtaca gagaccacgg aggagaagtc 360
atgaaacaaa tgcattctgga ggggacgaac cccagagcac ctgagagggc tccatattggg 420
agtccaggag cttgacacga gtggacctga gcagccatac cctgccggtg gactctgtgg 480
ggctggcggc cattctggac acagacagta agagggattc agaagcagcc agaggtccag 540
ttaaacccac ctacaacagc tttttcatct actgcaaagg cccctgccac aaggtccagc 600
ctggaaatct ccgagttcag tgtggcacct gcaaacaaagc aacctcacc ttggcccagg 660
gcccattctg ctgggacgat gtcttaattc caaacggat gagtgggtgag tgccagtctc 720
cagactgccc tggaaaccaga gctgaatttt tctttaaatg tggagcacac ccaacctcag 780
acaaggacac gtcggttagc ttgaacctga tcaccagcaa caggcgagc atcccttgca 840
tagcgtgcac agatgtcagg agccctgtcc tggcttccca gtgtaaccac cgtcacgtga 900
tctgtttgga ctgtttccac ttgtattgtg tcacaagact caacgatcgg cagtttgtcc 960
acgatgtcca acttggttac tccctgccgt gtgtagctgg ctgtcccaac tccctgatta 1020
aagagctcca tcacttcagg atccttgagg aagagcagta cactaggtac cagcagtatg 1080

```

gggccgagga atgctgtgctg caaatgggag gtgtgctgtg ccccgctcct ggctgtggag 1140  
 ctggactgct acctgaacag ggccagagga aagtcacctg cgaagggggc aacggcctgg 1200  
 gctgcggggtt tgttttctgc cgggactgta aggaagcata ccatgaaggg gattgcgact 1260  
 cactgctcga accctcagga gccactttctc aggcctacag ggtggacaaa agagccgctg 1320  
 agcaagctcg ctgggaggag gcctccaagg aaaccatcaa gaagaccacc aagccttgctc 1380  
 ctgctgcaa cgtgcccaatt gaaaaaaacg gaggatgtat gcacatgaag tgcctcagc 1440  
 cccagtgcga gctggagtgg tgctggaact gtggctgtga gtggaaccga gcctgcatgg 1500  
 gagatcactg gtttgacgtg tagagagaga tgtcacttgg ccctggagcg acaacctcaa 1560  
 gggaaactcc gaagattcct accttcctta gccatttctt cttctcgatg catataagca 1620  
 cataaatgcg cacacacaaa cacaggctgc agattacaga agcagccctt agatcctttc 1680  
 tagggcacc cagaaaaacc acagcaccgc ctggccccag ggggaggagg cacttttcagc 1740  
 ctctggctca ctogaatgtc agagcttaga tgagggtgca cctttgggtt ggattctgta 1800  
 gaagccatga gtgagggtgg aagtgttttc cagggttggt gccacgccct gggtaagtaa 1860  
 cacctctgag gattctcaga agcacacttg agatctgagg aacgctgctc tcatgtagta 1920  
 atcatctatt cccaaagggc cccctgcagt agtcaaaact atttgtttat cccccaaat 1980  
 cctatcttta caaatggtgc tgatgagatt acaaccctc tgtgtactaa tcagcttatc 2040  
 aaccaagtga gaacctagga aagctaattg gatggcagac tgcttaaate gcaggaggga 2100  
 ctcagaagcc aaacctactt cgtttcgttt cattatctgc aactttagaa agaaatgatc 2160  
 tttttttccc cctgaaaaga taacaaagtc tgcaatttgg tttggagtat tcctactgca 2220  
 gcctggaagt ttagcttcac tgtgaattta acagagaaag tgcctataaa gggggcgttt 2280  
 ttaagagaca atcccatgat gctgcgcaa tgctaacaac agggctcaga aacacaatgt 2340  
 ttatagaagg agcatccctc gaccatctga atgagagtat gcctgacccc ttccaccaca 2400  
 agtggggaca cctctgcata tctgtccct cctctgctgt taagccccag ggagccccat 2460  
 ccaccagtg gtccacaga cagggaata cacacacacc aagatagcct tcagatcaac 2520  
 atgcatcaca ctcaagtgtt aatctttcaa ggttttcttt tctttttcct gttttttatt 2580  
 tgttttgctt ttgctttttt tttttttttt tttgggtggt gtggggctac caaacttgag 2640  
 gcctagagct aaaaatcata tagaaatgat gttatcttgt ggtgtgagga aaggccagct 2700  
 ggcctaagtt cacacttttg tcccagtggc cctagactcc acccagccag ctcccaaaat 2760  
 gaaaagacca cctgtcaagc agcagtcagg agtctgatgt caccatcac tatttttttt 2820  
 ccatcattgt gcttgccctc gcctccctcc acaccgctgt gacgtaatcg cattgggaag 2880  
 ccaggacaat gtttgctggt ctgctttggg taaagggaact ccctgaagct ctgtggctct 2940  
 ccagtatggc cctttttcct tcctaacaga tgcataatgt ttcttcagaa tacaatagtg 3000  
 attcttaaaa taacccaaaa gacaggcatc cacagtgtgt gagcatgaat cacagcctgc 3060  
 attgtgtgag tgtgaatagt gggataaaaag tggatgtcag aagagtggaa atcaaacctc 3120  
 tgcaaagcaa tctttctctt tctgtgaagt gtattaagaa atacctgaag tctgtgtgtg 3180  
 tgggtggtacc cagactgtca atcaataaag acccagactg tcaatgaaaa aaaaaaaaaa 3240  
 aaaaaaaaaa aaaaaa 3255

&lt;210&gt; 19

&lt;211&gt; 3255

&lt;212&gt; DNA

&lt;213&gt; mouse

&lt;400&gt; 19

ctacagcagg ggaaggggga ggaggcctgg atgactaaac ctgacagaaa cgctgggtggg 60  
 aggctcgggc gggcgccagt gccgcgtag gtcccttctc accgcagcc accaccgcc 120  
 cggtgaccat gatagtgttt gtcaggttca actccagcta tggcttccca gtggaggtcg 180  
 attctgacac cagcatcttg cagctcaagg aagtgggtgc taagcgacag ggggttccag 240

ctgaccagct gcggtgtgatt tttgcccggga aggagcttcc gaatcacctg acggttcaaaa 300  
 actgtgacct ggaacaacag agtattgtac acatagtaca gagaccacgg aggagaagtc 360  
 atgaaacaaa tgcattctgga ggggacgaac cccagagcac ctgagagggc tccatatggg 420  
 agtccaggag cttgacacga gtggacctga gcagccatac cctgcccgtg gactctgtgg 480  
 ggctggcgggt cattctggac acagacagta agaggggattc agaagcagcc agaggtccag 540  
 ttaaaccacac ctacaacagc tttttcatct actgcaaagg cccctgccac aagggtccagc 600  
 ctggaaagct ccgagttcag tgtggcacct gcaacaagc aaccctcacc ttggcccagg 660  
 gcccatcttg ctgggacgat gtcttaattc caaacccgat gagtgggtgag tgccagtctc 720  
 cagactgccc tggaaccaga gctgaatttt tctttaaatg tggagcacac ccaacctcag 780  
 acaaggacac gtcggtagct ttgaacctga tcaccagcaa caggcgagc atcccttgca 840  
 tagcgtgcac agatgtcagg agccctgtcc tggctctcca gtgtaaccac cgtcacgtga 900  
 tctgttttga ctgtttccac ttgtattgtg tcacaagact caacgatcgg cagtttgtcc 960  
 acgatgctca acttggtctac tccctgccgt gtgtagctgg ctgtcccaac tccctgatta 1020  
 aagagctcca tcacttcagg atccctggag aagagcagta cactaggtac cagcagtatg 1080  
 gggccgagga atgcgtgctg caaatgggag gtgtgtgtgt ccccccgtcc ggctgtggag 1140  
 ctggactgct acctgaacag ggccagagga aagtcacctg cgaagggggc aacggcctgg 1200  
 gctgcccgtt tgttttctgc cgggactgta aggaagcata ccatgaaggg gattgagact 1260  
 cactgctcga accctcagga gccacttctc aggcctacag ggtggacaaa agagccgctg 1320  
 agcaagctcg ctgggaggag gcctccaagg aaaccatcaa gaagaccaac aagccttgtc 1380  
 ctgctgcaa cgtgccatt gaaaaaacg gaggatgtat gcacatgaag tgtcctcagc 1440  
 cccagtgcaa gctggagtgg tgctggaact gtggctgtga gtggaaccga gcctgcatgg 1500  
 gagatcactg gtttgacgtg tagagagaga tgtcacttgg ccctggacgc acaacctcaa 1560  
 gggaaactcc gaagattcct accttcctta gccatttctt cttctcgatg catataagca 1620  
 cataaatgcg cacacacaaa cacaggctgc agattacaga agcagccccct agatcctttc 1680  
 tagggcaccc acagaaaacc acagcacccg ctggccccag ggggaggagg cactttcagc 1740  
 ctctggctca ctcgaaatgc agagcttaga tgagggtgca cctttggttt ggattctgta 1800  
 gaagccatga gtgaggtggg aagtgttttc cagggttgtt gccacgccct gggtaagtaa 1860  
 cacctctgag gattctcaga agcacacttg agatctgagg aacgctgctc tcatgtagta 1920  
 atcatctatt cccaaaggcg cccctgcagt agtcaaaact atttgtttat ccccccaat 1980  
 cctatcttta caaatgggtg tgatgagatt acaaccctc tgtgtactaa tcagcttatc 2040  
 aaccaagtga gaacctagga aagctaattg gatggcagac tgcttaaatc gcagggagga 2100  
 ctcagaagcc aaacctactt ccgttcgttt cattatctgc aactttagaa agaaatgatc 2160  
 tttttttccc cctgaaaaga taacaaagtc tgcaatttgg tttggagtat tcctactgca 2220  
 gcctggaagt ttagcttcac tgtgaattta acagagaaag tgcctataaa gggggcgttt 2280  
 ttaagagaca atcccatgat gctgcgcaa tgctaacaac agggtaaga aacacaatgt 2340  
 ttatagaagg agcatccctc gaccatctga atgagagtat gcctgacccc tccaccaca 2400  
 agtggggaca cctctgcata tctgtccct cctctgctgt taagccccag ggagccccat 2460  
 ccaccagtg gtccacaga cagggaata cacacacacc aagatagcct tcagatcaac 2520  
 atgcatcaca ctcaagtgtt aatctttcaa ggttttcttt tctttttcct gttttttatt 2580  
 tgttttgcct ttgctttttt tttttttttt tttgggtgtg gtggggctac caaacttgag 2640  
 gcctagagct aaaaatcata tagaaatgat gttatcttgt ggtgtgagga aaggccagct 2700  
 ggcctaagtt cacacttttg tcccagtggt cctagactcc acccagccag ctcccaaat 2760  
 gaaaagacca cctgtcaagc agcagtcagg agtctgatgt caccatcac tttttttttt 2820  
 ccattcattgt gcttgccctc gcctccttcc acaccctgtg gacgtaatcg cattgggaag 2880  
 ccaggacaat gtttgctgtt ctgctttggg taaagggact ccctgaagct ctgtggctct 2940  
 ccagtatggt ccccttttcc tccaaacaga tgcatatgtt ttcttcagaa tacaatagtg 3000  
 attcttaaaa taaccacaaa gacaggcatc cacagtgtgt gagcatgaat cacagcctgc 3060  
 attgtgtgag tgtgaatagt gggataaaaag tggatgtcag aagagtggaa atcaaacctc 3120

```

tgcaaagcaa tctttctctt tctgtgaagt gtattaagaa atacctgaag tctgtgtgtg 3180
tgggtggtacc cagactgtca atcaataaag acccagactg tcaatgaaaa aaaaaaaaaa 3240
aaaaaaaaaa aaaaaa                                     3255

```

&lt;210&gt; 20

&lt;211&gt; 3255

&lt;212&gt; DNA

&lt;213&gt; mouse

&lt;400&gt; 20

```

ctcagcgagg ggaaggggga ggaggcctgg atgactaaac ctgacagaaa cgctgggtggg 60
aggctcgggc gggcgccagt gccgcgctag gtccttctcg acccgagcc accacccgcc 120
cgggtgaccat gatagtgttt gtcagggttca actccagcta tggcttccca gtggagggtcg 180
attctgacac cagcatcttg cagctcaagg aagtgggtgc taagcgacag ggggttccag 240
ctgaccagct gcgtgtgatt tttgccggga aggagcttcc gaatcacctg acggttcaaa 300
actgtgacct ggaacaacag agtattgtac acatagtaca gagaccacgg aggagaagtc 360
atgaaacaaa tgcattctgga ggggacgaac cccagagcac ctcagagggc tccatatggg 420
agtccaggag cttgacacga gtggacctga gcagccatac cctgccgggtg gactctgttg 480
ggctggcggt cattctggac acagacagta agagggattc agaagcagcc agagggtccag 540
ttaaaccac ctacaacagc tttttcatct actgcaaagg cccctgccac aagggtccagc 600
ctggaaagct ccgagttcag tgtggcacct gcaaacaagc aaccctcacc ttggcccagg 660
gcccattctt ctgggacgat gtcttaattc caaacggat gagtgggtgag tgccagtctc 720
cagactgccc tggaaccaga gctgaatttt tctttaaatg tggagcacac ccaacctcag 780
acaaggacac gtcggtagct ttgaacctga tcaccagcaa caggcgacgc atcccttgca 840
tagcgtgcac agatgtcagg agccctgtcc tggcttccca gtgtaaccac cgtcacgtga 900
tctgttttga ctgtttccac ttgtattgtg tcacaagact caacgatcgg cagtttgtcc 960
acgatgctca acttggctac tccctgccgt gtgtagctgg ctgtcccaac tccctgatta 1020
aagagctcca tcacttcagg atccttggag aagagcagta cactaggtag cagcagtatg 1080
gggcccagga atgcgtgctg caaatgggag gtgtgctgtg ccccccgtct ggctgtggag 1140
ctggactgct acctgaacag ggccagagga aagtcacctg cgaagggggc aacggcctgg 1200
gctgcggggt tgttttctgc cgggactgta aggaagcata ccatgaaggg gattgcgact 1260
cactgctcga accctcagga gccacttctc aggcctacag ggtggacaaa agagccgctg 1320
agcaagctcg ctgggaggag gcctccaagg aaaccatcaa gaagaccacc aagccttgtc 1380
ctcgctgcaa cgtgccaat gaaaaaacg gaggatgtat gcacatgaag tgtcctcagc 1440
cccagtgcaa gctggagtgg tgctggaact gtggctgtga gtagaaccga gcctgcatgg 1500
gagatcactg gtttgacgtg tagagagaga tgtcacttgg ccctggacgc acaacctcaa 1560
gggaaactcc gaagattcct accttcctta gccatttctt cttctcgatg catataagca 1620
cataaatgcg cacacacaaa cacaggctgc agattacaga agcagccctt agatcctttc 1680
tagggcaccc acagaaaacc acagcacccg ctggccccag ggggaggagg cactttcagc 1740
ctctggctca ctggaatgtc agagcttaga tgagggtgca ccttttggtt ggattctgta 1800
gaagccatga gtgagggtgg aagtgttttc cagggttgtt gccacgccct gggtaagtaa 1860
cacctctgag gattctcaga agcacacttg agatctgagg aacgctgctc tcatgtagta 1920
atcatctatt cccaaagggc cccctgcagt agtcaaaact atttgtttat cccccaaat 1980
cctatcttta caaatggtgc tgatgagatt acaaccctc tgtgtactaa tcagcttatc 2040
aaccaagtga gaacctagga aagctaattg gatggcagac tgcttaaata gcaggaggga 2100
ctcagaagcc aaacctactt ccgttcgttt cattatctgc aactttagaa agaaatgatc 2160
tttttttccc cctgaaaaga taacaaagtc tgcaatttgg tttggagtat tctactgca 2220
gcctggaagt ttagcttcac tgtgaattta acagagaaag tgcctataaa gggggcggtt 2280

```

```

ttaagagaca atcccatgat gctgcgccaa tgctaacaac aggggtcaaga aacacaatgt 2340
ttatagaagg agcatccctc gaccatctga atgagagtat gcctgacccc ttccaccaca 2400
agtgggggaca cctctgcata tctgctccct cctctgctgt taagccccag ggagccccat 2460
ccaccacagtg gtcctacaga cagggcaata cacacacacc aagatagcct tcagatcaac 2520
atgcatcaca ctcaagtgtt aatctttcaa ggttttcttt tctttttcct gttttttatt 2580
tgttttgctt ttgctttttt tttttttttt tttgggtggtg gtggggctac caaacttgag 2640
gcctagagct aaaaatcata tagaaatgat gttatcttgt ggtgtgagga aaggccagct 2700
ggcctaagtt cacacttttg tcccagtggc cctagactcc acccagccag ctcccaaaat 2760
gaaaagacca cctgtcaagc agcagtcagg agtctgatgt caccatcac tttttttttt 2820
ccatcattgt gcttgctctt gcctccttcc acaccgtgt gacgtaatcg cattgggaag 2880
ccaggacaat gtttgctgtt ctgctttggg taaagggact ccctgaagct ctgtggctct 2940
ccagtatggt cccttttctt tcctaacaga tgcataatgt ttcttcagaa tacaatagt 3000
attcttaaaa taacccaaaa gacaggcatc cacagtgtgt gagcatgaat cacagcctgc 3060
attgtgtgag tgtgaatagt gggataaaaag tggatgtcag aagagtggaa atcaaacctc 3120
tgcaaagcaa tctttctctt tctgtgaagt gtattaagaa atacctgaag tctgtgtgtg 3180
tggtggtacc cagactgtca atcaataaag acccagactg tcaatgaaaa aaaaaaaaaa 3240
aaaaaaaaaa aaaaaa 3255

```

&lt;210&gt; 21

&lt;211&gt; 105

&lt;212&gt; PRT

&lt;213&gt; mouse

&lt;400&gt; 21

```

Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu
  1               5               10              15

```

```

Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys
      20              25              30

```

```

Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys
      35              40              45

```

```

Glu Leu Pro Asn His Leu Thr Val Gln Leu Asn Pro Pro Thr Thr Ala
      50              55              60

```

```

Phe Ser Ser Thr Ala Lys Ala Pro Ala Thr Arg Ser Ser Leu Glu Ser
      65              70              75              80

```

```

Ser Glu Phe Ser Val Ala Pro Ala Asn Lys Gln Pro Ser Pro Trp Pro
      85              90              95

```

```

Arg Ala His Leu Ala Gly Thr Met Ser
      100              105

```

&lt;210&gt; 22

<211> 344  
 <212> PRT  
 <213> mouse

<400> 22

Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu  
 1 5 10 15

Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys  
 20 25 30

Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys  
 35 40 45

Glu Leu Pro Asn His Leu Thr Val Gln Gly Pro Ser Cys Trp Asp Asp  
 50 55 60

Val Leu Ile Pro Asn Arg Met Ser Gly Glu Cys Gln Ser Pro Asp Cys  
 65 70 75 80

Pro Gly Thr Arg Ala Glu Phe Phe Phe Lys Cys Gly Ala His Pro Thr  
 85 90 95

Ser Asp Lys Asp Thr Ser Val Ala Leu Asn Leu Ile Thr Ser Asn Arg  
 100 105 110

Arg Ser Ile Pro Cys Ile Ala Cys Thr Asp Val Arg Ser Pro Val Leu  
 115 120 125

Val Phe Gln Cys Asn His Arg His Val Ile Cys Leu Asp Cys Phe His  
 130 135 140

Leu Tyr Cys Val Thr Arg Leu Asn Asp Arg Gln Phe Val His Asp Ala  
 145 150 155 160

Gln Leu Gly Tyr Ser Leu Pro Cys Val Ala Gly Cys Pro Asn Ser Leu  
 165 170 175

Ile Lys Glu Leu His His Phe Arg Ile Leu Gly Glu Glu Gln Tyr Thr  
 180 185 190

Arg Tyr Gln Gln Tyr Gly Ala Glu Glu Cys Val Leu Gln Met Gly Gly  
 195 200 205

Val Leu Cys Pro Arg Pro Gly Cys Gly Ala Gly Leu Leu Pro Glu Gln  
 210 215 220

Gly Gln Arg Lys Val Thr Cys Glu Gly Gly Asn Gly Leu Gly Cys Gly



225                      230                      235                      240  
 Phe Val Phe Cys Arg Asp Cys Lys Glu Ala Tyr His Glu Gly Asp Cys  
                                  245                      250                      255  
 Asp Ser Leu Leu Glu Pro Ser Gly Ala Thr Ser Gln Ala Tyr Arg Val  
                                  260                      265                      270  
 Asp Lys Arg Ala Ala Glu Gln Ala Arg Trp Glu Glu Ala Ser Lys Glu  
                                  275                      280                      285  
 Thr Ile Lys Lys Thr Thr Lys Pro Cys Pro Arg Cys Asn Val Pro Ile  
                                  290                      295                      300  
 Glu Lys Asn Gly Gly Cys Met His Met Lys Cys Pro Gln Pro Gln Cys  
 305                                   310                      315                      320  
 Lys Leu Glu Trp Cys Trp Asn Cys Gly Cys Glu Trp Asn Arg Ala Cys  
                                  325                      330                      335  
 Met Gly Asp His Trp Phe Asp Val  
                                  340

<210> 23  
 <211> 63  
 <212> PRT  
 <213> mouse

<400> 23  
 Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu  
   1                      5                      10                      15  
 Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys  
                                  20                      25                      30  
 Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys  
                                  35                      40                      45  
 Glu Leu Pro Asn His Leu Thr Val Gln Leu Ala Val Pro Thr Pro  
                                  50                      55                      60

<210> 24  
 <211> 153  
 <212> PRT  
 <213> mouse

&lt;400&gt; 24

Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu  
 1 5 10 15

Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys  
 20 25 30

Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys  
 35 40 45

Glu Leu Pro Asn His Leu Thr Val Gln Asn Cys Asp Leu Glu Gln Gln  
 50 55 60

Ser Ile Val His Ile Val Gln Arg Pro Arg Arg Arg Ser His Glu Thr  
 65 70 75 80

Asn Ala Ser Gly Gly Asp Glu Pro Gln Ser Thr Ser Glu Gly Ser Ile  
 85 90 95

Trp Glu Ser Arg Ser Leu Thr Arg Val Asp Leu Ser Ser His Thr Leu  
 100 105 110

Pro Val Asp Ser Val Gly Leu Ala Val Ile Leu Asp Thr Asp Ser Lys  
 115 120 125

Arg Asp Ser Glu Ala Ala Arg Gly Pro Gly Pro Ile Leu Leu Gly Arg  
 130 135 140

Cys Leu Asn Ser Lys Pro Asp Glu Trp  
 145 150

&lt;210&gt; 25

&lt;211&gt; 194

&lt;212&gt; PRT

&lt;213&gt; mouse

&lt;400&gt; 25

Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu  
 1 5 10 15

Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys  
 20 25 30

Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys  
 35 40 45

Glu Leu Pro Asn His Leu Thr Val Gln Asn Cys Asp Leu Glu Gln Gln

50                                      55                                      60  
 Ser Ile Val His Ile Val Gln Arg Pro Arg Arg Arg Ser His Glu Thr  
 65                                      70                                      75                                      80  
 Asn Ala Ser Gly Gly Asp Glu Pro Gln Ser Thr Ser Glu Gly Ser Ile  
                                     85                                      90                                      95  
 Trp Glu Ser Arg Ser Leu Thr Arg Val Asp Leu Ser Ser His Thr Leu  
                                     100                                      105                                      110  
 Pro Val Asp Ser Val Gly Leu Ala Val Ile Leu Asp Thr Asp Ser Lys  
                                     115                                      120                                      125  
 Arg Asp Ser Glu Ala Ala Arg Gly Pro Val Lys Pro Thr Tyr Asn Ser  
                                     130                                      135                                      140  
 Phe Phe Ile Tyr Cys Lys Gly Pro Cys His Lys Val Gln Pro Gly Lys  
 145                                      150                                      155                                      160  
 Leu Arg Val Gln Cys Gly Thr Cys Lys Gln Ala Thr Leu Thr Leu Ala  
                                     165                                      170                                      175  
 Gln Asn Phe Ser Leu Asn Val Glu His Thr Gln Pro Gln Thr Arg Thr  
                                     180                                      185                                      190

Arg Arg

<210> 26  
 <211> 183  
 <212> PRT  
 <213> mouse

<400> 26  
 Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu  
                                     1                                      5                                      10                                      15  
 Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys  
                                     20                                      25                                      30  
 Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys  
                                     35                                      40                                      45  
 Glu Leu Pro Asn His Leu Thr Val Gln Asn Cys Asp Leu Glu Gln Gln  
                                     50                                      55                                      60

Ser Ile Val His Ile Val Gln Arg Pro Arg Arg Arg Ser His Glu Thr  
65 70 75 80

Asn Ala Ser Gly Gly Asp Glu Pro Gln Ser Thr Ser Glu Gly Ser Ile  
85 90 95

Trp Glu Ser Arg Ser Leu Thr Arg Val Asp Leu Ser Ser His Thr Leu  
100 105 110

Pro Val Asp Ser Val Gly Leu Ala Val Ile Leu Asp Thr Asp Ser Lys  
115 120 125

Arg Asp Ser Glu Ala Ala Arg Gly Pro Val Lys Pro Thr Tyr Asn Ser  
130 135 140

Phe Phe Ile Tyr Cys Lys Gly Pro Cys His Lys Val Gln Pro Gly Lys  
145 150 155 160

Leu Arg Val Gln Cys Gly Thr Cys Lys Gln Ala Thr Leu Thr Leu Ala  
165 170 175

Gln Leu Ala Val Pro Thr Pro  
180

<210> 27

<211> 296

<212> PRT

<213> mouse

<400> 27

Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu  
1 5 10 15

Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys  
20 25 30

Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys  
35 40 45

Glu Leu Pro Asn His Leu Thr Val Gln Asn Cys Asp Leu Glu Gln Gln  
50 55 60

Ser Ile Val His Ile Val Gln Arg Pro Arg Arg Arg Ser His Glu Thr  
65 70 75 80

Asn Ala Ser Gly Gly Asp Glu Pro Gln Ser Thr Ser Glu Gly Ser Ile  
85 90 95

Trp Glu Ser Arg Ser Leu Thr Arg Val Asp Leu Ser Ser His Thr Leu  
 100 105 110  
 Pro Val Asp Ser Val Gly Leu Ala Val Ile Leu Asp Thr Asp Ser Lys  
 115 120 125  
 Arg Asp Ser Glu Ala Ala Arg Gly Pro Val Lys Pro Thr Tyr Asn Ser  
 130 135 140  
 Phe Phe Ile Tyr Cys Lys Gly Pro Cys His Lys Val Gln Pro Gly Lys  
 145 150 155 160  
 Leu Arg Val Gln Cys Gly Thr Cys Lys Gln Ala Thr Leu Thr Leu Ala  
 165 170 175  
 Gln Gly Pro Ser Cys Trp Asp Asp Val Leu Ile Pro Asn Arg Met Ser  
 180 185 190  
 Gly Glu Cys Gln Ser Pro Asp Cys Pro Gly Thr Arg Ala Glu Phe Phe  
 195 200 205  
 Phe Lys Cys Gly Ala His Pro Thr Ser Asp Lys Asp Thr Ser Val Ala  
 210 215 220  
 Leu Asn Leu Ile Thr Ser Asn Arg Arg Ser Ile Pro Cys Ile Ala Cys  
 225 230 235 240  
 Thr Asp Val Arg Ser Pro Val Leu Val Phe Gln Cys Asn His Arg His  
 245 250 255  
 Val Ile Cys Leu Asp Cys Phe His Leu Tyr Cys Val Thr Arg Leu Asn  
 260 265 270  
 Asp Arg Gln Phe Val His Asp Ala Gln Leu Gly Tyr Ser Leu Pro Cys  
 275 280 285  
 Val Val Cys Phe Leu Pro Gly Leu  
 290 295

<210> 28  
 <211> 37  
 <212> PRT  
 <213> mouse

<400> 28  
 Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu

1                      5                      10                      15  
 Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys  
                     20                      25                      30  
 Arg Arg Gly Ser Ser  
                     35  
  
 <210> 29  
 <211> 53  
 <212> PRT  
 <213> mouse  
  
 <400> 29  
 Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu  
   1                      5                      10                      15  
 Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys  
                     20                      25                      30  
 Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys  
                     35                      40                      45  
 Glu Leu Pro Ile Thr  
                     50  
  
 <210> 30  
 <211> 77  
 <212> PRT  
 <213> mouse  
  
 <400> 30  
 Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu  
   1                      5                      10                      15  
 Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys  
                     20                      25                      30  
 Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys  
                     35                      40                      45  
 Glu Leu Pro Asn His Leu Thr Val Gln Asn Cys Asp Leu Glu Gln Gln  
                     50                      55                      60  
 Ser Ile Val His Ile Val Gln Arg Pro Arg Glu Lys Ser  
   65                      70                      75

<210> 31  
 <211> 14  
 <212> PRT  
 <213> mouse

<400> 31  
 Met Ile Val Thr Val Thr Trp Asn Asn Arg Val Leu Tyr Thr  
 1 5 10

<210> 32  
 <211> 464  
 <212> PRT  
 <213> mouse

<400> 32  
 Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu  
 1 5 10 15

Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys  
 20 25 30

Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys  
 35 40 45

Glu Leu Pro Asn His Leu Thr Val Gln Asn Cys Asp Leu Glu Gln Gln  
 50 55 60

Ser Ile Val His Ile Val Gln Arg Pro Arg Arg Arg Ser His Glu Thr  
 65 70 75 80

Asn Ala Ser Gly Gly Asp Glu Pro Gln Ser Thr Ser Glu Gly Ser Ile  
 85 90 95

Trp Glu Ser Arg Ser Leu Thr Arg Val Asp Leu Ser Ser His Thr Leu  
 100 105 110

Pro Val Asp Ser Val Gly Leu Ala Val Ile Leu Asp Thr Asp Ser Lys  
 115 120 125

Arg Asp Ser Glu Ala Ala Arg Gly Pro Val Lys Pro Thr Tyr Asn Ser  
 130 135 140

Phe Phe Ile Tyr Cys Lys Gly Pro Cys His Lys Val Gln Pro Gly Asn  
 145 150 155 160

Leu Arg Val Gln Cys Gly Thr Cys Lys Gln Ala Thr Leu Thr Leu Ala  
 165 170 175

Gln Gly Pro Ser Cys Trp Asp Asp Val Leu Ile Pro Asn Arg Met Ser  
 180 185 190

Gly Glu Cys Gln Ser Pro Asp Cys Pro Gly Thr Arg Ala Glu Phe Phe  
 195 200 205

Phe Lys Cys Gly Ala His Pro Thr Ser Asp Lys Asp Thr Ser Val Ala  
 210 215 220

Leu Asn Leu Ile Thr Ser Asn Arg Arg Ser Ile Pro Cys Ile Ala Cys  
 225 230 235 240

Thr Asp Val Arg Ser Pro Val Leu Val Phe Gln Cys Asn His Arg His  
 245 250 255

Val Ile Cys Leu Asp Cys Phe His Leu Tyr Cys Val Thr Arg Leu Asn  
 260 265 270

Asp Arg Gln Phe Val His Asp Ala Gln Leu Gly Tyr Ser Leu Pro Cys  
 275 280 285

Val Ala Gly Cys Pro Asn Ser Leu Ile Lys Glu Leu His His Phe Arg  
 290 295 300

Ile Leu Gly Glu Glu Gln Tyr Thr Arg Tyr Gln Gln Tyr Gly Ala Glu  
 305 310 315 320

Glu Cys Val Leu Gln Met Gly Gly Val Leu Cys Pro Arg Pro Gly Cys  
 325 330 335

Gly Ala Gly Leu Leu Pro Glu Gln Gly Gln Arg Lys Val Thr Cys Glu  
 340 345 350

Gly Gly Asn Gly Leu Gly Cys Gly Phe Val Phe Cys Arg Asp Cys Lys  
 355 360 365

Glu Ala Tyr His Glu Gly Asp Cys Asp Ser Leu Leu Glu Pro Ser Gly  
 370 375 380

Ala Thr Ser Gln Ala Tyr Arg Val Asp Lys Arg Ala Ala Glu Gln Ala  
 385 390 395 400

Arg Trp Glu Glu Ala Ser Lys Glu Thr Ile Lys Lys Thr Thr Lys Pro  
 405 410 415



Cys Pro Arg Cys Asn Val Pro Ile Glu Lys Asn Gly Gly Cys Met His  
 420 425 430

Met Lys Cys Pro Gln Pro Gln Cys Lys Leu Glu Trp Cys Trp Asn Cys  
 435 440 445

Gly Cys Glu Trp Asn Arg Ala Cys Met Gly Asp His Trp Phe Asp Val  
 450 455 460

<210> 33  
 <211> 464  
 <212> PRT  
 <213> mouse

<400> 33

Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu  
 1 5 10 15

Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys  
 20 25 30

Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys  
 35 40 45

Glu Leu Pro Asn His Leu Thr Val Gln Asn Cys Asp Leu Glu Gln Gln  
 50 55 60

Ser Ile Val His Ile Val Gln Arg Pro Arg Arg Arg Ser His Glu Thr  
 65 70 75 80

Asn Ala Ser Gly Gly Asp Glu Pro Gln Ser Thr Ser Glu Gly Ser Ile  
 85 90 95

Trp Glu Ser Arg Ser Leu Thr Arg Val Asp Leu Ser Ser His Thr Leu  
 100 105 110

Pro Val Asp Ser Val Gly Leu Ala Val Ile Leu Asp Thr Asp Ser Lys  
 115 120 125

Arg Asp Ser Glu Ala Ala Arg Gly Pro Val Lys Pro Thr Tyr Asn Ser  
 130 135 140

Phe Phe Ile Tyr Cys Lys Gly Pro Cys His Lys Val Gln Pro Gly Lys  
 145 150 155 160

Leu Arg Val Gln Cys Gly Thr Cys Lys Gln Ala Thr Leu Thr Leu Ala  
 165 170 175  
 Gln Gly Pro Ser Cys Trp Asp Asp Val Leu Ile Pro Asn Arg Met Ser  
 180 185 190  
 Gly Glu Cys Gln Ser Pro Asp Cys Pro Gly Thr Arg Ala Glu Phe Phe  
 195 200 205  
 Phe Lys Cys Gly Ala His Pro Thr Ser Asp Lys Asp Thr Ser Val Ala  
 210 215 220  
 Leu Asn Leu Ile Thr Ser Asn Arg Arg Ser Ile Pro Cys Ile Ala Cys  
 225 230 235 240  
 Thr Asp Val Arg Ser Pro Val Leu Val Phe Gln Cys Asn His Arg His  
 245 250 255  
 Val Ile Cys Leu Asp Cys Phe His Leu Tyr Cys Val Thr Arg Leu Asn  
 260 265 270  
 Asp Arg Gln Phe Val His Asp Ala Gln Leu Gly Tyr Ser Leu Pro Cys  
 275 280 285  
 Val Ala Gly Cys Pro Asn Ser Leu Ile Lys Glu Leu His His Phe Arg  
 290 295 300  
 Ile Leu Gly Glu Glu Gln Tyr Thr Arg Tyr Gln Gln Tyr Gly Ala Glu  
 305 310 315 320  
 Glu Cys Val Leu Gln Met Gly Gly Val Leu Cys Pro Arg Pro Gly Cys  
 325 330 335  
 Gly Ala Gly Leu Leu Pro Glu Gln Gly Gln Arg Lys Val Thr Cys Glu  
 340 345 350  
 Gly Gly Asn Gly Leu Gly Cys Gly Phe Val Phe Cys Arg Asp Cys Lys  
 355 360 365  
 Glu Ala Tyr His Glu Gly Asp Cys Asp Ser Leu Leu Glu Pro Ser Gly  
 370 375 380  
 Ala Thr Ser Gln Ala Tyr Arg Val Asp Lys Arg Ala Ala Glu Gln Ala  
 385 390 395 400  
 Arg Trp Glu Glu Ala Ser Lys Glu Thr Ile Lys Lys Thr Asn Lys Pro  
 405 410 415

Cys Pro Arg Cys Asn Val Pro Ile Glu Lys Asn Gly Gly Cys Met His  
 420 425 430

Met Lys Cys Pro Gln Pro Gln Cys Lys Leu Glu Trp Cys Trp Asn Cys  
 435 440 445

Gly Cys Glu Trp Asn Arg Ala Cys Met Gly Asp His Trp Phe Asp Val  
 450 455 460

<210> 34

<211> 451

<212> PRT

<213> mouse

<400> 34

Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu  
 1 5 10 15

Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys  
 20 25 30

Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys  
 35 40 45

Glu Leu Pro Asn His Leu Thr Val Gln Asn Cys Asp Leu Glu Gln Gln  
 50 55 60

Ser Ile Val His Ile Val Gln Arg Pro Arg Arg Arg Ser His Glu Thr  
 65 70 75 80

Asn Ala Ser Gly Gly Asp Glu Pro Gln Ser Thr Ser Glu Gly Ser Ile  
 85 90 95

Trp Glu Ser Arg Ser Leu Thr Arg Val Asp Leu Ser Ser His Thr Leu  
 100 105 110


Pro Val Asp Ser Val Gly Leu Ala Val Ile Leu Asp Thr Asp Ser Lys  
 115 120 125

Arg Asp Ser Glu Ala Ala Arg Gly Pro Val Lys Pro Thr Tyr Asn Ser  
 130 135 140

Phe Phe Ile Tyr Cys Lys Gly Pro Cys His Lys Val Gln Pro Gly Lys

145		150		155		160
Leu Arg Val Gln Cys Gly Thr Cys Lys Gln Ala Thr Leu Thr Leu Ala						
	165			170		175
Gln Gly Pro Ser Cys Trp Asp Asp Val Leu Ile Pro Asn Arg Met Ser						
	180			185		190
Gly Glu Cys Gln Ser Pro Asp Cys Pro Gly Thr Arg Ala Glu Phe Phe						
	195			200		205
Phe Lys Cys Gly Ala His Pro Thr Ser Asp Lys Asp Thr Ser Val Ala						
	210			215		220
Leu Asn Leu Ile Thr Ser Asn Arg Arg Ser Ile Pro Cys Ile Ala Cys						
	225			230		235
Thr Asp Val Arg Ser Pro Val Leu Val Phe Gln Cys Asn His Arg His						
	245			250		255
Val Ile Cys Leu Asp Cys Phe His Leu Tyr Cys Val Thr Arg Leu Asn						
	260			265		270
Asp Arg Gln Phe Val His Asp Ala Gln Leu Gly Tyr Ser Leu Pro Cys						
	275			280		285
Val Ala Gly Cys Pro Asn Ser Leu Ile Lys Glu Leu His His Phe Arg						
	290			295		300
Ile Leu Gly Glu Glu Gln Tyr Thr Arg Tyr Gln Gln Tyr Gly Ala Glu						
	305			310		315
Glu Cys Val Leu Gln Met Gly Gly Val Leu Cys Pro Arg Pro Gly Cys						
	325			330		335
Gly Ala Gly Leu Leu Pro Glu Gln Gly Gln Arg Lys Val Thr Cys Glu						
	340			345		350
Gly Gly Asn Gly Leu Gly Cys Gly Phe Val Phe Cys Arg Asp Cys Lys						
	355			360		365
Glu Ala Tyr His Glu Gly Asp Cys Asp Ser Leu Leu Glu Pro Ser Gly						
	370			375		380
Ala Thr Ser Gln Ala Tyr Arg Val Asp Lys Arg Ala Ala Glu Gln Ala						
	385			390		395
Arg Trp Glu Glu Ala Ser Lys Glu Thr Ile Lys Lys Thr Thr Lys Pro						

405					410					415					
Cys	Pro	Arg	Cys	Asn	Val	Pro	Ile	Glu	Lys	Asn	Gly	Gly	Cys	Met	His
420					425					430					
Met	Lys	Cys	Pro	Gln	Pro	Gln	Cys	Lys	Leu	Glu	Trp	Cys	Trp	Asn	Cys
435					440					445					
Gly Cys Glu															
450															



## SEQUENCE LISTING

<110> Biofrontera Pharmaceuticals AG  
Lubbert, Hermann

<120> TRANSGENIC ANIMAL MODEL FOR  
NEURODEGENERATIVE DISEASES

<130> STERN1.001APC

<140> 09/830,703

<141> 2001-04-26

<150> EP 99116766.9

<151> 1999-08-30

<160> 34

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 3255

<212> DNA

<213> Mus musculus

<400> 1

ctcagcgagg ggaaggggga ggaggcctgg atgactaaac ctgacagaaa cgctggtggg 60  
aggctcgggc gggcgccagt gcccgcgtag gtccttctcg acccgagcc accacccgcc 120  
cggtgaccat gatagtgtt gtcaggttca actccagcta tggcttcca gtggaggtcg 180  
attctgacac cagcatcttg cagctcaagg aagtggttgc taagcgacag ggggttccag 240  
ctgaccagct gcgtgtgatt tttgccggga aggagcttcc gaatcacctg acggttcaaa 300  
actgtgacct ggaacaacag agtattgtac acatagtaca gagaccacgg aggagaagtc 360  
atgaaacaaa tgcatctgga ggggacgaac cccagagcac ctgagagggc tccatatggg 420  
agtccaggag cttgacacga gtggacctga gcagccatac cctgccggtg gactctgtgg 480  
ggctggcggg cattctggac acagacagta agagggattc agaagcagcc agaggtcag 540  
ttaaaccacac ctacaacagc tttttcatct actgcaaagg cccctgccac aaggtccagc 600  
ctgaaaagct ccgagttcag tgtggcacct gcaaacaagc aaccctcacc ttggcccagg 660  
gccatcttgg ctgggacgat gtcttaattc caaacggat gagtgggtgag tgccagtctc 720  
cagactgccc tgggaaccaga gotgaatttt tctttaaatg tggagcacac ccaacctcag 780  
acaaggacac gtcggtagct ttgaacctga tcaccagcaa caggcgacg atcccttgca 840  
tagcgtgcac agatgtcagg agccctgtcc tggctctcca gtgtaaccac cgtcacgtga 900  
tctgtttgga ctgtttccac ttgtattgtg tcacaagact caacgatcgg cagtttgtcc 960  
acgatgctca acttggtctac tccctgccgt gtgtagctgg ctgtcccaac tccctgatta 1020  
aagagctcca tcacttcagg atccttggag aagagcagta cactaggtac cagcagtatg 1080  
gggccgagga atgcgtgctg caaatgggag gtgtgctgtg ccccgctcct ggctgtggag 1140  
ctggactgct acctgaacag ggccagagga aagtcacctg cgaagggggc aacggcctgg 1200  
gctgcgggtt tgttttctgc cgggactgta aggaagcata ccatgaaggg gattgcgact 1260  
cactgctcga accctcagga gccacttctc aggcctacag ggtggacaaa agagccgctg 1320  
agcaagctcg ctgggaggag gcctccaagg aaaccatcaa gaagaccacc aagcctgtc 1380  
ctcgctgcaa cgtgccatt gaaaaaacg gaggatgtat gcacatgaag tgtcctcagc 1440  
cccagtgcaa gctggagtgg tgetggaact gtggctgtga gtggaaccga gcctgcatgg 1500  
gagatcactg gtttgacgtg tagagagaga tgtcacttgg ccctggacgc acaacctcaa 1560  
gggaaactcc gaagattcct accttcctta gccatttctt cttctcgatg catataagca 1620  
cataaatgcg cacacacaaa cacaggctgc agattacaga agcagcccct agatcctttc 1680

tagggcacc	acagaaaacc	acagcacc	ctggcccc	ggggaggagg	cacttttcagc	1740
ctctggctca	ctcgaatgtc	agagcttaga	tgagggtgca	ccttttggtt	ggattctgta	1800
gaagccatga	gtgaggtggg	aagtgttttc	cagggttggt	gccacgccct	gggtaagtaa	1860
cacctctgag	gattctcaga	agcacacttg	agatctgagg	aacgctgctc	tcattgtagta	1920
atcatctatt	cccaaagggc	cccctgcagt	agtcaaaact	atttgtttat	ccccccaaat	1980
cctatcttta	caaatgggtg	tgatgagatt	acaaccctc	tgtgtactaa	tcagcttatc	2040
aaccaagtga	gaacctagga	aagctaattg	gatggcagac	tgcttaaata	gcaggaggga	2100
ctcagaagcc	aaacctactt	ccgttcgttt	cattatctgc	aacttttagaa	agaaatgatc	2160
tttttttccc	cctgaaaaga	taacaaagtc	tgcaatttgg	tttggagtat	tcctactgca	2220
gcctggaagt	ttagcttcac	tgtgaattta	acagagaaaag	tgctataaaa	gggggcgttt	2280
ttaagagaca	atcccatgat	gctgcgcca	tgctaacaac	aggggtcaaga	aacacaatgt	2340
ttatagaagg	agcatccctc	gaccatctga	atgagagtat	gcctgacccc	ttccaccaca	2400
agtggggaca	cctctgcata	tctgtccct	cctctgctgt	taagccccag	ggagccccat	2460
ccaccagtg	gtcctacaga	cagggaata	cacacacacc	aagatagcct	tcagatcaac	2520
atgcatcaca	ctcaagtgtt	aatctttcaa	ggttttcttt	tctttttcct	gtttttttatt	2580
tgttttgctt	ttgctttttt	tttttttttt	tttgggtggg	gtggggctac	caaacttgag	2640
gcctagagct	aaaaatcata	tagaaatgat	gttatcttgt	ggtgtgagga	aaggccagct	2700
ggcctaagtt	cacacttttg	tcccagtggt	cctagactcc	accagccag	ctcccaaaat	2760
gaaaagacca	cctgtcaagc	agcagtcagg	agtctgatgt	cacccatcac	tatttttttt	2820
ccatcattgt	gcttgccctc	gcctccttcc	acaccctgt	gacgtaatcg	cattgggaag	2880
ccaggacaat	gtttgtctgt	ctgctttggg	taaagggaact	ccctgaagct	ctgtggctct	2940
ccagtatggt	cccttttcc	tctaacaga	tgcatatgtt	ttcttcagaa	tacaatagtg	3000
attcttaaaa	taacccaaaa	gacaggcatc	cacagtgtgt	gagcatgaat	cacagcctgc	3060
attgtgtgag	tgtgaatagt	gggataaaaag	tggatgtcag	aagagtggaa	atcaaacctc	3120
tgcaaagcaa	tctttctctt	tctgtgaagt	gtattaagaa	atacctgaag	tctgtgtgtg	3180
tggtggtacc	cagactgtca	atcaataaag	accagactg	tcaatgaaaa	aaaaaaaaaa	3240
aaaaaaaaaa	aaaaa					3255

<210> 2

<211> 1459

<212> DNA

<213> Mus musculus

<400> 2

ctcacgggga	ggaggccttg	gatgactaaa	cctgacagaa	acgctggtgg	gaggctcggg	60
cgggcgccag	tgcccgctga	ggtccttctc	gacccgcagc	caccacccgc	ccggtgacca	120
tgatagtgtt	tgtcagggtt	aactccagct	atggcttccc	agtggaggtc	gattctgaca	180
ccagcatctt	gcagctcaag	gaagtgggtg	ctaagcgaca	gggggttcca	gctgaccagc	240
tgctgtgtgat	ttttgcccgg	aaggagcttc	cgaatcacct	gacggttcaa	aactgtgacc	300
tggacaaca	gagtattgta	cacatagtag	agagaccacg	gaggagaagt	catgaaacaa	360
atgcatctgg	aggggacgaa	ccccagagca	cctcagaggg	ctccatattg	gagtccagga	420
gcttgacacg	agtggacctg	agcagccata	ccctgccggg	ggactctgtg	gggctggcgg	480
tcattctgga	cacagacagt	aagagggtat	cagaagcagc	cagagggtcca	gcagttaaac	540
ccacctacaa	cagctttttc	atctactgca	aaggcccttg	ccacaaggtc	cagcctggaa	600
agctccgagt	tcagtgtggc	acctgcaaac	aagcaaccct	caccttgccc	cagggcccat	660
cttgctggga	cgatgtctta	attccaaacc	ggatgagtgg	tgagtgccag	tctccagact	720
gccctggaac	cagagctgaa	tttttcttta	aatgtggagc	acaccaaac	tcagacaagg	780
acacgtcggg	agctttgaac	ctgatcacca	gcaacaggcg	cagcatccct	tgcatagcgt	840
gcacagatgt	cagtcattct	cctctgtcat	ctgggtgcct	cgtgtggact	cggcctcatc	900
tccactgaac	cttggtcttt	aggactgtgc	aatagggtcg	cacctcctac	tgagaacaag	960
gcagcttctg	gtctcttggt	ttccttgctt	ccaacggcag	cattgactgt	acacccttca	1020
gtcctaccaa	ccccattacc	tggttgattt	ctttaccgct	tagcttctcc	aagatgccta	1080
tttccacaca	cagtttcttg	tcttccccat	ccccccatag	gtttatgcgc	atgagtaagc	1140
accgcacctc	atgagtttgt	gcttctgata	caagacttcc	tgggatcccc	gcttgagccc	1200
tagaatcccc	tggaaactggg	ttcagtcacc	tatcttcaat	agcctctttt	aaaagtgagt	1260

tcttgggctg gtgagatggc tcagtgggta agagcaccgc actgctcttc cgaagtccag 1320  
 agttcaaaat cccagcaacc acatgggtggc tcacaacccat ccgtaacaag atctgactcc 1380  
 ctcttctggt gtgtctgaag acagctacag tgtacttaca taaaataata aataaatctt 1440  
 aaaaaaaaaa aaaaaaaaaa 1459

<210> 3  
 <211> 857  
 <212> DNA  
 <213> Mus musculus

<400> 3  
 ctcagatgac taaacctgac agaaacgctg gtgggaggct cgggcgggcg ccagtgcccg 60  
 cgtaggtcct tctcgaccgc cagccaccac ccgcccgggt accatgatag tgtttgtcag 120  
 gttcaactcc agctatggct tcccagtgga ggtcgattct gacaccagca tcttgcagct 180  
 caaggaagtg gttgctaagc gacaggggggt tccagctgac cagctgcgtg tgatttttgc 240  
 cgggaaggag cttccgaatc acctgacggt tcaaaactgt gacctggaac aacagagtat 300  
 tgtacacata gtacagagac cacggaggag aagtcatgaa acaaatgcat ctggaggggga 360  
 cgaaccccag agcacctcag agggctccat atgggagtcc aggagcttga cacgagtggga 420  
 cctgagcagc cataccctgc cgggtggactc tgtggggctg gcggtcattc tggacacaga 480  
 cagtaagagg gattcagaag cagccagagg tccagcagtt aaacccacct acaacagctt 540  
 tttcatctac tgcaaaggcc cctgccacaa ggtccagcct ggaaagctcc gagttcagtg 600  
 tggcacctgc aaacaagcaa ccctcacctt ggcccagggc ccattcttgc gggacgatgt 660  
 cttaattcca aaccggatga gtggtgagtg ccagtctcca gactgccctg gaaccagagc 720  
 tgaatttttc tttaaatgtg gagcacaccc aacctcagac aaggacacgt cggtagcttt 780  
 gaacctgatc accagcaaca ggcgacagat cccttgcata gcgtgcacag atgtcagggt 840  
 tatgcgcatg agttagc 857

<210> 4  
 <211> 464  
 <212> PRT  
 <213> Mus musculus

<400> 4  
 Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu  
 1 5 10 15  
 Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys  
 20 25 30  
 Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys  
 35 40 45  
 Glu Leu Pro Asn His Leu Thr Val Gln Asn Cys Asp Leu Glu Gln Gln  
 50 55 60  
 Ser Ile Val His Ile Val Gln Arg Pro Arg Arg Arg Ser His Glu Thr  
 65 70 75 80  
 Asn Ala Ser Gly Gly Asp Glu Pro Gln Ser Thr Ser Glu Gly Ser Ile  
 85 90 95  
 Trp Glu Ser Arg Ser Leu Thr Arg Val Asp Leu Ser Ser His Thr Leu  
 100 105 110  
 Pro Val Asp Ser Val Gly Leu Ala Val Ile Leu Asp Thr Asp Ser Lys  
 115 120 125  
 Arg Asp Ser Glu Ala Ala Arg Gly Pro Val Lys Pro Thr Tyr Asn Ser  
 130 135 140  
 Phe Phe Ile Tyr Cys Lys Gly Pro Cys His Lys Val Gln Pro Gly Lys  
 145 150 155 160  
 Leu Arg Val Gln Cys Gly Thr Cys Lys Gln Ala Thr Leu Thr Leu Ala  
 165 170 175





				85				90					95				
Trp	Glu	Ser	Arg	Ser	Leu	Thr	Arg	Val	Asp	Leu	Ser	Ser	His	Thr	Leu		
			100					105					110				
Pro	Val	Asp	Ser	Val	Gly	Leu	Ala	Val	Ile	Leu	Asp	Thr	Asp	Ser	Lys		
		115					120					125					
Arg	Asp	Ser	Glu	Ala	Ala	Arg	Gly	Pro	Ala	Val	Lys	Pro	Thr	Tyr	Asn		
	130					135					140						
Ser	Phe	Phe	Ile	Tyr	Cys	Lys	Gly	Pro	Cys	His	Lys	Val	Gln	Pro	Gly		
145					150					155					160		
Lys	Leu	Arg	Val	Gln	Cys	Gly	Thr	Cys	Lys	Gln	Ala	Thr	Leu	Thr	Leu		
			165					170						175			
Ala	Gln	Gly	Pro	Ser	Cys	Trp	Asp	Asp	Val	Leu	Ile	Pro	Asn	Arg	Met		
		180					185						190				
Ser	Gly	Glu	Cys	Gln	Ser	Pro	Asp	Cys	Pro	Gly	Thr	Arg	Ala	Glu	Phe		
	195					200				205							
Phe	Phe	Lys	Cys	Gly	Ala	His	Pro	Thr	Ser	Asp	Lys	Asp	Thr	Ser	Val		
	210					215				220							
Ala	Leu	Asn	Leu	Ile	Thr	Ser	Asn	Arg	Arg	Ser	Ile	Pro	Cys	Ile	Ala		
225					230					235					240		
Cys	Thr	Asp	Val	Ser	His	Leu	Pro	Leu	Ser	Ser	Gly	Ala	Ser	Val	Trp		
			245					250						255			
Thr	Arg	Pro	His	Leu	His												
			260														

<210> 6

<211> 250

<212> PRT

<213> Mus musculus

<400> 6

Met	Ile	Val	Phe	Val	Arg	Phe	Asn	Ser	Ser	Tyr	Gly	Phe	Pro	Val	Glu		
1				5				10					15				
Val	Asp	Ser	Asp	Thr	Ser	Ile	Leu	Gln	Leu	Lys	Glu	Val	Val	Ala	Lys		
			20					25				30					
Arg	Gln	Gly	Val	Pro	Ala	Asp	Gln	Leu	Arg	Val	Ile	Phe	Ala	Gly	Lys		
		35				40					45						
Glu	Leu	Pro	Asn	His	Leu	Thr	Val	Gln	Asn	Cys	Asp	Leu	Glu	Gln	Gln		
	50					55				60							
Ser	Ile	Val	His	Ile	Val	Gln	Arg	Pro	Arg	Arg	Arg	Ser	His	Glu	Thr		
65				70						75				80			
Asn	Ala	Ser	Gly	Gly	Asp	Glu	Pro	Gln	Ser	Thr	Ser	Glu	Gly	Ser	Ile		
			85					90					95				
Trp	Glu	Ser	Arg	Ser	Leu	Thr	Arg	Val	Asp	Leu	Ser	Ser	His	Thr	Leu		
			100					105					110				
Pro	Val	Asp	Ser	Val	Gly	Leu	Ala	Val	Ile	Leu	Asp	Thr	Asp	Ser	Lys		
		115					120					125					
Arg	Asp	Ser	Glu	Ala	Ala	Arg	Gly	Pro	Ala	Val	Lys	Pro	Thr	Tyr	Asn		
	130					135					140						
Ser	Phe	Phe	Ile	Tyr	Cys	Lys	Gly	Pro	Cys	His	Lys	Val	Gln	Pro	Gly		
145					150					155					160		
Lys	Leu	Arg	Val	Gln	Cys	Gly	Thr	Cys	Lys	Gln	Ala	Thr	Leu	Thr	Leu		
			165					170						175			
Ala	Gln	Gly	Pro	Ser	Cys	Trp	Asp	Asp	Val	Leu	Ile	Pro	Asn	Arg	Met		
		180					185						190				

Ser	Gly	Glu	Cys	Gln	Ser	Pro	Asp	Cys	Pro	Gly	Thr	Arg	Ala	Glu	Phe				
195					200					205									
Phe	Phe	Lys	Cys	Gly	Ala	His	Pro	Thr	Ser	Asp	Lys	Asp	Thr	Ser	Val				
210					215					220									
Ala	Leu	Asn	Leu	Ile	Thr	Ser	Asn	Arg	Arg	Ser	Ile	Pro	Cys	Ile	Ala				
225					230					235					240				
Cys	Thr	Asp	Val	Arg	Phe	Met	Arg	Met	Ser										
245					250														

<210> 7  
 <211> 3014  
 <212> DNA  
 <213> Mus musculus

<400> 7

ctcagcgagg	ggaaggggga	ggaggcctgg	atgactaaac	ctgacagaaa	cgctgggtggg	60
aggctcgggc	gggcgccagt	gcccgcgtag	gtccttctcg	acccgcagcc	accacccgcc	120
cggtgaccat	gatatgtttt	gtcaggttca	actccagcta	tggcttccca	gtggagggtcg	180
attctgacac	cagcatcttg	cagctcaagg	aagtgggttg	taagcgacag	ggggttccag	240
ctgaccagct	gcgtgtgatt	tttgccggga	aggagcttcc	gaatcacctg	acggttcaat	300
taaacccacc	tacaacagct	ttttcatcta	ctgcaaaggc	ccctgccaca	aggtccagcc	360
tggaaagctc	cgagttcagt	gtggcacctg	caaacaagca	accctcacct	tggcccaggg	420
cccatcttgc	tgggacgatg	tcttaattcc	aaaccggatg	agtgggtgagt	gccagtctcc	480
agactgccct	ggaaccagag	ctgaattttt	ctttaaatgt	ggagcacacc	caacctcaga	540
caaggacacg	tccgtagctt	tgaacctgat	caccagcaac	aggcgagca	tcccttgcac	600
agcgtgcaca	gatgtcagga	gccctgtcct	ggctctccag	tgtaccacac	gtcacgtgat	660
ctgtttggac	tgtttccact	tgtatttgtt	cacaagactc	aacgatcggc	agtttgtcca	720
cgatgctcaa	cttggtactt	ccctgccgtg	tgtagctggc	tgtcccaact	ccctgattaa	780
agagctccat	cacttcagga	tccttggaga	agagcagtac	actaggtacc	agcagtatgg	840
ggccgaggaa	tgcgtgctgc	aaatgggagg	tgtgctgtgc	ccccgtcctg	gctgtggagc	900
tggactgcta	cctgaacagg	gccagaggaa	agtcacctgc	gaagggggca	acggcctggg	960
ctgcgggttt	gtttttctgcc	gggactgtaa	ggaagcatac	catgaagggg	attgcgactc	1020
actgctcgaa	ccctcaggag	ccacttctca	ggcctacagg	gtggacaaaa	gagccgctga	1080
gcaagctcgc	tgggaggagg	cctccaagga	aaccatcaag	aagaccacca	agccttgtcc	1140
tcgctgcaac	gtgccaatg	aaaaaaacgg	aggatgtatg	cacatgaagt	gtcctcagcc	1200
ccagtgcagg	ctggagtggg	gctggaactg	tggctgtgag	tggaaaccag	cctgcatggg	1260
agatcactgg	tttgacgtgt	agagagagat	gtcacttggc	cctggacgca	caacctcaag	1320
ggaaaactcc	aagattccta	ccttccttag	ccatttcttc	ttctcgatgc	atataagcac	1380
ataaatgcgc	acacacaaac	acaggctgca	gattacagaa	gcagccccta	gaccttttct	1440
agggcaccca	cagaaaacca	cagcaccgcg	tggccccagg	gggaggaggc	actttcagcc	1500
tctggctcac	tcgaatgtca	gagcttagat	gagggtgcac	ctttggtttg	gattctgtag	1560
aagccatgag	tgaggtggga	agtgttttcc	aggggtgttg	ccacgccctg	ggtaagtaac	1620
acctctgagg	attctcagaa	gcacacttga	gatctgagga	acgctgctct	catgtagtaa	1680
tcactctatt	ccaaagggcc	ccctgcagta	gtcaaaaact	tttgtttatc	cccccaaata	1740
ctatctttac	aaatgggtgt	gatgagatta	caaccctctt	gtgtactaat	cagcttatca	1800
accaagttag	aacctaggaa	agctaattgg	atggcagact	gcttaaatcg	cagggaggac	1860
tcagaagcca	aacctacttc	cgttcggttc	attatctgca	acttttagaa	gaaatgatct	1920
ttttttcccc	ctgaaaagat	aacaaagtct	gcaatttggg	ttggagtatt	cctactgcag	1980
cctggaagtt	tagcttcaact	gtgaatttaa	cagagaaagt	gcctataaag	ggggcgtttt	2040
taagagacaa	tcccatgatg	ctgcgccaat	gctaacaaca	gggtcaagaa	acacaatgtt	2100
tatagaagga	gcatccctcg	accatctgaa	tgagagtatg	cctgacccct	tccaccacaa	2160
gtggggacac	ctctgcatat	ctgctccctc	ctctgctgtt	aagccccagg	gagccccatc	2220
cacccagtgg	tcctacagac	agggcaatac	acacacacca	agatagcctt	cagatcaaca	2280
tgcacacac	tcaagtgtta	atctttcaag	gtttttcttt	ctttttcctg	ttttttattt	2340

gttttgc	ttt	ttttttttt	ttggtggtg	tggggctacc	aaacttgagg	2400
cctagagcta	aaaatcata	agaaatgatg	ttatcttgtg	gtgtgaggaa	aggccagctg	2460
gcctaagttc	acacttttgt	cccagtgccc	ctagactcca	cccagccagc	tcccaaatg	2520
aaaagaccac	ctgtcaagca	gcagtcagga	gtctgatgtc	acccatcact	attttttttc	2580
catcattgtg	cttgccctctg	cctccttcca	caccctgtgtg	acgtaatcgc	attgggaagc	2640
caggacaatg	tttgcctgtc	tgctttgggt	aaagggactc	cctgaagctc	tgtggctctc	2700
cagtatggtc	ccttttccct	cctaacagat	gcatatgttt	tcttcagaat	acaatagtga	2760
ttcttaaaat	aacccaaaag	acagggcatcc	acagtgtgtg	agcatgaatc	acagcctgca	2820
ttgtgtgagt	gtgaatagt	ggataaaaagt	ggatgtcaga	agagtggaaa	tcaaacctct	2880
gcaaagcaat	ctttctcttt	ctgtgaagt	tattaagaaa	tacctgaagt	ctgtgtgtgt	2940
ggtggtaccc	agactgtcaa	tcaataaaga	cccagactgt	caatgaaaaa	aaaaaaaaaa	3000
aaaaaaaaaa	aaaa					3014

<210> 8

<211> 2895

<212> DNA

<213> Mus musculus

<400> 8

ctcagcgagg	ggaaggggga	ggaggcctgg	atgactaaac	ctgacagaaa	cgctgggtggg	60
aggctcgggc	gggcgccagt	gcccgcgtag	gtccttctcg	acccgcagcc	accacccgcc	120
cggtgaccat	gatagtgttt	gtcaggttca	actccagcta	tggcttccca	gtggaggctcg	180
attctgacac	cagcatcttg	cagctcaagg	aagtgggtgc	taagcgacag	ggggttccag	240
ctgaccagct	gcgtgtgatt	tttgccggga	aggagcttcc	gaatcacctg	acggttcaag	300
gcccatcttg	ctgggacgat	gtcttaattc	caaaccggat	gagtgggtgag	tgccagtctc	360
cagactgccc	tggaaaccaga	gctgaatttt	tctttaaatg	tggagcacac	ccaacctcag	420
acaaggacac	gtcggtagct	ttgaacctga	tcaccagcaa	caggcgcagc	atcccttgca	480
tagcgtgcac	agatgtcagg	agccctgtcc	tggcttccca	gtgtaaccac	cgtcacgtga	540
tctgtttgga	ctgtttccac	ttgtattgtg	tcacaagact	caacgatcgg	cagtttgtcc	600
acgatgctca	acttggtctac	tccctgccgt	gtgtagctgg	ctgtcccaac	tccctgatta	660
aagagctcca	tcacttcagg	atccttggag	aagagcagta	cactaggtac	cagcagtatg	720
gggccgagga	atgcgtgctg	caaattgggag	gtgtgctgtg	ccccgtcct	ggctgtggag	780
ctggactgct	acctgaacag	ggccagagga	aagtcacctg	cgaagggggc	aacggcctgg	840
gtgcgcgggt	tgttttctgc	cgggactgta	aggaagcata	ccatgaaggg	gattgcgact	900
cactgctcga	accttcagga	gccacttctc	aggcctacag	ggtggacaaa	agagccgctg	960
agcaagctcg	ctgggaggag	gcctccaagg	aaaccatcaa	gaagaccacc	aagccttgtc	1020
ctcgtgcaa	cgtgcccaatt	gaaaaaacg	gaggatgtat	gcacatgaag	tgtcctcagc	1080
cccagtgcaa	gctggagtgg	tgttggaact	gtggctgtga	gtggaaccga	gcctgcatgg	1140
gagatcactg	gtttgacgtg	tagagagaga	tgtcacttgg	ccctggacgc	acaacctcaa	1200
gggaaactcc	gaagattcct	accttcctta	gccatttctt	cttctcgatg	catataagca	1260
cataaatgcg	cacacacaaa	cacaggctgc	agattacaga	agcagccctt	agatcctttc	1320
tagggcacc	acagaaaacc	acagcaccgc	ctggccccag	ggggaggagg	cacttttcagc	1380
ctctggctca	ctcgaatgtc	agagcttaga	tgagggtgca	ccttttggtt	ggattctgta	1440
gaagccatga	gtgagggtgg	aagtgttttc	cagggttggt	gccacgccct	gggtaagtaa	1500
cacctctgag	gattctcaga	agcacacttg	agatctgagg	aacgctgctc	tcagttagta	1560
atcatctatt	cccaaagggc	cccctgcagt	agtcaaaact	atttgtttat	ccccccaaat	1620
cctatcttta	caaattggtg	tgatgagatt	acaaccctc	tgtgtactaa	tcagcttatc	1680
aaccaagtga	gaacctagga	aagctaattg	gatggcagac	tgcttaaatc	gcagggagga	1740
ctcagaagcc	aaacctactt	ccgttcgttt	cattatctgc	aacttttagaa	agaaatgatc	1800
tttttttccc	cctgaaaaga	taacaaagtc	tgcaatttgg	tttgaggtat	tcctactgca	1860
gcctggaagt	ttagcttcac	tgtgaattta	acagagaaaag	tgctataaaa	gggggcgttt	1920
ttaagagaca	atcccatgat	gctgcgccaa	tgctaacaac	aggggtcaaga	aacacaatgt	1980
ttatagaagg	agcatccctc	gaccatctga	atgagagtat	gcctgacccc	ttccaccaca	2040
agtggggaca	cctctgcata	tctgtccct	cctctgctgt	taagccccag	ggagcccat	2100
ccaccagtg	gtcctacaga	cagggcaata	cacacacacc	aagatagcct	tcagatcaac	2160

atgcatacaca	ctcaagtgtt	aatcttttcaa	ggtttttcttt	tcttttttctt	gtttttttatt	2220
tgtttttgctt	ttgcttttttt	ttttttttttt	tttgggtggtg	gtgggggctac	caaacttgag	2280
gcctagagct	aaaaatcata	tagaaatgat	gttatcttgt	gggttgagga	aaggccagct	2340
ggcctaagtt	cacacttttg	tcccagtggtc	cctagactcc	accagccag	ctcccaaat	2400
gaaaagacca	cctgtcaagc	agcagtcagg	agtctgatgt	cacccatcac	tattttttttt	2460
ccatcattgt	gcttgctctt	gcctccttcc	acaccctgt	gacgtaatcg	cattgggaag	2520
ccaggacaat	gtttgctgtt	ctgctttggg	ttaaaggact	ccctgaagct	ctgtggctct	2580
ccagtatggt	cccttttctt	tcctaacaga	tgcataatgt	ttcttcagaa	tacaatagt	2640
attcttaaaa	taacccaaaa	gacaggcatc	cacagtgtgt	gagcatgaat	cacagcctgc	2700
attgtgtgag	tgtgaatagt	gggataaaag	tggatgtcag	aagagtggaa	atcaaacctc	2760
tgcaaagcaa	tctttctctt	tctgtgaagt	gtattaagaa	atacctgaag	tctgtgtgtg	2820
tggtggtacc	cagactgtca	atcaataaag	accagactg	tcaatgaaaa	aaaaaaaaaa	2880
aaaaaaaaaa	aaaaa					2895

<210> 9

<211> 2558

<212> DNA

<213> Mus musculus

<400> 9

ctcagcgagg	ggaaggggga	ggaggcctgg	atgactaaac	ctgacagaaa	cgctggtggg	60
aggctcgggc	gggcgcaggt	gcccgcgtag	gtccttctcg	acccgcagcc	accacccgcc	120
cggtgaccat	gatagtgttt	gtcaggttca	actccagcta	tggttccca	gtggagggtcg	180
attctgacac	cagcatcttg	cagctcaagg	aagtgggtgc	taagcgacag	ggggttccag	240
ctgaccagct	gcgtgtgatt	tttgccggga	aggagcttcc	gaatcacctg	acggttcaac	300
tggtgtgccc	aactccctga	ttaaagagct	ccatcacttc	aggatccttg	gagaagagca	360
gtacactagg	taccagcagt	atggggccga	ggaatgcgtg	ctgcaaattg	gaggtgtgct	420
gtgccccgt	cctggctgtg	gagctggact	gctacctgaa	cagggccaga	ggaaagtcac	480
ctgcgaagg	ggcaacggcc	tggtgtgctg	gtttgttttc	tgccgggact	gtaagggaagc	540
ataccatgaa	ggggatttgc	actcactgct	cgaaccctca	ggagccactt	ctcaggccta	600
caggttgga	aaaagagccg	ctgagcaagc	tcgtggggag	gaggcctcca	aggaaaccat	660
caagaagacc	accaagcctt	gtcctcgctg	caacgtgcca	attgaaaaaa	acggaggatg	720
tatgcacatg	aagtgtcctc	agccccagtg	caagctggag	tggtgtctga	actgtggctg	780
tgagtggaa	cgagcctgca	tggtgatgca	ctggtttgac	gtgtagagag	agatgtcact	840
tggtcctgga	cgcacaacct	caaggggaaac	tccgaagatt	cctaccttcc	ttagccattt	900
cttcttctcg	atgcatataa	gcacataaat	gcgcacacac	aaacacaggc	tgagattac	960
agaagcagcc	cctagatcct	ttctagggca	cccacagaaa	accacagcac	ccgctggccc	1020
cagggggagg	aggcactttc	agcctctggc	tactcgaat	gtcagagctt	agatgagggt	1080
gcacctttgg	tttggtattc	gtagaagcca	tgagtggagt	gggaagtgtt	ttccagggtt	1140
gttgccacgc	cctgggtgta	taacacctct	gaggattctc	agaagcacac	ttgagatctg	1200
aggaacgctg	ctctcatgta	gtaatcatct	attcccaaag	ggccccctgc	agtagtcaaa	1260
actatttggt	tatcccccca	aatcctatct	ttacaaatgg	tgctgatgag	attacaaccc	1320
ctctgtgtac	taatcagctt	atcaaccaag	tgagaacctt	ggaaagctaa	ttggatggca	1380
gactgcttaa	atcgcaggga	ggactcagaa	gccaacctta	cttccgttcc	tttcattatc	1440
tgcaacttta	gaaagaaatg	atcttttttt	ccccctgaaa	agataacaaa	gtctgcaatt	1500
tggtttggag	tattcctact	gcagcctgga	agtttagctt	cactgtgaat	ttaacagaga	1560
aagtgcctat	aaagggggcg	tttttaagag	acaatcccat	gatgctgcgc	caatgctaac	1620
aacaggggtca	agaaacacaa	tgtttataga	aggagcatcc	ctcgaccatc	tgaatgagag	1680
tatgcctgac	cccttccacc	acaagtgggg	acacctctgc	atatctgctc	cctcctctgc	1740
tgtaagccc	cagggagccc	catccaccca	gtggtcctac	agacagggca	atacacacac	1800
accaagatag	ccttcagatc	aacatgcata	acactcaagt	gttaatcttt	caagggtttc	1860
ttttcttttt	cctgtttttt	atgtgttttg	cttttgcttt	tttttttttt	ttttttgggtg	1920
gtggtggggc	taccaaactt	gaggcctaga	gctaaaaatc	atatagaaat	gatgttatct	1980
tgtggtgtga	ggaaaggcca	gctggcctaa	gttcacactt	ttgtcccagt	ggccctagac	2040
tccaccagc	cagctcccaa	aatgaaaaga	ccacctgtca	agcagcagtc	aggagtctga	2100

tgtcaccat	cactat	ttccatcat	tgtgcttgc	tctgcctcct	tccacacccg	2160
tgtgacgtaa	tgcattggg	aagccaggac	aatgtttgct	gttctgcttt	gggtaaagg	2220
actccctgaa	gctctgtggc	tctccagtat	ggctccctttt	ccttcctaac	agatgcatat	2280
gttttcttca	gaatacaata	gtgattctta	aaataaccca	aaagacaggc	atccacagtg	2340
tgtgagcatg	aatcacagcc	tgcattgtgt	gagtgatgaat	agtgggataa	aagtggatgt	2400
cagaagagtg	gaaatcaaac	ctctgcaaag	caatctttct	ctttctgtga	agtgtattaa	2460
gaaatacctg	aagtctgtgt	gtgtgggtgt	acccagactg	tcaatcaata	aagacccaga	2520
ctgtcaatga	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa			2558

<210> 10

<211> 3136

<212> DNA

<213> Mus musculus

<400> 10

ctcagcgagg	ggaaggggga	ggaggcctgg	atgactaaac	ctgacagaaa	cgctgggtggg	60
aggctcgggc	gggcgcaggt	gcccgcgtag	gtccttctcg	acccgcagcc	accacccgcc	120
cggtgaccat	gatagtgttt	gtcaggttca	actccagcta	tggttccca	gtggagggtcg	180
attctgacac	cagcatcttg	cagctcaagg	aagtgggtgc	taagcgacag	gggggtccag	240
ctgaccagct	gcgtgtgatt	tttgccggga	aggagcttcc	gaatcacctg	acggttcaaa	300
actgtgacct	ggaacaacag	agtattgtac	acatagtaca	gagaccacgg	aggagaagtc	360
atgaaacaaa	tgcattctgga	ggggacgaac	cccagagcac	ctcagagggc	tccatatggg	420
agtccaggag	cttgacacga	gtggacctga	gcagccatac	cctgccggtg	gactctgtgg	480
ggctggcggg	cattctggac	acagacagta	agagggattc	agaagcagcc	agagggtccag	540
ggcccatctt	gctgggacga	tgtcttaatt	ccaaaccgga	tgagtgggtga	gtgccagtct	600
ccagactgcc	ctggaaccag	agctgaattt	ttctttaaat	gtggagcaca	cccaacctca	660
gacaaggaca	cgtcggtagc	tttgaacctg	atcaccagca	acaggcgcag	catcccttgc	720
atagcgtgca	cagatgtcag	gagccctgtc	ctggtcttcc	agtgtaacca	ccgtcacgtg	780
atctgtttgg	actgtttcca	cttgattgtt	gtcacaagac	tcaacgatcg	gcagtttgtc	840
cacgatgtct	aacttggtca	ctccctgccg	tgtgtagctg	gctgtcccaa	ctccctgatt	900
aaagagctcc	atcaacttcag	gatccttgga	gaagagcagt	acactaggta	ccagcagtat	960
ggggccgagg	aatgcgtgct	gcaaatggga	gggtgtgctgt	gccccctgcc	tggtgtgga	1020
gctggactgc	tacctgaaca	gggcccagagg	aaagtcacct	gcgaaggggg	caacggcctg	1080
ggctgcgggt	ttgttttctg	ccgggactgt	aaggaagcat	accatgaagg	ggattgcgac	1140
tcaactgctc	aaccttcagg	agccacttct	caggcctaca	gggtggacaa	aagagccgct	1200
gagcaagctc	gctgggagga	ggcctccaag	gaaaccatca	agaagaccac	caagccttgt	1260
cctcgctgca	acgtgccaat	tgaaaaaaac	ggaggatgta	tgcacatgaa	gtgtcctcag	1320
ccccagtgca	agctggagtg	gtgctggaac	tgtggctgtg	agtggaaccg	agcctgcatg	1380
ggagatcact	ggtttgacgt	gtagagagag	atgtcacttg	gccctggacg	cacaacctca	1440
agggaaaactc	cgaagattcc	taccttcctt	agccatttct	tcttctcgat	gcatataagc	1500
acataaatgc	gcacacacaa	acacaggctg	cagattacag	aagcagcccc	tagatccttt	1560
ctagggcacc	cacagaaaac	cacagcacc	gctggcccca	gggggaggag	gcactttcag	1620
cctctggctc	actcgaatgt	cagagcttag	atgagggtgc	acctttggtt	tggtattctgt	1680
agaagccatg	agtgagggtg	gaagtgtttt	ccagggttgt	tgccacgccc	tggttaagta	1740
acacctctga	ggattctcag	aagcacactt	gagatctgag	gaacgctgct	ctcatgtagt	1800
aatcatctat	tcccaaagg	ccccctgcag	tagtcaaaac	tatttggtta	ttcccccaaa	1860
tcctatcttt	acaaatggtg	ctgatgagat	tacaaccctt	ctgtgtacta	atcagcttat	1920
caaccaagtg	agaacctagg	aaagctaatt	ggatggcaga	ctgcttaaat	cgcagggagg	1980
actcagaagc	caaacctact	tccgttctgt	tcattatctg	caactttaga	aagaaatgat	2040
ctttttttcc	ccctgaaaag	ataacaaagt	ctgcaatttg	gtttggagta	ttcctactgc	2100
agcctggaag	tttagcttca	ctgtgaattt	aacagagaaa	gtgcctataa	agggggcggt	2160
tttaagagac	aatcccatga	tgtgcgcca	atgctaacaa	cagggtcaag	aaacacaatg	2220
tttatagaag	gagcatccct	cgaccatctg	aatgagagta	tgctgacct	cttccaccac	2280
aagtggggac	acctctgcat	atctgtctcc	tcctctgctg	ttaagcccca	gggagcccca	2340
tccaccctgt	ggctctacag	acagggcaat	acacacacac	caagatagcc	ttcagatcaa	2400

catgcatcac	actcaagtgt	taatctttca	aggttttctt	ttctttttcc	tgttttttat	2460
ttgttttgct	tttgcttttt	tttttttttt	ttttggtggt	ggtggggcta	ccaaacttga	2520
ggcctagagc	taaaaatcat	atagaaatga	tgttatcttg	tggtgtgagg	aaaggccagc	2580
tggcctaagt	tcacactttt	gtcccagtg	ccctagactc	cacccagcca	gctcccaaaa	2640
tgaaaagacc	acctgtcaag	cagcagtcag	gagctgatg	tcacccatca	ctattttttt	2700
tccatcattg	tgcttgcttc	tgcttccttc	cacacccgtg	tgacgtaatc	gcattgggaa	2760
gccaggacaa	tgtttgctgt	tctgctttgg	gtaaagggac	tccctgaagc	tctgtggctc	2820
tccagtatgg	tccctttttc	ttcctaacag	atgcatatgt	tttcttcaga	atacaatagt	2880
gattcttaaa	ataacccaaa	agacaggcat	ccacagtgtg	tgagcatgaa	tcacagcctg	2940
cattgtgtga	gtgtgaatag	tgggataaaa	gtggatgtca	gaagagtggg	aatcaaacct	3000
ctgcaaagca	atctttctct	ttctgtgaag	tgtattaaga	aatacctgaa	gtctgtgtgt	3060
gtggtgttac	ccagactgtc	aatcaataaa	gaccagact	gtcaatgaaa	aaaaaaaaaa	3120
aaaaaaaaaa	aaaaaa					3136

<210> 11

<211> 3170

<212> DNA

<213> Mus musculus

<400> 11

ctcagcgagg	ggaaggggga	ggaggcctgg	atgactaaac	ctgacagaaa	cgctgggtggg	60
aggctcgggc	gggcgcagct	gcccgcgtag	gtccttctcg	acccgcagcc	accacccgcc	120
cggtgaccat	gatatgtttt	gtcaggttca	actccagcta	tggttccca	gtggagggtcg	180
attctgacac	cagcatcttg	cagctcaagg	aagtgggtgc	taagcgacag	ggggttccag	240
ctgaccagct	gcgtgtgatt	tttgccggga	aggagcttcc	gaatcacctg	acggttcaaa	300
actgtgacct	ggaacaacag	agtattgtac	acatagtaca	gagaccacgg	aggagaagtc	360
atgaaacaaa	tgcattctgga	ggggacgaac	cccagagcac	ctcagagggc	tccatatggg	420
agtccaggag	cttgacacga	gtggacctga	gcagccatac	cctgccggtg	gactctgtgg	480
ggctggcggg	cattctggac	acagacagta	agagggattc	agaagcagcc	agagggtccag	540
ttaaacccac	ctacaacagc	tttttcatct	actgcaaagg	ccccgtccac	aagggtccagc	600
ctggaaaagct	ccgagttcag	tgtggcacct	gcaaacaagc	aaccctcacc	ttggcccaga	660
atttttcttt	aaatgtggag	cacacccaac	ctcagacaag	gacacgtcgg	tagctttgaa	720
cctgatcacc	agcaacaggc	gcagcatccc	ttgcatagcg	tgacagatg	tcaggagccc	780
tgtcctggtc	ttccagtgtg	accacgtca	cgtgatctgt	ttggactgtt	tccacttgta	840
tttgttcaca	agactcaacg	atcggcagtt	tgtccacgat	gctcaacttg	gctactccct	900
gccgtgtgta	gctggctgtc	ccaactccct	gattaaagag	ctccatcact	tcaggatcct	960
tggaagaagag	cagtacacta	ggtaccagca	gtatggggcc	gaggaatgag	tgctgcaaat	1020
gggaggtgtg	ctgtgcccc	gtcctggctg	tggaagctgga	ctgctacctg	aacagggcca	1080
gaggaagtc	acctgcgaag	ggggcaacgg	cctgggctgc	gggtttgttt	tctgccggga	1140
ctgtaaggaa	gcataccatg	aaggggattg	cgactcactg	ctcgaaccct	caggagccac	1200
ttctcaggcc	tacagggtgg	acaaaagagc	cgctgagcaa	gctcgctggg	aggaggcctc	1260
caaggaaaacc	atcaagaaga	ccaccaagcc	ttgtcctcgc	tgcaacgtgc	caattgaaaa	1320
aaacggagga	tgtatgcaca	tgaagtgtcc	tcagccccag	tgcaagctgg	agtgggtgctg	1380
gaactgtggc	tgtgagtggg	accgagcctg	catgggagat	cactggtttg	acgtgtagag	1440
agagatgtca	cttgcccttg	gacgcacaac	ctcaagggaa	actccgaaga	ttcctacctt	1500
ccttagccat	ttcttcttct	cgatgcatac	aagcacataa	atgcgcacac	acaaacacag	1560
gctgcagatt	acagaagcag	cccctagatc	ctttctaggg	cacccacaga	aaaccacagc	1620
acccgctggc	cccagggggg	ggaggcactt	tcagcctctg	gctcactcga	atgtcagagc	1680
ttagatgagg	gtgcaccttt	ggtttggtat	ctgtagaagc	catgagttag	gtgggaagtg	1740
ttttccaggg	ttgttgccac	gccctgggta	agtaaacact	ctgaggattc	tcagaagcac	1800
acttgagatc	tgaggaaacg	tgtctcatg	tagtaatcat	ctattcccaa	agggccccct	1860
gcagtagtca	aaactatttg	tttatcccc	caaatacctat	ctttacaaat	ggtgctgatg	1920
agattacaac	ccctctgtgt	actaatcagc	ttatcaacca	agtgagaacc	taggaaagct	1980
aattggatgg	cagactgctt	aaatcgcagg	gaggactcag	aagccaaacc	tacttccgtt	2040
cgtttcatta	tctgcaactt	tagaaagaaa	tgatcttttt	ttccccctga	aaagataaca	2100

aagtctgcaa	tttggtttgg	agtattccta	ctgcagcctg	gaagtttagc	ttcactgtga	2160
atttaacaga	gaaagtgcct	ataaaggggg	cgtttttaag	agacaatccc	atgatgctgc	2220
gccaatgcta	acaacagggt	caagaaacac	aatgtttata	gaaggagcat	ccctcgacca	2280
tctgaatgag	agtatgcctg	accccttcca	ccacaagtgg	ggacacctct	gcataatctgc	2340
tccctcctct	gctgttaagc	cccagggagc	cccatccacc	cagtggtcct	acagacaggg	2400
caatacacac	acaccaagat	agccttcaga	tcaacatgca	tcacactcaa	gtgttaatct	2460
ttcaaggttt	tcttttcttt	ttcctgtttt	ttatttgttt	tgcttttgct	tttttttttt	2520
ttttttttgg	tgggtggtgg	gctaccaaac	ttgaggccta	gagctaaaaa	tcatatagaa	2580
atgatgttat	cttgtggtgt	gaggaaaggc	cagctggcct	aagttcacac	ttttgtccca	2640
gtggccctag	actccaccca	gccagctccc	aaaatgaaaa	gaccacctgt	caagcagcag	2700
tcaggagtct	gatgtcacc	atcactat	tttttccatc	attgtgcttg	cctctgcctc	2760
cttccacacc	cgtgtgacgt	aatcgcat	ggaagccagg	acaatgtttg	ctgttctgct	2820
ttgggtaaag	ggactccctg	aagctctgtg	gctctccagt	atggtccctt	ttccttccta	2880
acagatgcat	atgttttctt	cagaatacaa	tagtgattct	taaaataacc	caaaagacag	2940
gcatccacag	tgtgtgagca	tgaatcacag	cctgcattgt	gtgagtgtga	atagtgggat	3000
aaaagtggat	gtcagaagag	tggaaatcaa	acctctgcaa	agcaatcttt	ctctttctgt	3060
gaagtgtatt	aagaaatacc	tgaagtctgt	gtgtgtggtg	gtacccagac	tgtcaatcaa	3120
taaagaccca	gactgtcaat	gaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa		3170

<210> 12

<211> 2918

<212> DNA

<213> Mus musculus

<400> 12

ctcagcgagg	ggaaggggga	ggaggcctgg	atgactaaac	ctgacagaaa	cgctgggtggg	60
aggctcgggc	gggcgcaggt	gcccgcgtag	gtccttctcg	acccgcagcc	accacccgcc	120
cggtgaccat	gatagtgttt	gtcaggttca	actccagcta	tggcttccca	gtggagggtcg	180
attctgacac	cagcatcttg	cagctcaagg	aagtgggtgc	taagcgacag	gggggtccag	240
ctgaccagct	gcgtgtgatt	tttgccggga	aggagcttcc	gaatcacctg	acggttcaaa	300
actgtgacct	ggaacaacag	agtattgtac	acatagtaca	gagaccacgg	aggagaagtc	360
atgaaacaaa	tgcattctgga	ggggacgaac	cccagagcac	ctcagagggc	tccatatggg	420
agtccaggag	cttgacacga	gtggacctga	gcagccatac	cctgccgggtg	gactctgtgg	480
ggctggcggt	cattctggac	acagacagta	agagggtatc	agaagcagcc	agagggtccag	540
ttaaacccac	ctacaacagc	tttttcatct	actgcaaagg	ccccctgccac	aagggtccagc	600
ctggaaaagct	ccgagttcag	tgtggcacct	gcaaacaagc	aaccttcacc	ttggcccagc	660
tggctgtccc	aactccctga	ttaaagagct	ccatcacttc	aggatccttg	gagaagagca	720
gtacactagg	taccagcagt	atggggccga	ggaatgcgtg	ctgcaaattg	gaggtgtgct	780
gtgccccgt	cctggctgtg	gagctggact	gctacctgaa	cagggccaga	ggaaagtcac	840
ctgcgaaggg	ggcaacggcc	tgggtgcgg	gtttgttttc	tgccgggact	gtaaggaagc	900
ataccatgaa	ggggatttgc	actcaactgt	cgaaccctca	ggagccactt	ctcaggccta	960
caggtgtggac	aaaagagccg	ctgagcaagc	tcgtggggag	gaggcctcca	aggaaaccat	1020
caagaagacc	accaagcctt	gtcctcgctg	caacgtgcca	attgaaaaaa	acggaggatg	1080
tatgcacatg	aagtgtcctc	agccccagtg	caagctggag	tgggtgctgga	actgtggctg	1140
tgagtggaac	cgagcctgca	tgggagatca	ctggtttgac	gtgtagagag	agatgtcact	1200
tggccctgga	cgcacaacct	caagggaaac	tccgaagatt	cctaccttcc	ttagccattt	1260
cttcttctcg	atgcatataa	gcacataaat	gcgcacacac	aaacacaggc	tgcagattac	1320
agaagcagcc	cctagatcct	ttctagggca	cccacagaaa	accacagcac	ccgctggccc	1380
cagggggagg	aggcactttc	agcctctggc	tcactcgaat	gtcagagctt	agatgagggt	1440
gcacctttgg	tttggattct	gtagaagcca	tgagtgaggt	gggaagtgtt	ttccaggggt	1500
gttgccacgc	cctgggttaag	taacacctct	gaggattctc	agaagcacac	ttgagatctg	1560
aggaacgctg	ctctcatgta	gtaatcatct	attcccaaag	ggccccctgc	agtagtcaaa	1620
actatttgtt	tatcccccca	aatcctatct	ttacaaatgg	tgctgatgag	attacaaccc	1680
ctctgtgtac	taatcagctt	atcaaccaag	tgagaacctta	ggaaagctaa	ttggatggca	1740
gactgcttaa	atcgcaggga	ggactcagaa	gccaaacctta	cttccgttctg	tttcattatc	1800



tgcaacttta	gaaagaaatg	atcttttttt	ccccctgaaa	agataacaaa	gtctgcaatt	1860
tggtttggag	tattcctact	gcagcctgga	agtttagctt	cactgtgaat	ttaacagaga	1920
aagtgcctat	aaagggggcg	tttttaagag	acaatcccat	gatgctgcgc	caatgctaac	1980
aacagggtca	agaaacacaa	tgtttataga	aggagcatcc	ctcgaccatc	tgaatgagag	2040
tatgcctgac	cccttccacc	acaagtgggg	acacctctgc	atatctgctc	cctcctctgc	2100
tgtaaagccc	caggagagccc	catccaccca	gtggtcctac	agacagggca	atacacacac	2160
accaagatag	ccttcagatc	aacatgcatc	acactcaagt	gttaatcttt	caaggttttc	2220
ttttcttttt	cctgtttttt	atgtgttttg	cttttgcttt	tttttttttt	ttttttggtg	2280
gtggtggggc	taccaaactt	gaggcctaga	gctaaaaatc	atatagaaat	gatgttatct	2340
tgtggtgtga	ggaaaggcca	gctggcctaa	gttcacactt	ttgtcccagt	ggccctagac	2400
tccaccagc	cagctcccaa	aatgaaaaga	ccacctgtca	agcagcagtc	aggagtctga	2460
tgtcacccat	cactattttt	tttccatcat	tgtgcttgcc	tctgcctcct	tccacaccgc	2520
tgtgacgtaa	tgcattggg	aagccaggac	aatgtttgct	gttctgcttt	gggtaaagg	2580
actccctgaa	gctctgtggc	tctccagtat	ggctcccttt	ccttcctaac	agatgcata	2640
gttttcttca	gaatacaata	gtgattctta	aaataaccca	aaagacaggc	atccacagtg	2700
tgtgagcatg	aatcacagcc	tgcattgtgt	gagtggtgaat	agtgggataa	aagtggatgt	2760
cagaagagtg	gaaatcaaac	ctctgcaaag	caatctttct	ctttctgtga	agtgtattaa	2820
gaaatacctg	aagtctgtgt	gtgtggtggt	accagactg	tcaatcaata	aagaccaga	2880
ctgtcaatga	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa			2918

<210> 13

<211> 3043

<212> DNA

<213> Mus musculus

<400> 13

ctcagcgagg	ggaaggggga	ggaggcctgg	atgactaaac	ctgacagaaa	cgctgggtggg	60
aggctcgggc	gggcgcaggt	gcccgcgtag	gtccttctcg	acccgcagcc	accacccgcc	120
cggtgaccat	gatagtgttt	gtcaggttca	actccagcta	tggttccca	gtggagggtcg	180
attctgacac	cagcatcttg	cagctcaagg	aagtgggtgc	taagcgacag	ggggttccag	240
ctgaccagct	gcgtgtgatt	tttgccggga	aggagcttcc	gaatcacctg	acggttcaaa	300
actgtgacct	ggaacaacag	agtattgtac	acatagtaca	gagaccacgg	aggagaagtc	360
atgaaacaaa	tgcattctgga	ggggacgaac	cccagagcac	ctcagagggc	tccatatggg	420
agtccaggag	cttgacacga	gtggacctga	gcagccatac	cctgccgggtg	gactctgtgg	480
ggctggcggg	cattctggac	acagacagta	agagggtatc	agaagcagcc	agagggtccag	540
ttaaaccac	ctacaacagc	tttttcatct	actgcaaagg	ccccgtccac	aagggtccagc	600
ctggaaaagct	ccgagttcag	tgtggcacct	gcaaacaagc	aacctcacc	ttggcccagg	660
gcccattctg	ctgggacgat	gtcttaattc	caaaccggat	gagtgggtgag	tgccagtctc	720
cagactgccc	tggaaaccaga	gctgaatttt	tctttaaatg	tggagcacac	ccaacctcag	780
acaaggacac	gtcggtagct	ttgaacctga	tcaccagcaa	caggcgcagc	atcccttgca	840
tagcgtgcac	agatgtcagg	agccctgtcc	tggtcttcca	gtgtaaccac	cgtcacgtga	900
tctgtttgga	ctgtttccac	ttgtattgtg	tcacaagact	caacgatcgg	cagtttgtcc	960
acgatgctca	acttggtctac	tccctgcccgt	gtgtagtttg	ttttctgccg	ggactgtaag	1020
gaagcatacc	atgaagggga	ttgcgactca	ctgctcgaac	cctcaggagc	cacttctcag	1080
gcctacaggg	tggacaaaag	agccgctgag	caagctcgct	gggaggaggc	ctccaaggaa	1140
accatcaaga	agaccaccaa	gccttgctct	cgctgcaacg	tgccaattga	aaaaaacgga	1200
ggatgtatgc	acatgaagtg	tctcagccc	cagtgcgaagc	tggagtgggtg	ctggaactgt	1260
ggctgtgagt	ggaaccgagc	ctgcatggga	gatcactggg	ttgacgtgta	gagagagatg	1320
tcacttggcc	ctggacgcac	aacctcaagg	gaaactccga	agattcctac	cttccttagc	1380
catttcttct	tctcgatgca	tataagcaca	taaagtgcga	cacacaaaca	caggctgcag	1440
attacagaag	cagcccctag	atcctttcta	gggcacccac	agaaaaccac	agcaccgcgt	1500
ggccccaggg	ggaggaggca	ctttcagcct	ctggctcact	cgaatgtcag	agcttagatg	1560
agggtgcacc	tttggttttg	attctgtaga	agccatgagt	gagggtgggaa	gtgttttcca	1620
gggttgttgc	cacgccctgg	gtaagtaaca	cctctgagga	ttctcagaag	cacacttgag	1680
atctgaggaa	cgctgctctc	atgtagtaat	catctattcc	caaagggccc	cctgcagtag	1740

tcaaaactat	ttgtttatcc	ccccaaatcc	tatctttaca	aatggtgctg	atgagattac	1800
aacccctctg	tgtactaatc	agcttatcaa	ccaagtgaga	acctaggaaa	gctaattgga	1860
tggcagactg	cttaaatcgc	agggaggact	cagaagccaa	acctacttcc	gttcgtttca	1920
ttatctgcaa	ctttagaaag	aaatgatctt	tttttcccc	tgaaaagata	acaaagtctg	1980
caatttggtt	tggagtattc	ctactgcagc	ctggaagttt	agcttcactg	tgaatttaac	2040
agagaaagtg	cctataaagg	gggctgtttt	aagagacaat	cccatgatgc	tgcgccaatg	2100
ctaacaacag	ggtcaagaaa	cacaatgttt	atagaaggag	catccctcga	ccatctgaat	2160
gagagtatgc	ctgacccctt	ccaccacaag	tggggacacc	tctgcataatc	tgctccctcc	2220
tctgctgtta	agccccaggg	agccccatcc	acccagtggg	cctacagaca	gggcaataca	2280
cacacaccaa	gatagccttc	agatcaacat	gcacacact	caagtgttaa	tctttcaagg	2340
ttttcttttc	tttttctgt	tttttatttg	ttttgctttt	gctttttttt	tttttttttt	2400
tgggtggtgt	ggggctacca	aacttgaggc	ctagagctaa	aaatcatata	gaaatgatgt	2460
tatcttgtgg	tgtgaggaaa	ggccagctgg	cctaagttca	cacttttgtc	ccagtggccc	2520
tagactccac	ccagccagct	cccaaatga	aaagaccacc	tgtaagcag	cagtcaggag	2580
tctgatgtca	cccatcacta	ttttttttcc	atcattgtgc	ttgcctctgc	ctccttccac	2640
accctgtgga	cgtaatcgca	ttgggaagcc	aggacaatgt	ttgctgttct	gctttgggta	2700
aagggactcc	ctgaagctct	gtggctctcc	agtatgggtc	cttttccttc	ctaacagatg	2760
catatgtttt	cttcagaata	caatagtgat	tcttaaaata	acccaaaaga	caggcatcca	2820
cagtgtgtga	gcatgaatca	cagcctgcat	tgtgtgagtg	tgaatagtgg	gataaaagtg	2880
gatgtcgaaa	gagtggaaat	caaacctctg	caaagcaatc	tttctctttc	tgtgaagtgt	2940
attaagaaat	acctgaagtc	tgtgtgtgtg	gtggtaccca	gactgtcaat	caataaagac	3000
ccagactgtc	aatgaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaa		3043

<210> 14

<211> 3253

<212> DNA

<213> Mus musculus

<400> 14

ctcagcgagg	ggaaggggga	ggaggcctgg	atgactaaac	ctgacagaaa	cgctgggtggg	60
aggctcgggc	gggcgccagt	gcccgcgtag	gtccttctcg	acccgcagcc	accacccgcc	120
cggtgaccat	gatagtgttt	gtcaggttca	actccagcta	tggcttccca	gtggagggtcg	180
attctgacac	cagcatcttg	cagctcaagg	aagtgggtgc	taagcgacgg	ggttccagct	240
gaccagctgc	gtgtgatttt	tgcggggaag	gagcttccga	atcacctgac	ggttcaaaac	300
tgtgacctgg	aacaacagag	tattgtacac	atagtagaga	gaccacggag	gagaagtcat	360
gaaacaaatg	catctggagg	ggacgaaccc	cagagcacct	cagaggggtc	catatgggag	420
tccaggagct	tgacacgagt	ggacctgagc	agccataccc	tgcgggtgga	ctctgtgggg	480
ctggcggtca	ttctggacac	agacagtaag	agggattcag	aagcagccag	aggtccagtt	540
aaacccacct	acaacagctt	tttcatctac	tgcaaaggcc	cctgccacaa	ggccagcct	600
ggaaagctcc	gagttcagtg	tggcacctgc	aaacaagcaa	ccctcacctt	ggcccagggc	660
ccatcttgct	gggacgatgt	cttaattcca	aaccggatga	gtggtgagtg	ccagtctcca	720
gactgccttg	gaaccagagc	tgaatttttc	tttaaagtgt	gagcacaccc	aacctcagac	780
aaggacacgt	cggtagcttt	gaacctgata	accagcaaca	ggcgcagcat	cccttgcata	840
gcgtgcacag	atgtcaggag	ccctgtcctg	gtcttccagt	gtaaccaccg	tcacgtgata	900
tgtttggact	gtttccactt	gtattgtgtc	acaagactca	acgatcggca	gtttgtccac	960
gatgtcaaac	ttggctactc	cctgcccgtg	gtagctggct	gtcccaactc	cctgattaaa	1020
gagctccatc	acttcaggat	ccttgaggaa	gagcagtaca	ctaggtacca	gcagtatggg	1080
gccgaggaat	gcgtgtctga	aatgggaggt	gtgctgtgcc	ccgtccttgg	ctgtggagct	1140
ggactgttac	ctgaacaggg	ccagaggaaa	gtcacctgcg	aagggggcaa	cggcctgggc	1200
tgcggttttg	ttttctgccc	ggactgtaag	gaagcatacc	atgaagggga	ttgcgactca	1260
ctgctcgaac	cctcaggagc	cacttctcag	gcctacaggg	tggacaaaag	agccgctgag	1320
caagctcgct	gggaggaggc	ctccaaggaa	accatcaaga	agaccaccaa	gccttgtcct	1380
cgctgcaacg	tgccaattga	aaaaaacgga	ggatgtatgc	acatgaagtg	tcctcagccc	1440
cagtgaagc	tggagtgggt	ctggaactgt	ggctgtgagt	ggaaccgagc	ctgcatggga	1500
gatcactggt	ttgacgtgta	gagagagatg	tcacttggcc	ctggacgcac	aacctcaagg	1560

```

gaaactccga agattcctac cttccttagc catttcttct tctcgatgca tataagcaca 1620
taaattgcga cacacaaaca caggctgcag attacagaag cagcccctag atcctttcta 1680
gggacccac agaaaaccac agcaccgcgt ggccccaggg ggaggaggca ctttcagcct 1740
ctggctcact cgaatgtcag agcttagatg aggggtgcacc tttggtttgg attctgtaga 1800
agccatgagt gaggtgggaa gtgttttcca ggggtgttgc cacgccctgg gtaagtaaca 1860
cctctgagga ttctcagaag cacacttgag atctgaggaa cgctgctctc atgtagtaat 1920
catctattcc caaaggggccc cctgcagtag tcaaaactat ttgtttatcc ccccaaatcc 1980
tatctttaca aatggtgctg atgagattac aaccctctg tgtactaatc agcttatcaa 2040
ccaagtgaga acctaggaaa gctaattgga tggcagactg cttaaactgc agggaggact 2100
cagaagccaa acctacttcc gttcgtttca ttatctgcaa ctttagaaag aaatgatctt 2160
tttttcccc tgaaaagata acaaagtctg caatttggtt tggagtattc ctactgcagc 2220
ctggaagttt agcttccactg tgaatttaac agagaaagtg cctataaagg gggcgttttt 2280
aagagacaat cccatgatgc tgcgccaatg ctaacaacag ggtcaagaaa cacaatgttt 2340
atagaaggag catccctcga ccatctgaat gagagtatgc ctgaccctt ccaccacaag 2400
tggggacacc totgcatatc tgctccctcc tctgctgtta agccccaggg agccccatcc 2460
accagtggt cctacagaca gggcaatata cacacaccaa gatagccttc agatcaacat 2520
gcatcacact caagtgttaa tctttcaagg ttttcttttc ttttctctgt tttttatttg 2580
ttttgctttt gctttttttt tttttttttt tgggtgggtg ggggctacca aacttgaggc 2640
ctagagctaa aaatcatata gaaatgatgt tatcttgtgg tgtgaggaaa ggccagctgg 2700
cctaagttca cacttttgtc ccagtggccc tagactccac ccagccagct cccaaaatga 2760
aaagaccacc tgtcaagcag cagtcaggag tctgatgtca cccatcacta ttttttttcc 2820
atcattgtgc ttgectctgc ctccctccac acccgtgtga cgtaatcgca ttgggaagcc 2880
aggacaatgt ttgctgttct gctttgggta aagggactcc ctgaagctct gtggctctcc 2940
agtatggtcc cttttccttc ctaacagatg catatgtttt cttcagaata caatagtgat 3000
tcttaaaata acccaaaaga caggcatcca cagtgtgtga gcatgaatca cagcctgcat 3060
tgtgtgagtg tgaatagtgg gataaaagtg gatgtcagaa gagtggaaat caaacctctg 3120
caaagcaatc tttctctttc tgtgaagtgt attaagaaat acctgaagtc tgtgtgtgtg 3180
gtggtaccca gactgtcaat caataaagac ccagactgtc aatgaaaaaa aaaaaaaaaa 3240
aaaaaaaaaa aaa 3253

```

<210> 15

<211> 3254

<212> DNA

<213> Mus musculus

<400> 15

```

ctcagcgagg ggaaggggga ggaggcctgg atgactaaac ctgacagaaa cgctggtggg 60
aggctcgggc gggcgccagt gcccgcgtag gtccttctcg acccgagcc accacccgcc 120
cggtgaccat gatagtgtt gtcaggttca actccagcta tggcttccca gtggaggtcg 180
attctgacac cagcatcttg cagctcaagg aagtggttgc taagcgacag ggggttccag 240
ctgaccagct gcgtgtgatt tttgcgggga aggagcttcc gatcacctga cggttcaaaa 300
ctgtgacctg gaacaacaga gtattgtaca catagtacag agaccacgga ggagaagtca 360
tgaaacaaat gcatctggag gggacgaacc ccagagcacc tcagaggggt ccatatggga 420
gtccaggagc ttgacacgag tggacctgag cagccatacc ctgccggtgg actctgtggg 480
gctggcggtc attctggaca cagacagtaa gagggattca gaagcagcca gaggtccagt 540
taaaccacc tacaacagct ttttcateta ctgcaaaggc ccctgccaca aggtccagcc 600
tggaagctc cgagttcagt gtggcacctg caaacaagca accctcacct tggcccaggg 660
cccatcttgc tgggacgatg tottaattcc aaaccggatg agtgggtgagt gccagtctcc 720
agactgccct ggaaccagag ctgaattttt ctttaaagt ggagcacacc caacctcaga 780
caaggacacg tcggtagctt tgaacctgat caccagcaac aggcgcagca tcccttgcat 840
agcgtgcaca gatgtcagga gccctgtcct ggtcttccag tgtaaccacc gtcacgtgat 900
ctgtttggac tgtttccact tgtatttgtt cacaagactc aacgatcggc agtttgtcca 960
cgatgctcaa cttggctact cctgcctgtg tgtagctggc tgtcccaact ccctgattaa 1020
agagctccat cacttcagga tccctggaga agagcagtac actaggtacc agcagtatgg 1080
ggccgaggaa tgcgtgctgc aaatgggagg tgtgctgtgc ccccgctctg gctgtggagc 1140

```

```

tggactgcta cctgaacagg gccagaggaa agtcacctgc gaagggggca acggcctggg 1200
ctgcgggttt gttttctgcc gggactgtaa ggaagcatac catgaagggg attgcgactc 1260
actgctcgaa cctcaggag ccacttctca ggcctacagg gtggacaaaa gagccgctga 1320
gcaagctcgc tgggaggagg cctccaagga aaccatcaag aagaccacca agccttgtcc 1380
tcgctgcaac gtgccaattg aaaaaaacgg aggatgtatg cacatgaagt gtcctcagcc 1440
ccagtgaag ctggagtggg gctggaactg tggctgtgag tggaaaccgag cctgcatggg 1500
agatcactgg tttgacgtgt agagagagat gtcacttggc cctggacgca caacctcaag 1560
ggaaactccg aagattccta ctttccttag ccatttcttc ttctcgatgc atataagcac 1620
ataaatgcgc acacacaaac acaggctgca gattacagaa gcagccccta gatcctttct 1680
agggcaccca cagaaaacca cagcaccgcg tggccccagg gggaggaggc actttcagcc 1740
tctggctcac tcgaatgtca gagcttagat gagggtgcac ctttggtttg gattctgtag 1800
aagccatgag tgagggtggg agtggtttcc aggggtgttg ccacgccctg ggtaagtaac 1860
acctctgagg attctcagaa gcacacttga gatctgagga acgctgctct catgtagtaa 1920
tcatctattc ccaaagggcc cctgcagta gtcaaaacta tttgtttatc ccccaaatc 1980
ctatctttac aaatggtgct gatgagatta caaccctct gtgtactaat cagcttatca 2040
accaagtgag aacctaggaa agctaattgg atggcagact gcttaaactc caggaggagc 2100
tcagaagcca aacctacttc cgttcgtttc attatctgca actttagaaa gaaatgatct 2160
ttttttcccc ctgaaaagat aacaaagtct gcaatttggg ttggagtatt cctactgcag 2220
cctggaagtt tagcttcaact gtgaatttaa cagagaaagt gcctataaag ggggcgtttt 2280
taagagacaa tcccatgatg ctgcgccaat gctaacaaca gggcaagaa acacaatgtt 2340
tatagaagga gcatccctcg accatctgaa tgagagtatg cctgaccctc tccaccacaa 2400
gtgggggacac ctctgcatac ctgctccctc ctctgctgtt aagccccagg gagccccatc 2460
caccagtggt tcctacagac agggcaatac acacacacca agatagcctt cagatcaaca 2520
tgcacacacac tcaagtgtta atctttcaag gttttctttt ctttttcttg ttttttatct 2580
gttttgcttt tgcttttttt tttttttttt ttggtggtgg tggggctacc aaacttgagg 2640
cctagagcta aaaatcatat agaaatgatg ttatcttggt gtgtgaggaa aggccagctg 2700
gcctaagttc aactttttgt ccagtgggcc ctgactcca cccagccagc tcccaaatg 2760
aaaagaccac ctgtcaagca gcagtcagga gtctgatgtc acccatcact attttttttc 2820
catcattgtg cttgcctctg cctccttcca caccgtgtg acgtaatcgc attgggaagc 2880
caggacaatg tttgctgttc tgctttgggt aaagggactc cctgaagctc tgtggctctc 2940
cagtatgggt ccttttccct cctaacagat gcataatgtt tcttcagaat acaatagtga 3000
ttcttaaaat aacccaaaag acaggcatcc acagtgtgtg agcatgaatc acagcctgca 3060
ttgtgtgagt gtgaatagtg ggataaaaagt ggatgtcaga agagtggaaa tcaaacctct 3120
gcaaagcaat ctttctcttt ctgtgaagtg tattaagaaa tacctgaagt ctgtgtgtgt 3180
gggtgtaccc agactgtcaa tcaataaaga cccagactgt caatgaaaaa aaaaaaaaaa 3240
aaaaaaaaaa aaaa 3254

```

<210> 16  
 <211> 3253  
 <212> DNA  
 <213> Mus musculus

```

<400> 16
ctcagcgagg ggaaggggga ggaggcctgg atgactaaac ctgacagaaa cgctggtggg 60
aggctcgggc gggcgccagt gcccgctag gtccttctcg acccgagcc accaccgcc 120
cggtgaccat gatagtgttt gtcaggttca actccagcta tggcttccca gtggaggtcg 180
attctgacac cagcatcttg cagctcaagg aagtggttgc taagcgacag ggggttccag 240
ctgaccagct gcgtgtgatt tttgcgggga aggagcttcc gaatcacctg acggttcaaa 300
actgtgacct ggaacaacag agtattgtac acatagtaca gagaccaggg gagaagtcac 360
gaaacaaatg catctggagg ggaogaacc cagagcacct cagagggctc catatgggag 420
tccaggagct tgacacgagt ggacctgagc agccataccc tgccggtgga ctctgtgggg 480
ctggcggtca ttctggacac agacagtaag agggattcag aagcagccag aggtccagtt 540
aaaccacact acaacagctt tttcatctac tgcaaaggcc cctgccacaa ggtccagcct 600
ggaaagctcc gagttcagtg tggcacctgc aaacaagcaa cctcacctt ggcccagggc 660
ccatcttgct gggacgatgt cttaattcca aaccggatga gtggtgagtg ccagtctcca 720

```

```

gactgccttg gaaccagagc tgaatttttc tttaaatgtg gagcacaccc aacctcagac 780
aaggacacgt cggtagcttt gaacctgata accagcaaca ggcgagcat cctttgcata 840
gcgtgcacag atgtcaggag cctgtcctg gtcttccagt gtaaccaccg tcacgtgata 900
tggttggaact gtttccactt gtattgtgtc acaagactca acgatcggca gtttgtccac 960
gatgtcaaac ttggctactc cctgccgtgt gtagctggct gtcccaactc cctgattaaa 1020
gagctccatc acttcaggat cctgggagaa gagcagtaca ctaggtagca gcagtatggg 1080
gccgaggaat gcgtgctgca aatgggaggt gtgctgtgcc cccgtcctgg ctgtggagct 1140
ggactgctac ctgaacaggg ccagaggaaa gtcacctgcg aagggggcaa cggcctgggc 1200
tgcggttttg ttttctgccg ggactgtaag gaagcatacc atgaagggga ttgcgactca 1260
ctgctcgaac cctcaggagc cacttctcag gcctacaggg tggacaaaag agccgctgag 1320
caagctcgct gggaggaggc ctccaaggaa accatcaaga agaccaccaa gccttgtcct 1380
cgctgcaacg tgccaattga aaaaaacgga ggatgtatgc acatgaagtg tcctcagccc 1440
cagtgcgaagc tggagtgggt ctggaactgt ggctgtgagt ggaaccgagc ctgcatggga 1500
gatcactggt ttgacgtgta gagagagatg tcacttggcc ctggacgcac aacctcaagg 1560
gaaactccga agattcctac cttccttagc catttcttct tctcgatgca tataagcaca 1620
taaatgcgca cacacaaaca caggctgcag attacagaag cagcccctag atcctttcta 1680
gggcacccac agaaaaccac agcaccgcgt ggcccaggg ggaggaggca ctttcagcct 1740
ctggctcact cgaatgtcag agcttagatg aggggtgcacc tttggttttg attctgtaga 1800
agccatgagt gaggtgggaa gtgttttcca ggggtgttgc cagccctgg gtaagtaaca 1860
cctctgagga ttctcagaag cacacttgag atctgaggaa cgctgctctc atgtagtaat 1920
catctattcc caaaggggcc cctgcagtag tcaaaactat ttgtttatcc ccccaaatcc 1980
tatctttaca aatggtgctg atgagattac aaccctctg tgtactaatc agcttatcaa 2040
ccaagtgaga acctaggaaa gctaattgga tggcagactg cttaaatcgc agggaggact 2100
cagaagccaa acctacttcc gtctgtttca ttatctgcaa ctttagaaag aaatgatctt 2160
tttttcccc tgaaaagata acaaagtctg caatttgggt tggagtattc ctactgcagc 2220
ctggaagtgt agcttccactg tgaatttaac agagaaagtg cctataaagg gggcgttttt 2280
aagagacaat cccatgatgc tgcgccaatg ctaacaacag ggtcaagaaa cacaatgttt 2340
atagaaggag catccctcga ccatctgaat gagagtatgc ctgaccctt ccaccacaag 2400
tggggacacc tctgcataatc tgcctcctcc tctgctgtta agccccaggg agccccatcc 2460
accagtggt cctacagaca gggcaatata cacacaccaa gatagccttc agatcaacat 2520
gcatcacact caagtgttaa tctttcaagg ttttcttttc ttttctctgt tttttatttg 2580
ttttgctttt gctttttttt tttttttttt tgggtgggtg ggggctacca aacttgaggc 2640
ctagagctaa aaatcatata gaaatgatgt tatcttgtgg tgtgaggaaa ggccagctgg 2700
cctaagtcca cacttttgtc ccagtgggcc tagactccac ccagccagct cccaaaatga 2760
aaagaccacc tgtcaagcag cagtcaggag tctgatgtca cccatcacta ttttttttcc 2820
atcattgtgc ttgcctctgc ctccctccac acccggtgta cgtaategca ttgggaagcc 2880
aggacaatgt ttgctgttct gctttgggtg aagggactcc ctgaagctct gtggctctcc 2940
agtatggtcc cttttccttc ctaacagatg catatgtttt cttcagaata caatagtgat 3000
tcttaaaata acccaaaaaga caggcatcca cagtgtgtga gcatgaatca cagcctgcat 3060
tgtgtgagtg tgaatagtgg gataaaagtg gatgtcagaa gagtggaaat caaacctctg 3120
caaagcaatc tttctctttc tgtgaagtgt attaagaaat acctgaagtc tgtgtgtgtg 3180
gtgtaccca gactgtcaat caataaagac ccagactgtc aatgaaaaaa aaaaaaaaaa 3240
aaaaaaaaaa aaa 3253

```

<210> 17

<211> 3092

<212> DNA

<213> Mus musculus

<400> 17

```

ctcagcgagg ggaaggggga ggaggcctgg atgactaaac ctgacagaaa cgctgggtggg 60
aggctcgggc gggcgccagt gcccgctag gtccttctcg acccgagcc accaccgcc 120
cggtgacat gatagtaact gtgacctgga acaacagagt attgtacaca tagtacagag 180
accacggagg agaagtcata aaacaaatgc atctggagg gacgaacccc agagcacctc 240
agagggtccc atatgggagt ccaggagctt gacacgagtg gacctgagca gccataccct 300

```

```

gccggtggac tctgtggggc tggcgggtcat tctggacaca gacagtaaga gggattcaga 360
agcagccaga ggtccagtta aaccacaccta caacagcttt ttcactact gcaaaggccc 420
ctgccacaag gtccagcctg gaaagctccg agttcagtggt ggcacctgca aacaagcaac 480
cctcaccttg gccaggggcc catcttgctg ggacgatgtc ttaattccaa accggatgag 540
tggtgagtgc cagtctccag actgccctgg aaccagagct gaatttttct ttaaagtgg 600
agcacacca acctcagaca aggacacgtc ggtagctttg aacctgatca ccagcaacag 660
gcgcagcatc ccttgcatag cgtgcacaga tgtcaggagc cctgtcctgg tcttccagt 720
taaccaccgt cacgtgatct gtttgactg tttccacttg tattgtgtca caagactcaa 780
cgatcggcag tttgtccacg atgctcaact tggctactcc ctgccgtgtg tagctggctg 840
tcccaactcc ctgattaaag agctccatca cttcaggatc cttggagaag agcagtacac 900
taggtaccag cagtatgggg ccgaggaatg cgtgctgcaa atgggagggtg tgctgtgccc 960
ccgtcctggc tgtggagctg gactgctacc tgaacagggc cagaggaaag tcacctgcga 1020
agggggcaac ggccctgggct gcgggtttgt tttctgccgg gactgtaagg aagcatacca 1080
tgaaggggat tgcgactcac tgctcgaacc ctcaggagcc acttctcagg cctacagggt 1140
ggacaaaaga gccgctgagc aagctcgctg ggaggaggcc tccaaggaaa ccatcaagaa 1200
gaccaccaag ccttgtcctc gctgcaacgt gccaatgaa aaaaacggag gatgtatgca 1260
catgaagtgt cctcagcccc agtgcaagct ggagtgggtc tggaaactgtg gctgtgagt 1320
gaaccgagcc tgcattggag atcactgggt tgacgtgtag agagagatgt cacttggccc 1380
tggaacgaca acctcaagg aaactccgaa gattcctacc ttccttagcc atttcttct 1440
ctcgatgcat ataagcacat aaatgcgcac acacaaacac aggtctcaga ttacagaagc 1500
agccccctaga tcttttctag ggcaccaca gaaaaccaca gcacctgctg gccccagggg 1560
gaggaggcac tttcagcctc tggctcactc gaatgtcaga gcttagatga ggggtgcacct 1620
ttggtttgga ttctgtagaa gccatgagtg aggtgggaag tgttttccag ggttgttgcc 1680
acgccctggg taagtaacac ctctgaggat tctcagaagc acacttgaga tctgaggaac 1740
gctgctctca tgtagtaatc atctattccc aaagggcccc ctgcagtagt caaaactatt 1800
tgtttatccc cccaaatcct atctttacaa atgggtgctg tgagattaca acccctctgt 1860
gtactaatca gcttatcaac caagtgaaga cctaggaaag ctaattggat ggcagactgc 1920
ttaaatcgca gggaggactc agaagccaaa cctacttccg ttcgtttcat tatctgcaac 1980
tttagaaaga aatgatcttt ttttccccct gaaaagataa caaagtctgc aatttggttt 2040
ggagtattcc tactgcagcc tggaagttaa gcttactgt gaatttaaca gagaaagtgc 2100
ctataaaggg ggctgtttta agagacaatc ccatgatgct gcgccaatgc taacaacagg 2160
gtcaagaaac acaatgttta tagaaggagc atccctcgac catctgaatg agagtatgcc 2220
tgaccccttc caccacaagt ggggacacct ctgcatactc gctccctcct ctgctgttaa 2280
gccccaggga gccccatcca ccagtggtc ctacagacag ggcaatacac acacaccaag 2340
atagccttca gatcaacatg catcacactc aagtgttaat ctttcaagg tttcttttct 2400
ttttcctgtt ttttatttgt tttgcttttg cttttttttt tttttttttt ggtgggtggg 2460
gggctaccaa acttgaggcc tagagctaaa aatcatatag aaatgatgtt atcttgggt 2520
gtgaggaaag gccagctggc ctaagttcac acttttgtcc cagtggccct agactccacc 2580
cagccagctc ccaaaatgaa aagaccacct gtcaagcagc agtcaggagt ctgatgtcac 2640
ccatcactat tttttttcca tcattgtgct tgctgttctg tcttccaca cccgtgtgac 2700
gtaatcgcat tgggaagcca ggacaatgtt tgctgttctg ctttgggtaa agggactccc 2760
tgaagctctg tggtctcca gtatgggtccc ttttcttccc taacagatgc atatgttttc 2820
ttcagaatac aatagtgtt cttaaaataa cccaaaagac aggcattccac agtgtgtgag 2880
catgaatcac agcctgcatt gtgtgagtgt gaatagtggg ataaaagtgg atgtcagaag 2940
agtggaaatc aaacctctgc aaagcaatct ttctctttct gtgaagtgt ttaagaaata 3000
cctgaagtct gtgtgtgtgg tggtaaccag actgtcaatc aataaagacc cagactgtca 3060
atgaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa 3092

```

<210> 18

<211> 3255

<212> DNA

<213> Mus musculus

<400> 18

ctcagcgagg ggaaggggga ggaggcctgg atgactaaac ctgacagaaa cgctgggtggg 60

```

aggctcgggc gggcgccagt gcccgcgtag gtccttctcg acccgagcc accacccgcc 120
cggtgaccat gatagtgttt gtcaggttca actccagcta tggcttccca gtggaggctcg 180
attctgacac cagcatcttg cagctcaagg aagtgggtgc taagcgacag ggggttccag 240
ctgaccagct gcgtgtgatt tttgccggga aggagcttcc gaatcacctg acggttcaaa 300
actgtgacct ggaacaacag agtattgtac acatagtaca gagaccacgg aggagaagtc 360
atgaaacaaa tgcattctgga ggggacgaac cccagagcac ctgagagggc tccatatggg 420
agtccaggag cttgacacga gtggacctga gcagccatac cctgccggtg gactctgtgg 480
ggctggcggg cattctggac acagacagta agagggattc agaagcagcc agagggtccag 540
ttaaacccac ctacaacagc tttttcatct actgcaaagg cccctgccac aagggtccagc 600
ctggaaatct ccgagttcag tgtggcacct gcaaacaagc aaccctcacc ttggcccagg 660
gcccattctg ctgggacgat gtcttaattc caaacggat gagtgggtgag tgccagtctc 720
cagactgccc tggaaaccaga gctgaatttt tctttaaatg tggagcacac ccaacctcag 780
acaaggacac gtcggtagct ttgaacctga tcaccagcaa caggcgagc atcccttgca 840
tagcgtgcac agatgtcagg agccctgtcc tggctctcca gtgtaaccac cgtcacgtga 900
tctgtttgga ctgtttccac ttgtattgtg tcacaagact caacgatcgg cagtttgtcc 960
acgatgtca acttggctac tccctgccgt gtgtagctgg ctgtcccaac tccctgatta 1020
aagagctcca tcaacttcagg atccttggag aagagcagta cactaggtac cagcagtatg 1080
gggccgagga atgcgtgctg caaatgggag gtgtgctgtg ccccgctcct ggctgtggag 1140
ctggactgct acctgaacag ggccagagga aagtcacctg cgaagggggc aacggcctgg 1200
gctgcgggtt tgttttctgc cgggactgta aggaagcata ccatgaaggg gattgcgact 1260
cactgctcga accctcagga gccacttctc aggcctacag ggtggacaaa agagccgctg 1320
agcaagctcg ctgggaggag gcctccaagg aaaccatcaa gaagaccacc aagccttgct 1380
ctcgtgcaa cgtgccatt gaaaaaacg gaggatgtat gcacatgaag tgtcctcagc 1440
cccagtgcaa gctggagtgg tgcaggact gtggctgtga gtggaaccga gcctgcatgg 1500
gagatcactg gtttgacgtg tagagagaga tgtcacttgg cctggacgc acaacctcaa 1560
gggaaactcc gaagattcct accttcttta gccatttctt cttctcgatg catataagca 1620
cataaatgcg cacacacaaa cacaggctgc agattacaga agcagccct agatcctttc 1680
tagggcacc acagaaaacc acagcaccgc ctggccccag ggggaggagg cactttcagc 1740
ctctggctca ctgcaatgtc agagcttaga tgagggtgca cctttggtt ggattctgta 1800
gaagccatga gtgagggtgg aagtgttttc cagggttgtt gccacgccct gggtaagtaa 1860
cacctctgag gattctcaga agcacacttg agatctgagg aacgctgctc tcatgtagta 1920
atcatctatt ccaaagggc cccctgcagt agtcaaaact atttgtttat ccccccacat 1980
cctatcttta caaatgggtg tgatgagatt acaaccctc tgtgtactaa tcagcttatc 2040
aaccaagtga gaacctagga aagctaattg gatggcagac tgcttaaatc gcaggaggga 2100
ctcagaagcc aaacctactt ccgttcgttt cattatctgc aactttagaa agaaatgatc 2160
tttttttccc cctgaaaaga taacaaagtc tgcaatttgg tttggagtat tctactgca 2220
gcctggaagt ttagcttcac tgtgaattta acagagaaag tgcctataaa gggggcgctt 2280
ttaagagaca atcccatgat gctgcgccaa tgctaacaac aggggtcaaga aacacaatgt 2340
ttatagaagg agcatccctc gaccatctga atgagagtat gcctgacccc tccaccaca 2400
agtggggaca cctctgcata tctgtccct cctctgctgt taagccccag ggagccccat 2460
ccaccagtg gtcctacaga cagggaata cacacacacc aagatagcct tcagatcaac 2520
atgcatcaca ctcaagtgtt aatctttcaa ggttttctt tcttttctc gttttttatt 2580
tgttttgctt ttgctttttt ttttttttt tttgggtgtg gtggggctac caaacttgag 2640
gcctagagct aaaaatcata tagaaatgat gttatcttgt ggtgtgagga aaggccagct 2700
ggcctaagtt cacacttttg tccagtggt cctagactcc acccagccag ctcccaaat 2760
gaaaagacca cctgtcaagc agcagtcagg agtctgatgt caccatcac tattttttt 2820
ccatcattgt gcttgctct gctccttcc acaccgtgt gacgtaatcg cattgggaag 2880
ccaggacaat gtttgctgtt ctgctttggg taaagggact cctgaagct ctgtggctct 2940
ccagtatggt cccttttct tctaacaga tgcataatgt ttcttcagaa tacaatagt 3000
attcttaaaa taacccaaaa gacaggcatc cacagtgtgt gagcatgaat cacagcctgc 3060
attgtgtgag tgtgaatagt gggataaaag tggatgtcag aagagtggaa atcaaacctc 3120
tgcaaagcaa tctttctctt tctgtgaagt gtattaagaa atacctgaag tctgtgtgtg 3180
tggtgtgacc cagactgtca atcaataaag acccagactg tcaatgaaaa aaaaaaaaaa 3240
aaaaaaaaa aaaaaa 3255

```

<210> 19  
 <211> 3255  
 <212> DNA  
 <213> Mus musculus

<400> 19

```

ctcagcgagg ggaaggggga ggaggcctgg atgactaaac ctgacagaaa cgctgggtggg 60
aggctcgggc gggcgccagt gcccgcgtag gtccttctcg acccgagcc accacccgcc 120
cggtgaccat gatagtgttt gtcaggttca actccagcta tggcttcca gtggagggtcg 180
attctgacac cagcatcttg cagctcaagg aagtgggtgc taagcgacag ggggttccag 240
ctgaccagct gcgtgtgatt tttgccggga aggagcttcc gaatcacctg acggttcaaa 300
actgtgacct ggaacaacag agtattgtac acatagtaca gagaccacgg aggagaagtc 360
atgaaacaaa tgcattctgga ggggacgaac ccagagcac ctgagagggc tccatatggg 420
agtccaggag cttgacacga gtggacctga gcagccatac cctgccggtg gactctgtgg 480
ggctggcggg cattctggac acagacagta agagggttc agaagcagcc agagggtccag 540
ttaaacccac ctacaacagc tttttcatct actgcaaagg cccctgccac aagggtccagc 600
ctggaaagct ccgagttcag tgtggcacct gcaaacaagc aaccctcacc ttggcccagg 660
gcccattctg ctgggacgat gtcttaattc caaacggat gagtgggtgag tgccagtctc 720
cagactgccc tggaaaccaga gctgaatttt tctttaaatg tggagcacac ccaacctcag 780
acaaggacac gtcggtagct ttgaacctga tcaccagcaa caggcgacgc atcccttgca 840
tagcgtgcac agatgtcagg agccctgtcc tggcttcca gtgtaaccac cgtcacgtga 900
tctgtttgga ctgtttccac ttgtattgtg tcacaagact caacgatcgg cagtgtgtcc 960
acgatgctca acttggctac tccctgccgt gtgtagctgg ctgtcccaac tccctgatta 1020
aagagctcca tcacttcagg atccttggag aagagcagta cactaggtac cagcagtatg 1080
gggcccagga atgcgtgctg caaatgggag gtgtgctgtg ccccgctcct ggctgtggag 1140
ctggactgct acctgaacag ggccagagga aagtcacctg cgaagggggc aacggcctgg 1200
gctgcgggtt tgttttctgc cgggactgta aggaagcata ccatgaaggg gattgcgact 1260
cactgctcga accctcagga gccacttctc aggcctacag ggtggacaaa agagccgctg 1320
agcaagctcg ctgggaggag gcctccaagg aaaccatcaa gaagaccaac aagccttgtc 1380
ctcgtgcaa cgtgccatt gaaaaaacg gaggatgtat gcacatgaag tgtcctcagc 1440
cccagtgcaa gctggagtgg tgcaggaaat gtggctgtga gtggaaccga gcctgcatgg 1500
gagatcactg gtttgacgtg tagagagaga tgtcacttgg ccctggacgc acaacctcaa 1560
gggaaactcc gaagattcct accttccctta gccatttctt cttctcgatg catataagca 1620
cataaatgcg cacacacaaa cacaggctgc agattacaga agcagccctc agatcctttc 1680
tagggcacc acagaaaacc acagcaccgc ctggcccagc ggggaggagg cactttcagc 1740
ctctggctca ctgcaatgtc agagcttaga tgagggtgca cctttgggtt ggattctgta 1800
gaagccatga gtgagggtgg aagtgttttc cagggttgtt gccacgccct gggtaagtaa 1860
cacctctgag gattctcaga agcacacttg agatctgagg aacgctgctc tcatgtagta 1920
atcatctatt cccaaagggc cccctgcagt agtcaaaact atttgtttat cccccaaaat 1980
cctatcttta caaatgggtg tgatgagatt acaaccctc tgtgtactaa tcagcttatc 2040
aaccaagtga gaacctagga aagctaattg gatggcagac tgcttaaate gcaggaggga 2100
ctcagaagcc aaacctactt ccgttcgttt cattatctgc aacttttaga agaaatgatc 2160
ttttttccc cctgaaaaga taacaaagtc tgcaatttgg tttggagtat tctactgca 2220
gcctggaagt ttagcttcac tgtgaattta acagagaaag tgcctataaa gggggcggtt 2280
ttaagagaca atccatgat gctgcgccaa tgctaacaac aggggtcaaga aacacaatgt 2340
ttatagaagg agcatccctc gaccatctga atgagagtat gcctgacccc ttccaccaca 2400
agtggggaca cctctgcata tctgtccct cctctgctgt taagccccag ggagccccat 2460
ccaccagtg gtcctacaga cagggaata cacacacacc aagatagcct tcagatcaac 2520
atgcatcaca ctcaagtgtt aatctttcaa ggttttcttt tcttttctct gttttttatt 2580
tgttttgctt ttgctttttt ttttttttt tttgggtgtg gtggggctac caaacttgag 2640
gcctagagct aaaaatcata tagaaatgat gttatcttgt ggtgtgagga aaggccagct 2700
ggcctaagtt cacacttttg tcccagtggc cctagactcc acccagccag ctcccaaat 2760
gaaaagacca cctgtcaagc agcagtcagg agtctgatgt caccatcac ttttttttt 2820
ccatcattgt gcttgctct gcctccttcc acaccgtgt gacgtaatcg cattgggaag 2880
ccaggacaat gtttgctgtt ctgctttggg taaagggact ccctgaagct ctgtggctct 2940

```



ccagtatggt	cccttttctt	tcctaacaga	tgcataatggt	ttcttcagaa	tacaatagtg	3000
attcttaaaa	taacccaaaa	gacaggcatc	cacagtgtgt	gagcatgaat	cacagcctgc	3060
attgtgtgag	tgtgaatagt	gggataaaag	tggatgtcag	aagagtggaa	atcaaacctc	3120
tgcaaagcaa	tctttctctt	tctgtgaagt	gtattaagaa	atacctgaag	tctgtgtgtg	3180
tggtggtacc	cagactgtca	atcaataaag	acccagactg	tcaatgaaaa	aaaaaaaaaa	3240
aaaaaaaaaa	aaaaa					3255

<210> 20

<211> 3255

<212> DNA

<213> Mus musculus

<400> 20

ctcagcgagg	ggaaggggga	ggaggcctgg	atgactaaac	ctgacagaaa	cgctggtggg	60
aggctcgggc	gggcgccagt	gcccgcgtag	gtccttctcg	acccgcagcc	accacccgcc	120
cggtgaccat	gatatgtttt	gtcaggttca	actccagcta	tggcttccca	gtggagggtcg	180
attctgacac	cagcatcttg	cagctcaagg	aagtgggtgc	taagcgacag	ggggttccag	240
ctgaccagct	gcgtgtgatt	tttgccggga	aggagcttcc	gaatcacctg	acggttcaaa	300
actgtgacct	ggaacaacag	agtattgtac	acatagtaca	gagaccacgg	aggagaagtc	360
atgaaacaaa	tgcattctgga	ggggacgaac	cccagagcac	ctcagagggc	tccatatggg	420
agtccaggag	cttgacacga	gtggacctga	gcagccatac	cctgccggtg	gactctgtgg	480
ggctggcggg	cattctggac	acagacagta	agagggattc	agaagcagcc	agagggtccag	540
ttaaacccac	ctacaacagc	tttttcatct	actgcaaagg	ccccgccac	aagggtccagc	600
ctggaaaagct	ccgagttcag	tgtggcacct	gcaaacaagc	aacctcacc	ttggcccagg	660
gcccattctg	ctgggacgat	gtcttaattc	caaaccggat	gagtgggtgag	tgccagtctc	720
cagactgccc	tggaaaccaga	gctgaatttt	tctttaaatg	tggagcacac	ccaacctcag	780
acaaggacac	gtcggtagct	ttgaacctga	tcaccagcaa	caggcgacgc	atcccttgca	840
tagcgtgcac	agatgtcagg	agccctgtcc	tggctctcca	gtgtaaccac	cgtaacgtga	900
tctgtttgga	ctgtttccac	ttgtattgtg	tcacaagact	caacgatcgg	cagtttgtcc	960
acgatgctca	acttggttac	tccctgccgt	gtgtagctgg	ctgtcccaac	tccctgatta	1020
aagagctcca	tcacttcagg	atccttggag	aagagcagta	cactaggtac	cagcagtatg	1080
gggccgagga	atgcgtgctg	caaattggag	gtgtgctgtg	ccccgtcct	ggctgtggag	1140
ctggactgct	acctgaacag	ggccagagga	aagtcacctg	cgaagggggc	aacggcctgg	1200
gctgcgggtt	tgttttctgc	cgggactgta	aggaagcata	ccatgaaggg	gattgcgact	1260
cactgctcga	acctcagga	gccacttctc	aggcctacag	ggtggacaaa	agagccgctg	1320
agcaagctcg	ctgggaggag	gcctccaagg	aaaccatcaa	gaagaccacc	aagccttgtc	1380
ctcgctgcaa	cgtgcccaatt	gaaaaaaacg	gaggatgtat	gcacatgaag	tgtcctcagc	1440
ccagtgcaa	gctggagtg	tgttggaact	gtggctgtga	gtagaaccga	gcctgcatgg	1500
gagatcactg	gtttgacgtg	tagagagaga	tgtcacttgg	ccctggacgc	acaacctcaa	1560
gggaaactcc	gaagattcct	accttccctta	gccatttctt	cttctcgatg	catataagca	1620
cataaatgcg	cacacacaaa	cacaggctgc	agattacaga	agcagccctc	agatcctttc	1680
tagggcacc	acagaaaacc	acagcaccgc	ctggccccag	ggggaggagg	cactttcagc	1740
ctctggctca	ctcgaatgtc	agagcttaga	tgagggtgca	cctttgggtt	ggattctgta	1800
gaagccatga	gtgagggtgg	aagtgttttc	cagggttggt	gccacgcctc	gggtaagtaa	1860
cacctctgag	gattctcaga	agcacacttg	agatctgagg	aacgctgctc	tcagttagta	1920
atcatctatt	cccaaagggc	cccctgcagt	agtcaaaact	atttgtttat	ccccccaaat	1980
cctatcttta	caaattgggtg	tgatgagatt	acaaccctc	tgtgtactaa	tcagcttatc	2040
aaccaagtga	gaacctagga	aagctaattg	gatggcagac	tgcttaaata	gcaggaggga	2100
ctcagaagcc	aaacctactt	ccgttcgttt	cattatctgc	aacttttagaa	agaaatgata	2160
tttttttccc	cctgaaaaga	taacaaagtc	tgcaatttgg	tttggagtat	tcctactgca	2220
gcctggaagt	ttagcttcac	tgtgaattta	acagagaaaag	tgctataaaa	gggggcgttt	2280
ttaagagaca	atcccatgat	gctgcgccaa	tgctaacaac	aggggtcaaga	aacacaatgt	2340
ttatagaagg	agcatccctc	gaccatctga	atgagagtat	gcctgacccc	ttccaccaca	2400
agtggggaca	cctctgcata	tctgtccctc	cctctgctgt	taagccccag	ggagccccat	2460
ccaccagtg	gtcctacaga	cagggaata	cacacacacc	aagatagcct	tcagatcaac	2520

```

atgcatcaca ctcaagtgtt aatctttcaa ggttttcttt tctttttcct gttttttatt 2580
tgttttgctt ttgctttttt tttttttttt tttgggtgtg gtggggctac caaacttgag 2640
gcctagagct aaaaatcata tagaaatgat gttatcttgt ggtgtgagga aaggccagct 2700
ggcctaagtt cacacttttg tcccagtggt cctagactcc acccagccag ctcccaaat 2760
gaaaagacca cctgtcaagc agcagtcagg agtctgatgt cacccatcac tttttttttt 2820
ccatcattgt gcttgctctt gcctccttcc acaccctgtg gacgtaatcg cattgggaag 2880
ccaggacaat gtttgctgtt ctgctttggg taaagggact ccctgaagct ctgtggctct 2940
ccagtatggg cctttttcct tcctaacaga tgcataatgt ttcttcagaa tacaatagt 3000
attcttaaaa taacccaaaa gacaggcatc cacagtgtgt gagcatgaat cacagcctgc 3060
attgtgtgag tgtgaatagt gggataaaag tggatgtcag aagagtggaa atcaaacctc 3120
tgcaaagcaa tctttctctt tctgtgaagt gtattaagaa atacctgaag tctgtgtgtg 3180
tggtggtacc cagactgtca atcaataaag acccagactg tcaatgaaaa aaaaaaaaaa 3240
aaaaaaaaaa aaaaaa 3255

```

<210> 21  
 <211> 105  
 <212> PRT  
 <213> Mus musculus

```

<400> 21
Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu
  1             5             10             15
Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys
             20             25             30
Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys
             35             40             45
Glu Leu Pro Asn His Leu Thr Val Gln Leu Asn Pro Pro Thr Thr Ala
             50             55             60
Phe Ser Ser Thr Ala Lys Ala Pro Ala Thr Arg Ser Ser Leu Glu Ser
65             70             75             80
Ser Glu Phe Ser Val Ala Pro Ala Asn Lys Gln Pro Ser Pro Trp Pro
             85             90             95
Arg Ala His Leu Ala Gly Thr Met Ser
             100             105

```

<210> 22  
 <211> 344  
 <212> PRT  
 <213> Mus musculus

```

<400> 22
Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu
  1             5             10             15
Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys
             20             25             30
Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys
             35             40             45
Glu Leu Pro Asn His Leu Thr Val Gln Gly Pro Ser Cys Trp Asp Asp
             50             55             60
Val Leu Ile Pro Asn Arg Met Ser Gly Glu Cys Gln Ser Pro Asp Cys
65             70             75             80
Pro Gly Thr Arg Ala Glu Phe Phe Phe Lys Cys Gly Ala His Pro Thr
             85             90             95
Ser Asp Lys Asp Thr Ser Val Ala Leu Asn Leu Ile Thr Ser Asn Arg

```



Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu  
 1 5 10 15  
 Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys  
 20 25 30  
 Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys  
 35 40 45  
 Glu Leu Pro Asn His Leu Thr Val Gln Asn Cys Asp Leu Glu Gln Gln  
 50 55 60  
 Ser Ile Val His Ile Val Gln Arg Pro Arg Arg Arg Ser His Glu Thr  
 65 70 75 80  
 Asn Ala Ser Gly Gly Asp Glu Pro Gln Ser Thr Ser Glu Gly Ser Ile  
 85 90 95  
 Trp Glu Ser Arg Ser Leu Thr Arg Val Asp Leu Ser Ser His Thr Leu  
 100 105 110  
 Pro Val Asp Ser Val Gly Leu Ala Val Ile Leu Asp Thr Asp Ser Lys  
 115 120 125  
 Arg Asp Ser Glu Ala Ala Arg Gly Pro Gly Pro Ile Leu Leu Gly Arg  
 130 135 140  
 Cys Leu Asn Ser Lys Pro Asp Glu Trp  
 145 150

<210> 25

<211> 194

<212> PRT

<213> Mus musculus

<400> 25

Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu  
 1 5 10 15  
 Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys  
 20 25 30  
 Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys  
 35 40 45  
 Glu Leu Pro Asn His Leu Thr Val Gln Asn Cys Asp Leu Glu Gln Gln  
 50 55 60  
 Ser Ile Val His Ile Val Gln Arg Pro Arg Arg Arg Ser His Glu Thr  
 65 70 75 80  
 Asn Ala Ser Gly Gly Asp Glu Pro Gln Ser Thr Ser Glu Gly Ser Ile  
 85 90 95  
 Trp Glu Ser Arg Ser Leu Thr Arg Val Asp Leu Ser Ser His Thr Leu  
 100 105 110  
 Pro Val Asp Ser Val Gly Leu Ala Val Ile Leu Asp Thr Asp Ser Lys  
 115 120 125  
 Arg Asp Ser Glu Ala Ala Arg Gly Pro Val Lys Pro Thr Tyr Asn Ser  
 130 135 140  
 Phe Phe Ile Tyr Cys Lys Gly Pro Cys His Lys Val Gln Pro Gly Lys  
 145 150 155 160  
 Leu Arg Val Gln Cys Gly Thr Cys Lys Gln Ala Thr Leu Thr Leu Ala  
 165 170 175  
 Gln Asn Phe Ser Leu Asn Val Glu His Thr Gln Pro Gln Thr Arg Thr  
 180 185 190  
 Arg Arg

<210> 26  
 <211> 183  
 <212> PRT  
 <213> Mus musculus

<400> 26  
 Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu  
 1 5 10 15  
 Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys  
 20 25 30  
 Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys  
 35 40 45  
 Glu Leu Pro Asn His Leu Thr Val Gln Asn Cys Asp Leu Glu Gln Gln  
 50 55 60  
 Ser Ile Val His Ile Val Gln Arg Pro Arg Arg Arg Ser His Glu Thr  
 65 70 75 80  
 Asn Ala Ser Gly Gly Asp Glu Pro Gln Ser Thr Ser Glu Gly Ser Ile  
 85 90 95  
 Trp Glu Ser Arg Ser Leu Thr Arg Val Asp Leu Ser Ser His Thr Leu  
 100 105 110  
 Pro Val Asp Ser Val Gly Leu Ala Val Ile Leu Asp Thr Asp Ser Lys  
 115 120 125  
 Arg Asp Ser Glu Ala Ala Arg Gly Pro Val Lys Pro Thr Tyr Asn Ser  
 130 135 140  
 Phe Phe Ile Tyr Cys Lys Gly Pro Cys His Lys Val Gln Pro Gly Lys  
 145 150 155 160  
 Leu Arg Val Gln Cys Gly Thr Cys Lys Gln Ala Thr Leu Thr Leu Ala  
 165 170 175  
 Gln Leu Ala Val Pro Thr Pro  
 180

<210> 27  
 <211> 296  
 <212> PRT  
 <213> Mus musculus

<400> 27  
 Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu  
 1 5 10 15  
 Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys  
 20 25 30  
 Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys  
 35 40 45  
 Glu Leu Pro Asn His Leu Thr Val Gln Asn Cys Asp Leu Glu Gln Gln  
 50 55 60  
 Ser Ile Val His Ile Val Gln Arg Pro Arg Arg Arg Ser His Glu Thr  
 65 70 75 80  
 Asn Ala Ser Gly Gly Asp Glu Pro Gln Ser Thr Ser Glu Gly Ser Ile  
 85 90 95  
 Trp Glu Ser Arg Ser Leu Thr Arg Val Asp Leu Ser Ser His Thr Leu  
 100 105 110  
 Pro Val Asp Ser Val Gly Leu Ala Val Ile Leu Asp Thr Asp Ser Lys  
 115 120 125

Arg Asp Ser Glu Ala Ala Arg Gly Pro Val Lys Pro Thr Tyr Asn Ser  
 130 135 140  
 Phe Phe Ile Tyr Cys Lys Gly Pro Cys His Lys Val Gln Pro Gly Lys  
 145 150 155 160  
 Leu Arg Val Gln Cys Gly Thr Cys Lys Gln Ala Thr Leu Thr Leu Ala  
 165 170 175  
 Gln Gly Pro Ser Cys Trp Asp Asp Val Leu Ile Pro Asn Arg Met Ser  
 180 185 190  
 Gly Glu Cys Gln Ser Pro Asp Cys Pro Gly Thr Arg Ala Glu Phe Phe  
 195 200 205  
 Phe Lys Cys Gly Ala His Pro Thr Ser Asp Lys Asp Thr Ser Val Ala  
 210 215 220  
 Leu Asn Leu Ile Thr Ser Asn Arg Arg Ser Ile Pro Cys Ile Ala Cys  
 225 230 235 240  
 Thr Asp Val Arg Ser Pro Val Leu Val Phe Gln Cys Asn His Arg His  
 245 250 255  
 Val Ile Cys Leu Asp Cys Phe His Leu Tyr Cys Val Thr Arg Leu Asn  
 260 265 270  
 Asp Arg Gln Phe Val His Asp Ala Gln Leu Gly Tyr Ser Leu Pro Cys  
 275 280 285  
 Val Val Cys Phe Leu Pro Gly Leu  
 290 295

<210> 28  
 <211> 37  
 <212> PRT  
 <213> Mus musculus

<400> 28  
 Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu  
 1 5 10 15  
 Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys  
 20 25 30  
 Arg Arg Gly Ser Ser  
 35

<210> 29  
 <211> 53  
 <212> PRT  
 <213> Mus musculus

<400> 29  
 Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu  
 1 5 10 15  
 Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys  
 20 25 30  
 Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys  
 35 40 45  
 Glu Leu Pro Ile Thr  
 50

<210> 30

<211> 77  
 <212> PRT  
 <213> Mus musculus

<400> 30  
 Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu  
   1                  5                  10                  15  
 Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys  
                   20                  25                  30  
 Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys  
                   35                  40                  45  
 Glu Leu Pro Asn His Leu Thr Val Gln Asn Cys Asp Leu Glu Gln Gln  
           50                  55                  60  
 Ser Ile Val His Ile Val Gln Arg Pro Arg Glu Lys Ser  
 65                  70                  75

<210> 31  
 <211> 14  
 <212> PRT  
 <213> Mus musculus

<400> 31  
 Met Ile Val Thr Val Thr Trp Asn Asn Arg Val Leu Tyr Thr  
   1                  5                  10

<210> 32  
 <211> 464  
 <212> PRT  
 <213> Mus musculus

<400> 32  
 Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu  
   1                  5                  10                  15  
 Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys  
                   20                  25                  30  
 Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys  
                   35                  40                  45  
 Glu Leu Pro Asn His Leu Thr Val Gln Asn Cys Asp Leu Glu Gln Gln  
           50                  55                  60  
 Ser Ile Val His Ile Val Gln Arg Pro Arg Arg Arg Ser His Glu Thr  
 65                  70                  75                  80  
 Asn Ala Ser Gly Gly Asp Glu Pro Gln Ser Thr Ser Glu Gly Ser Ile  
                   85                  90                  95  
 Trp Glu Ser Arg Ser Leu Thr Arg Val Asp Leu Ser Ser His Thr Leu  
                   100                  105                  110  
 Pro Val Asp Ser Val Gly Leu Ala Val Ile Leu Asp Thr Asp Ser Lys  
                   115                  120                  125  
 Arg Asp Ser Glu Ala Ala Arg Gly Pro Val Lys Pro Thr Tyr Asn Ser  
           130                  135                  140  
 Phe Phe Ile Tyr Cys Lys Gly Pro Cys His Lys Val Gln Pro Gly Asn  
 145                  150                  155                  160  
 Leu Arg Val Gln Cys Gly Thr Cys Lys Gln Ala Thr Leu Thr Leu Ala  
                   165                  170                  175

Gln Gly Pro Ser Cys Trp Asp Asp Val Leu Ile Pro Asn Arg Met Ser  
 180 185 190  
 Gly Glu Cys Gln Ser Pro Asp Cys Pro Gly Thr Arg Ala Glu Phe Phe  
 195 200 205  
 Phe Lys Cys Gly Ala His Pro Thr Ser Asp Lys Asp Thr Ser Val Ala  
 210 215 220  
 Leu Asn Leu Ile Thr Ser Asn Arg Arg Ser Ile Pro Cys Ile Ala Cys  
 225 230 235 240  
 Thr Asp Val Arg Ser Pro Val Leu Val Phe Gln Cys Asn His Arg His  
 245 250 255  
 Val Ile Cys Leu Asp Cys Phe His Leu Tyr Cys Val Thr Arg Leu Asn  
 260 265 270  
 Asp Arg Gln Phe Val His Asp Ala Gln Leu Gly Tyr Ser Leu Pro Cys  
 275 280 285  
 Val Ala Gly Cys Pro Asn Ser Leu Ile Lys Glu Leu His His Phe Arg  
 290 295 300  
 Ile Leu Gly Glu Glu Gln Tyr Thr Arg Tyr Gln Gln Tyr Gly Ala Glu  
 305 310 315 320  
 Glu Cys Val Leu Gln Met Gly Gly Val Leu Cys Pro Arg Pro Gly Cys  
 325 330 335  
 Gly Ala Gly Leu Leu Pro Glu Gln Gly Gln Arg Lys Val Thr Cys Glu  
 340 345 350  
 Gly Gly Asn Gly Leu Gly Cys Gly Phe Val Phe Cys Arg Asp Cys Lys  
 355 360 365  
 Glu Ala Tyr His Glu Gly Asp Cys Asp Ser Leu Leu Glu Pro Ser Gly  
 370 375 380  
 Ala Thr Ser Gln Ala Tyr Arg Val Asp Lys Arg Ala Ala Glu Gln Ala  
 385 390 395 400  
 Arg Trp Glu Glu Ala Ser Lys Glu Thr Ile Lys Lys Thr Thr Lys Pro  
 405 410 415  
 Cys Pro Arg Cys Asn Val Pro Ile Glu Lys Asn Gly Gly Cys Met His  
 420 425 430  
 Met Lys Cys Pro Gln Pro Gln Cys Lys Leu Glu Trp Cys Trp Asn Cys  
 435 440 445  
 Gly Cys Glu Trp Asn Arg Ala Cys Met Gly Asp His Trp Phe Asp Val  
 450 455 460

<210> 33

<211> 464

<212> PRT

<213> Mus musculus

<400> 33

Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu  
 1 5 10 15  
 Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys  
 20 25 30  
 Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys  
 35 40 45  
 Glu Leu Pro Asn His Leu Thr Val Gln Asn Cys Asp Leu Glu Gln Gln  
 50 55 60  
 Ser Ile Val His Ile Val Gln Arg Pro Arg Arg Arg Ser His Glu Thr  
 65 70 75 80  
 Asn Ala Ser Gly Gly Asp Glu Pro Gln Ser Thr Ser Glu Gly Ser Ile



				85					90					95					
Trp	Glu	Ser	Arg	Ser	Leu	Thr	Arg	Val	Asp	Leu	Ser	Ser	His	Thr	Leu				
				100					105					110					
Pro	Val	Asp	Ser	Val	Gly	Leu	Ala	Val	Ile	Leu	Asp	Thr	Asp	Ser	Lys				
				115				120					125						
Arg	Asp	Ser	Glu	Ala	Ala	Arg	Gly	Pro	Val	Lys	Pro	Thr	Tyr	Asn	Ser				
				130			135					140							
Phe	Phe	Ile	Tyr	Cys	Lys	Gly	Pro	Cys	His	Lys	Val	Gln	Pro	Gly	Lys				
145					150					155					160				
Leu	Arg	Val	Gln	Cys	Gly	Thr	Cys	Lys	Gln	Ala	Thr	Leu	Thr	Leu	Ala				
				165					170						175				
Gln	Gly	Pro	Ser	Cys	Trp	Asp	Asp	Val	Leu	Ile	Pro	Asn	Arg	Met	Ser				
			180					185					190						
Gly	Glu	Cys	Gln	Ser	Pro	Asp	Cys	Pro	Gly	Thr	Arg	Ala	Glu	Phe	Phe				
		195					200					205							
Phe	Lys	Cys	Gly	Ala	His	Pro	Thr	Ser	Asp	Lys	Asp	Thr	Ser	Val	Ala				
	210					215					220								
Leu	Asn	Leu	Ile	Thr	Ser	Asn	Arg	Arg	Ser	Ile	Pro	Cys	Ile	Ala	Cys				
225					230					235					240				
Thr	Asp	Val	Arg	Ser	Pro	Val	Leu	Val	Phe	Gln	Cys	Asn	His	Arg	His				
				245					250					255					
Val	Ile	Cys	Leu	Asp	Cys	Phe	His	Leu	Tyr	Cys	Val	Thr	Arg	Leu	Asn				
			260					265						270					
Asp	Arg	Gln	Phe	Val	His	Asp	Ala	Gln	Leu	Gly	Tyr	Ser	Leu	Pro	Cys				
		275					280					285							
Val	Ala	Gly	Cys	Pro	Asn	Ser	Leu	Ile	Lys	Glu	Leu	His	His	Phe	Arg				
	290				295					300									
Ile	Leu	Gly	Glu	Glu	Gln	Tyr	Thr	Arg	Tyr	Gln	Gln	Tyr	Gly	Ala	Glu				
305					310					315					320				
Glu	Cys	Val	Leu	Gln	Met	Gly	Gly	Val	Leu	Cys	Pro	Arg	Pro	Gly	Cys				
				325					330					335					
Gly	Ala	Gly	Leu	Leu	Pro	Glu	Gln	Gly	Gln	Arg	Lys	Val	Thr	Cys	Glu				
			340					345					350						
Gly	Gly	Asn	Gly	Leu	Gly	Cys	Gly	Phe	Val	Phe	Cys	Arg	Asp	Cys	Lys				
		355					360					365							
Glu	Ala	Tyr	His	Glu	Gly	Asp	Cys	Asp	Ser	Leu	Leu	Glu	Pro	Ser	Gly				
	370					375					380								
Ala	Thr	Ser	Gln	Ala	Tyr	Arg	Val	Asp	Lys	Arg	Ala	Ala	Glu	Gln	Ala				
385					390					395					400				
Arg	Trp	Glu	Glu	Ala	Ser	Lys	Glu	Thr	Ile	Lys	Lys	Thr	Asn	Lys	Pro				
				405					410					415					
Cys	Pro	Arg	Cys	Asn	Val	Pro	Ile	Glu	Lys	Asn	Gly	Gly	Cys	Met	His				
			420					425					430						
Met	Lys	Cys	Pro	Gln	Pro	Gln	Cys	Lys	Leu	Glu	Trp	Cys	Trp	Asn	Cys				
	435					440						445							
Gly	Cys	Glu	Trp	Asn	Arg	Ala	Cys	Met	Gly	Asp	His	Trp	Phe	Asp	Val				
	450					455					460								

<210> 34  
 <211> 451  
 <212> PRT  
 <213> Mus musculus

<400> 34



435  
Gly Cys Glu  
450

440

445